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Renal cell carcinoma (RCC) is the most lethal of all urologic malignancies and 
it is relatively radio-resistant and intrinsically resistant to almost all available 
chemotherapeutics. Clinically, the upregulation of survivin, an inhibitor of 
apoptosis protein, is viewed as a molecular signature of unfavourable disease 
outcome and a diagnostic biomarker of tumour onset and recurrence. The first 
aim of this study was to investigate the role of survivin in RCC and the efficacy 
of a small molecule inhibitor of survivin, YM155 on the viability of a panel of 
RCC cell lines. Cells without functional VHL protein expressed higher levels 
of survivin and there was a general trend towards higher expression of survivin 
in RCC clinical samples. Silencing survivin led to significant decreases in cell 
growth and survival and induced profound apoptosis. YM155 exhibited 
nanomolar growth inhibitory activities on the RCC panel of cells and effectively 
down-regulated survivin in a dose dependent manner. However, its potent 
growth inhibitory activity was independent of VHL status and survivin levels. 
Therefore, the second aim was to elucidate possible mechanism(s) of action of 
YM155 on RCC and its effect on the progression of the disease. Microarray 
analyses revealed that molecules associated with p53 connection pathway may 
be implicated. Elevated levels of p53 activity and initiation of cell cycle arrest 
at the late S and early G2 phases were significant by 24h. Changes in expression 
of various cell cycle regulatory proteins indicated that the DNA damage 
response pathway was activated. Biomolecules in the NF-κB signaling pathway 
were also disrupted. YM155 suppressed p65 NF-κB binding to survivin 
promoter but increased the binding to IL8 promoter at 24h. Profound induction 
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of apoptosis was detected by 48h. Based on the above observations, the third 
aim examined approaches to developing new and more effective therapeutic 
strategies through the use of YM155 combinations. The in vitro combination of 
YM155 with sorafenib pointed to synergism. An in vivo assessment of YM155 
on patient-derived RCC xenograft in SCID mice showed that YM155 slowed 
down growth of the tumour xenograft. The positive impact of YM155 in the 
mitigation of cancer progression supports the view that it may be a potential 
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1.1 Renal cell carcinoma (RCC) 
Urologic malignancies of the kidney are responsible for 1-2% of all cancer 
deaths in Singapore, with an age-standardized incidence of 6.2 per 100 000 in 
men and 3.1 per 100 000 in women1. In the United States and Europe, age-
adjusted incidence rates have increased approximately 2-3% annually over the 
past 30 years2-5. This trend is also observed in Singapore with rates almost 
doubling over the last 40 years1. The higher rates of detection are a likely 
consequence of the prevalent use of sensitive imaging technologies such as 
ultrasonography and computed tomography (CT) for the investigation of 
abdominal or gastrointestinal complaints. RCC is the most common form of 
kidney cancer (72%) and being heterogeneous in nature, disease progression 
has been difficult to monitor despite the availability of prognostic scoring 
systems based on conventional clinical and pathological indices6. It is a very 
lethal urologic malignancy as approximately 1/3rd of patients would have 
exhibited visceral metastasis7 at the time of diagnosis and half of the remaining 
patients would eventually develop distant metastases8. Population-based cancer 
survival data revealed that more than 40% of patients with RCC die from the 
disease9-11, in contrast with bladder and prostate carcinomas which have 
approximately ½ the mortality rates12-15.  
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1.1.1 Histological subtypes of RCC 
RCC is not a homogenous malignancy but comprise of a few different 
histological subtypes16, each of which is distinguished from the other by the (i) 
region of the renal epithelium from which it originates, (ii) the gene mutations 
involved in its pathogenesis and (iii) the unique clinical course and outcome of 
the disease17-19 (Table 1.1). Besides clear cell RCC, other common histological 
subtypes are Type 1 (5%) and Type 2 (10%) papillary RCC, chromophobe 
tumours (4-5%) and collecting duct/medullary cell tumours (<1%)20, 21 (Figure 
1.1). Clear cell RCC appears to arise primarily from the proximal convoluted 
tubules, while chromophobe and papillary RCC originate from the distal 
components of the nephron22.  
Since early 1990s, significant efforts have been invested in advancing the 
understanding of how molecular genetics drive RCC pathogenesis. Apart from 
RCC that arises sporadically, known familial syndromes that predispose to renal 
tumours have been identified. These hereditary types of RCC have a low rate of 
occurrence (~5%) and include: (i) von Hippel-Lindau (VHL) disease; (ii) 
hereditary papillary renal cell carcinoma (HPRC); (iii) hereditary 
leiomyomatosis renal cancer (HLRC); and (iv) Birt-Hogg-Dube (BHD) 
syndrome23. Each hereditary type has characteristics molecular alterations, 
which are often reflected in the development of distinctive histological 
features24. Molecular genetic analyses of familial cases provide important 
insight into the molecular mechanisms driving cancer initiation and progression. 
This knowledge would in turn improve the understanding of sporadic RCC and 
can potentially translate into more effective therapeutic strategies for the clinical 





Subtype Histological features Somatic alterations Genetic alterations Clinical features 
Clear cell  
Yellowish tumour, round 
or polygonal clear cells 








3p (90%), 14q, 
8p, and 9p and 





Basophilic or eosinophilic 
cells arranged in papillary 
or tubular configuration. 





Gains of 7, 8q, 
12q, 16p, 17, 
20, and loss of 
9p. Papillary 
type 2 with 
gains of 8q, 







Chromophobe Distinct cell borders and a voluminous cytoplasm. Perinuclear halo with 
numerous microvesicles TP53 
Loss of 
chromosomes 
1, 2, 6, 10, 13, 
and 17 Not defined 
Collecting duct 
Consists of mixture of 
dilated tubules and 
papillary structures. Cells 
taking columnar pattern 
with hobnail appearance, 
presence of mucinous 
material, desmoplastic 
stroma 




























Papillary or nested 
architecture, granular and 
eosinophilic cells with 















Table 1.1. Classification of renal cell carcinoma and their associated 








Figure 1.1. Distribution of common histological subtypes of renal cell 
carcinoma. Adapted from Shuch et al, 201519. 
 
Inherited syndrome Gene Chromosome location Histology 
VHL disease  VHL  3p25  Clear cell  
Hereditary papillary RCC  MET  7q31  Papillary (type 1)  
Hereditary leiomyomatosis 
and RCC  FH 1p42  Papillary (type 2)  
Birt-Hogg-Dube (BHD) 
syndrome  FLCN  17p11  All (especially chromophobe)  
Tuberous sclerosis complex  TSC1/2  9q34/16p13  Clear cell, papillary, and chromophobe  
Cowden syndrome  PTEN  10q23  Clear cell, papillary, and chromophobe  
Hereditary pheochromocytoma 
and paraganglioma  SDH B/C/D 1p36/1q23/11q23 
Clear cell, 
unclassified/eosinophilic variant  
Chromosome 3 translocation 
renal cell  –  
Translocations 
(3:6,3:8,3:11)  Clear cell  
Unnamed  MITF  3p14  Not yet defined  
 
Table 1.2. List of known hereditary RCC. Adapted from Shuch et al, 201519. 
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Approximately 75% of all clear cell RCC is associated with the inactivating 
VHL mutation. Other genetic abnormalities include alterations of chromosome 
3p and gain/loss of chromosomes 8p, 9p, 14q, 7 and 17. Papillary RCC is 
associated with the activation of the Met proto-oncogene and chromosome 
trisomies while the other histological subtypes do not have well-defined genetic 
alterations. Table 1.2 gives a summary of tumour suppressor genes and 
oncogenes that contribute to the development of familial and sporadic RCC16, 
25-28. Recently, five new frequently mutated genes associated with the clear cell 
RCC were discovered. These genes encode four proteins; KDM6A/UTX, SETD2, 
KDM5C/JARID1C and MLL229 which are responsible for the methylation and 
demethylation of histone residues and hence control gene transcription. 
 
1.1.2 Clinical presentations, pathological grading and staging 
Most cases of sporadic clear cell RCC occur in older patients (≥ 60 years) with 
a higher incidence in males than females (1.6:1). About 30% of the patients 
present with advanced loco-regional or metastatic disease. Renal masses remain 
asymptomatic and clinically undetectable until the advanced stages mainly due 
to their retro-peritoneal locations8. With the increasing use of noninvasive 
imaging for the evaluation of a variety of nonspecific symptoms, more than 50% 
of RCCs are now detected accidentally during abdominal ultrasounds or CT 
scans. Hence, it is rare for a patient to present with the classic traits of RCC, 
namely flank pain, gross hematuria and palpable abdominal mass30. Clinical 
indicators of advanced disease include constitutional symptoms, such as fever, 
weight loss, night sweats, or physical signs such as palpable cervical 
lymphadenopathy. Non-reducing varicocele or bilateral lower extremity edema 
6 
 
suggest venous involvement and patients may also present with symptoms 
directly attributable to metastatic disease, such as bone pain or persistent 
cough31.  
The Tumour, Nodes and Metastasis (TNM) staging system for RCC was 
recommended as a predictive guide to the patient’s risk of disease progression, 
mortality outcome, response to treatment modalities and/or suitability for 
clinical trials and data comparison (Table 1.3). For the grading of RCC based 
on cell-based features such as nuclear size, shape and the presence or absence 
of prominent nucleoli, the Fuhrman's classification system is preferred and has 
demonstrated prognostic significance independent of tumour stage32 (Table 1.4). 
 
1.1.3 Treatment of RCC 
For patients with early stage RCC, surgery by radical nephrectomy remains the 
preferred option for localised RCC, provided tumours can be excised with an 
adequate surgical margin. Under these conditions, the prognosis is excellent and 
hence, it is currently held up as the “gold standard” among treatment strategies. 
The operation involves early ligation of the renal vessels, removal of the kidney 
outside the Gerota's fascia, with or without removal of the ipsilateral adrenal 
gland depending on tumour location and evidence of invasiveness33, 34. 
Literature reports indicate 5-year survival rate of 75% or more after radical 
nephrectomy for stage I (T1–T2) tumours35, 36. However, about 30% of the RCC 
patients who undergo radical nephrectomy eventually demonstrate local 
recurrence or distant metastasis37, with the incidence depending on tumour stage 




Tumour (T) Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour ≤ 7 cm, limited to kidney 
T1a Tumour ≤ 4 cm, limited to kidney 
T1b Tumour > 4 cm but ≤ 7 cm, limited to kidney 
T2 Tumour > 7 cm, limited to kidney 
T2a Tumour > 7cm but ≤ 10cm, limited to kidney 
T2b Tumour > 10 cm, limited to kidney 
T3 Tumour extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond the Gerota’s fascia 
T3a 
Tumour grossly extends into the renal vein or its segmental 
(muscle-containing) branches, or tumor invades perirenal and/or 
renal sinus fat but not beyond the Gerota fascia 
T3b Tumour grossly extends into the vena cava below the diaphragm 
T3c Tumour grossly extends into the vena cava above the diaphragm or invades the wall of the vena cava 
T4 Tumour invades beyond the Gerota fascia (including contiguous extension into the ipsilateral adrenal gland) 
Lymph Node (N) Description 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
Metastasis (M) Description 
M0 No distant metastasis 
M1 Distant metastasis 
TNM stage grouping 
Stage I T1                      N0                    M0 
Stage II T2                      N0                    M0 
Stage III T3                      N0                    M0 T1, T2, T3         N1                    M0 
Stage IV T4                      Any N              M0 Any T                Any N              M1 
 
Table 1.3. The tumour, nodes and metastasis (TNM) classification for RCC. 
Adapted from Sobin et al, 2009; Wittekind, 2012 40, 41 . 
 
Grade Nuclear size Nuclear outline Nucleoli 
1 10µm Round, uniform Absent or inconspicuous 
2 15µm Irregular Small (visible at 400x magnification) 
3 20µm Irregular Prominent 
4 >20µm Bizarre, often multilobed Prominent, heavy chromatin clumps present 
 




As mentioned earlier, about 1/3rd of patients exhibit visceral metastasis at the 
time of diagnosis8, 42. The overall clinical prognosis varies from less than 1 year 
for approximately 50% of the patients to more than 5 years for 10% of the 
patients43. Treatment strategies for metastatic RCC are very limited as it is 
unresponsive to conventional chemo- and radio- therapies, thus making it one 
of the most difficult tumours to treat44. In the last decade, cytokine-based 
immunotherapy using interleukin (IL)-2 or interferon (IFN)-α is the only 
effective treatment for metastatic RCC disease. However, it is far from 
satisfactory as only a subset of patients (10-15%) respond to the treatment but 
often with severe side effects45-48.   
 
1.1.4 Biology and genetics of RCC 
According to Hanahan and Weinberg49, all cancer cells acquire essential 
biological capabilities during their development into a malignant phenotype. 
These include sustained proliferative signaling, evasion of growth suppressors, 
avoidance of immune destruction, sustained replicative immortality, tumour-
promoting inflammation, activating invasion and metastasis, induction of 
angiogenesis, genome instability and mutation, resistance to cell death and 
deregulated cellular energetics. From a therapeutic point of view, drugs can be 
developed to interfere with different molecular targets in the mechanistic 
pathways that lead to the acquisition of these functional capabilities. In order to 
do so, there is a need to understand the molecular biology underlying the 
development of RCC so that pathways critical to its pathogenesis can be 
effectively intercepted by chemotherapeutics.  
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1.1.4.1 von Hippel-Lindau (VHL) gene 
The VHL gene is located on chromosome 3p25-26 and consists of three exons. 
It produces two transcripts that translate to three proteins (pVHL). The first VHL 
mRNA encodes two proteins due to the internal translational initiation start site 
(ATG) at codon 54. The larger product is made up of 213 amino acids and gives 
a molecular weight of approximately 24 to 30 kDa (VHL30)50. A second shorter 
isoform of pVHL comprises 160 amino acids and is approximately 19 kDa 
(VHL19)51-54. Both isoforms appear to retain tumour suppressor activity. The 
second mRNA transcript lacks exon 2 due to alternative splicing and has been 
identified to encode a defective protein (no tumour suppressor activity) 
exclusively in tumours55. Studies had shown that pVHL shuttles between the 
nucleus and cytoplasm56-59 and VHL30 is located primarily in the cytoplasm, 
while VHL19 resides primarily in the nucleus, indicating that the functions of 
these isoforms may overlap but are not identical51, 60. 
 
1.1.4.2 Functions of pVHL 
The ability of pVHL to regulate protein expression at the post-transcriptional 
level is one of its better understood functions. pVHL functions as a E3 ubiquitin 
ligase. It forms a stable complex with Rbx1, Cul2, elongin B and elongin C and 
serves as a binding and substrate recognition component61, 62 for the 
ubiquitination of targeted proteins. Following substrate binding, these 
complexes promote the proteasomal degradation of the target protein by 
covalently attaching polyubiquitin residues onto the protein63.  
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The tumour suppressor activity of pVHL is clearly seen in the way it regulates 
the activity of hypoxia-inducible factor (HIF). The heterodimeric HIF-1 (HIF-
1α and HIF-1β subunits) is a sequence-specific DNA-binding transcription 
factor64, 65. The regulation of the expression of HIF-1α determines the 
transcription activity of HIF-1 as the other subunit HIF-1β is expressed 
constitutively in cells66. The HIF subunits respond to changes in available 
oxygen in the cellular environment and they are very unstable in normoxic 
conditions. Under such conditions, the highly conserved proline residues within 
the oxygen-dependent degradation (ODD) domain of HIF-1α are 
hydroxylated67-70. The asparagine residues at the COOH-terminal 
transactivation domain (CAD) of HIF-1α are also hydroxylated by an 
asparaginyl hydroxylase, Factor Inhibiting HIF1 (FIH-1)71. Hydroxylation of 
HIF-1α by FIH-1 blocks the association of HIFs with the transcriptional co-
activator CREB-binding protein (CBP)/p300, thus suppressing transcription 
activation. Instead, HIF-1 binds to the β domain of pVHL, undergoes 
polyubiquitination and subsequently degradation by the proteasome72-74. Under 
conditions of cellular hypoxia, the pVHL-HIF interaction is disrupted due to the 
loss of oxygen-dependent hydroxylation of specific proline and asparagine 
residues on HIF-1α, thus leading to brisk stabilisation and translocation of HIF-
1 to the nucleus where it forms a transcriptional complex with aryl hydrocarbon 
receptor nuclear translocator (ARNT) and CBP/p300. The complex binds to 
hypoxia response elements (HREs) in the promoter region and activates gene 






Figure 1.2. pVHL/HIF oxygen sensing pathway. Hypoxia-inducible factors (HIFs) 
are transcription factors that respond to changes in available oxygen in the cellular 
environment. In conditions of physiologic oxygen availability and normal VHL gene 
function, pVHL is the substrate recognition component of an ubiquitin ligase 
complex that targets HIFs for proteolysis. In conditions of cellular hypoxia, the 
pVHL-HIF interaction is disrupted due to the loss of oxygen-dependent 
hydroxylation of specific proline residues on HIF, thus leading to brisk stabilisation 
and translocation of HIF to the nucleus. When the VHL gene is defective, this 
interaction is dysfunctional even in the presence of adequate oxygen. As such, HIF 
is not subjected to proteolysis and this leads to constitutive activation of the hypoxia 
response pathway and transcriptional activation of genes involved in tumour 




1.1.4.3 VHL inactivation 
Mutations in the α- and β- domain of pVHL abrogate protein binding and 
degradation due to failure in the formation of the pVHL ubiquitin complex. In 
RCC, all hereditary VHL-related and approximately 75% of sporadic cases 
harbour the biallelic VHL inactivation via loss of heterozygosity, promoter 
methylation or intragenic deletion75-77. Familial VHL-related clear cell RCC is 
an autosomal dominant disease78 of rare occurrence (frequency of 1 per 36 000). 
In this condition,  one allele of the defective gene is inherited and the disease is 
manifested following inactivation or silencing of the remaining wild-type VHL 
allele, consistent with the Knudson ‘two hit’ model79.  
As a result of the defective VHL gene, the pVHL-HIF-1 interaction is 
dysfunctional even in the presence of adequate oxygen. As such, HIF-1 is not 
subjected to proteolysis and this leads to constitutive activation of the hypoxia 
response pathway and transcriptional activation of genes involved in tumour 
proliferation. Genes involved in short-term adaptation of hypoxia include 
inducible nitric oxide synthase (iNOS) to increase vasodilation, glycolytic 
enzymes such as aldolase A and phosphoglycerate kinase to increase glycolysis, 
glucose transporter-1 (GLUT-1) to increase glucose uptake, pyruvate 
dehydrogenase kinase (PDK1) to inhibit mitochondrial respiration and cyclin-
dependent kinase inhibitors p21 and p27 to decrease cell proliferation. When 
cells lack a functional pVHL, long term cellular adaption is achieved through 
the relief of hypoxia by stimulating angiogenesis. These pro-angiogenic genes 
are mainly regulated by HIF, which include vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF), angiopoietin-1, angiopoietin-
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2, basic fibroblast growth factor (bFGF), Tie2 and monocyte chemoattractant 
protein–1 (MCP-1). 
 
1.1.5 Molecular targeted therapy for RCC 
It is recognised that the pVHL/HIF pathway plays a critical role in the 
pathogenesis of clear cell RCC80-82. This is consistent with the fact that biallelic 
VHL mutation or inactivation by methylation can be found in most cases (~75%) 
of sporadic clear cell RCC76, 77. Thus, multiple strategies are being investigated 
to target the various aspects of the pVHL/HIF pathway and their associated 
pathways/molecules.  
One approach that has proven to be highly effective is the deployment of agents 
that specifically target angiogenesis. RCC is characterised by highly vascular 
features in both the primary and metastatic sites of the disease. This is due to 
the persistent up-regulation of pro-angiogenic factors, VEGF83 and PDGF, 
which are the main driving forces in renal tumour angiogenesis. The molecular 
relationship between VHL, VEGF and hypoxia signaling in the biology of clear 
cell RCC has established the angiogenesis pathway as a therapeutic treatment 
strategy of choice and indeed the introduction of agents that specifically target 
angiogenesis has revolutionised the treatment strategies and effectively changed 
the management of patients with RCC. Significant benefits have accrued to 
patients in terms of stabilisation of disease, improvement in quality of life and 
overall duration of survival46, 84-86. Currently, there are six molecular targeted 
therapeutic agents that have been approved by the US Food and Drug 







Figure 1.3. Selected current targeted therapies in metastatic RCC. 













IFN-α 11 vs 5 47 vs 12 26.4 vs 21.8 




Sorafenib Clear cell mRCC; PD after 1 systemic 
therapy Placebo 5.5 vs 2.8 ~10 vs 2
17.8 vs 
15.2 
Skin rash, hand-foot 
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proteinuria, dry skin, 
infections, 
neutropenia, anemia 
Temsirolimus Poor prognosis mRCC; no prior systemic 
therapy IFN-α 
3.8 vs 1.9 
(T); 3.7 





4.8 (T + 
IFN-α)
10.9 vs 7.3 
(T); 8.4 vs 









Everolimus Clear cell mRCC; prior VEGFR TKI 



















Placebo 9.2 vs 4.2 30 vs 3 Not reached
Nausea, vomiting, 
diarrhea, hand-foot 
syndrome, hair or skin 
color changes, joint or 
muscle pain, fatigue 
Abbreviations: IFN-α, interferon-α; mRCC, metastatic renal cell carcinoma; ORR, objective response rate; OS, 
overal survival; PD,progressive disease; PFS, progression-free survival; T, temsirolimus; TKI, tyrosine kinase 
inhibitor; VEGFR, vascular endothelial growth factor; C, Comparator. 
 
 
Table 1.5. A summary of approved targeted therapies in pivotal phase III 




They are (i) tyrosine kinase inhibitors (TKIs); sunitinib, sorafenib and 
pazopanib, which inhibit the tyrosine kinase domain activation of vascular 
endothelial growth factor receptor (VEGFR) and platelet-derived growth factor 
receptor (PDGFR), (ii) mammalian target of rapamycin (mTOR) inhibitors 
temsirolimus and everolimus, and (iii) a monoclonal VEGF antibody, 
bevacizumab in combination with IFN-α (Figure 1.3). A summary of the clinical 
efficacies of these approved therapeutic agents is listed in Table 1.5. 
 
1.1.6 Disadvantages and limitations of current targeted therapy 
In spite of the therapeutic benefits of molecular targeting anti-angiogenic agents, 
approximately 60% of the patients do not respond to these drugs. Targeted 
therapies are expected to be less toxic than traditional chemotherapy due to the 
higher dependence of cancer cells on specific targets as compared to normal 
cells. Yet, they induce significant adverse reactions that require dose reduction, 
thus diminishing its clinical efficacy89, 90. For example, up to 35% of patients 
on sorafenib required dose reduction and of these, half ceased treatment due to 
adverse effects. In fact, Asians are noted to be more prone to developing adverse 
effects and thus have higher discontinuation rates91.  
Another limitation of molecular targeted therapy is that more than one active 
oncogenic pathway is commonly involved in oncogenesis. The use of a single 
therapeutic class will invariably promote tumour cell adaption and 
compensation by the release of higher concentrations of the targeted growth 
factors. Alternatively, expression of growth factors that are not targeted by the 
agent may be upregulated and confer resistance to tumour cells. Support for 
these views come from clinical observations that treatment responses were often 
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not sustained (less than 10-12 months)92 and usually accompanied by the clonal 
expansion of resistant tumour cells.  
In view of the inherent disadvantages and limitations of current molecular 
mono-targeted therapy, sequential therapy using various targeted agents is 
becoming the standard of care. The success of combination therapies would 
require a better understanding of the biology of the disease development, and 
mechanisms of action of the agents to be used in the combination. Combinations 
that are additive or synergistic will ensure a more complete blockade of aberrant 
molecules and their associated signaling pathways. Furthermore, combination 
therapy can circumvent or delay the development of resistance. In addition to 
identifying molecular targets for RCC and agents that can act on these targets, 
another pressing need is to identify a molecular biomarker that is able to predict 
treatment outcomes in RCC. At present, conventional clinical and pathologic 
indices provide reasonable assessments of patient response and disease 
progression6 but are insufficient in patient management given the heterogeneous 
behaviour of RCC. As such, there is a critical need to identify potential 
molecular biomarkers which can be used to detect disease recurrence after 
treatment and enhance the accuracy of existing prognostic indices. Furthermore, 
molecular biomarkers will complement conventional clinical and pathological 
indices used in monitoring disease progression. Thus, the search for a suitable 
therapeutic target and an ideal molecular biomarker predictive of treatment 
responses in RCC are critical endpoints. Hypothetically, a patient-derived RCC 
xenograft model can be used for preclinical drug testing to identify molecular 
biomarkers capable of predicting treatment response to the new therapeutics. 
This approach will be less costly and time-consuming.   
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1.2 Apoptosis  
Apoptosis is a form of programmed cell death and was recognised as a normal 
biological phenomenon in animal tissues by histologists in the nineteenth 
century. It was not until 1972 that apoptosis was linked to a unique cell-death 
process distinct from the unordered demise of cells by necrosis (Table 1.6). Up 
till then, apoptosis was investigated in an artificial cell culture environment and 
in the absence of engulfment by phagocytic cells, the degradation of the 
remnants of apoptotic cells closely resembled that of necrosis. Since its 
discovery, apoptosis has emerged as one of the most extensively-studied 
subjects among cell biologists. Apoptosis is an evolutionarily conserved cellular 
suicide program characterized by distinct biochemical pathways. It is a means 
by which an organism eliminates unnecessary or unhealthy cells in the course 
of its development or following cellular stress such as DNA damage93. In 
contrast, cancer cells are less sensitive to similar stresses and readily violate cell 
cycle regulation checkpoints49. Once these malignant cells acquire resistance to 
apoptosis, cells continue to proliferate and in the process accumulate many 
genetic abnormalities. Evasion of apoptosis is a key process in cancer 
development and progression. Notably, current anti-cancer therapeutic 
strategies such as chemotherapy, radiotherapy, immunotherapy, molecular 
targeted therapy, share the same primary objective of eliminating malignant 
cells by the induction of apoptosis. It is important to acquire an in-depth 
understanding of the apoptotic pathway as it not only provides insight into 
cancer pathogenesis and therapy resistance but also reveal useful indicators on 






Provoking stimuli   
  Programmed tissue remodeling Metabolic stresses
 Maintenance of cell pool size Absence of nutrients 
 Genomic damage Changes in pH, temperature 
 Metabolic  derangement Hypoxia, anoxia
 Hypoxia  
 Imbalances in signaling pathways  
     
Morphological 
changes   
Affected cells Individual cells Groups of cells
Cell membrane Blebbing Loss of integrity
Cell volume Decreased Increased
Chromatin Condensed Fragmented
Lysosomes Unaffected Abnormal
Mitochondria Leaky due to pore formation involving Bcl-2 family Swell
Inflammatory response None Marked
Cell fate Apoptotic bodies consumed by neighbouring cells Lysis
     
Molecular changes    
Gene activity Required for program Not needed
Chromosomal DNA Cleaved at specific sites Random cleavage
Intracellular calcium Increased Unaffected
Ion pumps Continue to function Lost
 
 





1.2.1 Biochemical features 
During apoptosis, three specific biochemical changes are observed. These are 
the activation of a set of enzymes belonging to the cysteine protease family 
known as caspases, breakdown of DNA and proteins and recognition of the 
physical changes of the plasma membrane by phagocytic cells95.  
The activation of caspases is a distinct feature of apoptosis. All known caspases 
(cysteine-aspartic proteases) selectively cleave a regulated set of target proteins 
at Asp-Xxx bonds (always after an aspartate residue) and are regarded as the 
central executioners of the apoptotic pathway96. Caspases cleave key cellular 
components that are required for normal cellular function. For instance, the 
condensation of the chromatin and nuclear budding is a result of specific 
cleavage of nuclear lamins97, 98. A  decreased in cell volume is probably caused 
by cleavage of cytoskeletal proteins99 and membrane blebbing due to cleavage 
of PAK2100. Caspases also activate degradative enzymes such as DNases which 
cleave DNA in the nucleus although degradation of DNA is also observed in 
necrotic cells. To promote removal by macrophages, apoptotic cells undergo 
plasma membrane changes that trigger phagocytosis. One such change is the 
translocation of phosphatidylserine residues from the inner to outer membrane 
where they are recognized and cleared by macrophages.   
There are two types of caspases; initiator and effector caspases. Both are 
synthesized initially as inactive pro-caspases containing a prodomain and their 
rapid activation is regulated via post-translation modification. In response to an 
apoptotic stimuli, regulated proteins interact through the prodomain and activate 
the initiator caspases (caspase -2, -8, -9 and -10), which will in turn cleave the 
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inactive forms of effector caspases (caspase -3, -6 and -7), thereby leading to 
their activation. These effector caspases then cleave other protein substrates to 
trigger apoptosis. Besides the apoptotic caspases, there is another class of 
caspases (caspase -1, -4, -5, -13 and -14) which are mainly involved in the 
processing of cytokines during inflammatory process101-103. They have limited 
roles in apoptosis. 
 
1.2.2 Mechanisms 
Caspases are activated by three initiation pathways. Two of them are commonly 
known and are referred to as extrinsic (death receptor) and intrinsic 
(mitochondrial) pathways of apoptosis. Both pathways converge onto a 
common route leading to apoptosis. The intrinsic endoplasmic reticulum 
pathway is the third initiation pathway but is less known.    
 
1.2.2.1 The extrinsic death receptor pathway 
The extrinsic death receptor pathway involves transmembrane death receptors 
that are members of the tumour necrosis factor (TNF) receptor gene superfamily 
and their respective death ligands. Members of this family are defined by a 
common extracellular domain capable of binding to extrinsic death ligands and 
a cytoplasmic death domain responsible for transmitting the death signal from 
the cell surface to the intracellular signaling pathways104. Two of the most well 
characterized death receptors are type 1 TNF receptor (TNFR1) and Fas (CD95) 







Figure 1.4. The extrinsic death receptor pathway. Five families of “death 
receptors” proteins are displayed on the surface of various types of 
mammalian cells. The cytoplasmic tails of these receptors act via FADD 
protein to assemble DISC, and proceed to convert procaspases 8 to active 
caspases 8. These then converged on the caspase cascade that is activated 




Upon ligand binding, adaptor proteins such as TNF receptor-associated death 
domain (TRADD) and Fas-associated death domain (FADD) are recruited to 
the cytoplasmic death domains to form the death-inducing signalling complex 
(DISC)106. DISC activates pro-caspase 8 to caspase 8 which subsequently 
cleaves downstream executioner caspases to initiate apoptosis (Figure 1.4). 
 
1.2.2.2 The intrinsic mitochondrial pathway 
The intrinsic signaling mitochondrial pathway involves non-receptor–mediated 
intracellular signals such as irreparable genetic damage, oxidative stress and 
hypoxia within the cell. The regulation of this pathway is controlled by two 
main groups of the Bcl-2 family of proteins, namely the anti-apoptotic proteins 
(Bcl-2, Bcl-xl, Bcl-w and Mcl-1) and pro-apoptotic proteins (Bax, Bak, Bid, 
Bad, Bcl-xs, Bim, Bik and Hrk)107. In response to an apoptotic stimulus, pro-
apoptotic members of the Bcl-2 family increase the permeability of the outer 
mitochondrial membrane, resulting in the release of cytochrome c into the 
cytoplasm108. In contrast, anti-apoptotic proteins regulate apoptosis by blocking 
the mitochondrial release of cytochrome c. On its release, cytochrome c forms 
a complex with Apaf-1 and caspase 9 to form an apoptosome, which in turn 
promotes the activation of caspase 3109, 110 (Figure 1.5). Thus, the initiation of 








Figure 1.5. The intrinsic mitochondrial pathway. The outer mitochondrial 
membrane creates a critical gate that determines the life or death of the cell. 
Pro- or anti- apoptotic signals work to open or close the channels on the 
outer membrane. Cytochrome c aggregates with Apaf-1 to form the seven-
spoked apoptosome. The latter attracts and convert procaspase 9 to active 
caspase 9 which in turn cleaves and activate pro-caspase 3, 6, 7. These 
executioner caspases cleave various “death substrates”, whose products 
create the apoptotic phenotype. IAPs inactivate caspases. Smac/DIABLO 




Upon disruption of the outer mitochondrial membrane, other apoptotic factors 
normally found in the mitochondrial intermembrane space are also released into 
the cytoplasm. These include second mitochondria-derived activator of caspase 
(Smac), apoptosis inducing factor (AIF), Omi/high temperature requirement 
protein A (HtrA2) and direct IAP binding protein with low pI (DIABLO). 
Smac/DIABLO or Omi/HtrA2 bind to Inhibitor of Apoptosis (IAP) proteins and 
disrupt the interaction between IAPs and caspase -3, -7, -9.   
 
1.2.2.3 The execution phase 
Both extrinsic and intrinsic pathways converge onto caspase 3. Caspase 3 
cleaves the inhibitor of the caspase-activated DNases to enable nuclear 
apoptosis to proceed. Cleavage of various “death substrates” contributes to the 
classical morphological changes observed in apoptosis. 
 
1.2.2.4 The intrinsic endoplasmic reticulum pathway 
In response to cellular stresses such as free radicals, hypoxia or glucose 
starvation, the endoplasmic reticulum unfolds proteins and reduces protein 
synthesis in the cell. The activation of pro-caspase 12 has been reported to 
involve calpain-dependent removal of the prodomain, self-cleavage between the 
p20 and p10 subunits at amino acid D318, cleavage by caspase 7 or dissociation 
from the TNF receptor associated factor 2 (TRAF2)112-114. Activated caspase 12 
can cleave procaspase-9 and subsequent activation of caspase-3, leading to the 




1.2.3 Dysregulation of apoptosis 
Dysregulation of the apoptotic process play a vital role in tumorigenesis. When 
potentially malignant cells are allowed to survive over extended periods, they 
accumulate genetic alterations that predispose the cells towards malignancy. In 
general, there several strategies that a malignant cell can adopt to evade 
apoptosis and the mechanisms can be broadly categorize into: 1) imbalance 
between anti-apoptotic and pro-apoptotic proteins, 2) reduced caspase activity, 
3) impaired death receptor signaling and 4) deregulated activity of other survival 
pathways 
 
1) Imbalance between anti-apoptotic and pro-apoptotic proteins 
The Bcl-2 family is a group of evolutionally related proteins that function as 
apoptosis regulators. They comprised anti-apoptotic and pro-apoptotic proteins 
and they govern the permeabilization of the mitochondrial outer membrane117. 
Members of the Bcl-2 family share one or more of the four characteristic Bcl-2 
homology (BH) domains which are crucial for their functions. They are 
classified into two groups according to their functions (Figure 1.6A). 
The first group (Bcl-2, Bcl-xl, A1, Bcl-w, Mcl-1) contains all four BH domains 
and they function as anti-apoptotic (pro-survival) proteins by blocking the 
apoptotic stimuli. The second group functions as pro-apoptotic proteins and are 
further subdivided to two classes. The Bax family (Bax, Bak, Bok) has several 
domains that are homologous to the first group, while the “BH3-only” family 










Figure 1.6 Bcl-2 and related proteins. A) Members of the Bcl-2 family of 
proteins are involved in both preventing and promoting apoptosis. They 
share one or more of the four Bcl-2 homology (BH) domains. Several also 
have transmembrane (TM) domain for membrane anchoring. B) Each 
member has its own set of antagonistic partners. If left unopposed, pro-
apoptotic proteins will promote apoptosis by opening the mitochondrial 
membrane channel. Adapted from Weinberg, 2014105 . 
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Members of the Bax family usually reside at the outer mitochondrial membrane 
or cytosol in their inactive states, whereas inactive members of the BH3-only 
family are found predominantly in the cytosol. In times of cellular stress, both 
classes are activated and/or translocated to the mitochondria to initiate 
apoptosis118. The sensitivity of cells to apoptosis depends on the balance of pro- 
and anti-apoptotic Bcl-2 proteins. An excess of pro-apoptotic proteins will 
sensitize cells to apoptosis whereas an excess of anti-apoptotic proteins will 
cause cells to be more resistant. An imbalance of anti-apoptotic and pro-
apoptotic members of the Bcl-2 family leads to dysregulated apoptosis. 
Each member of the Bcl-2 family of proteins has its own set of antagonistic 
partners. If left unopposed, pro-apoptotic proteins will promote apoptosis by 
opening the mitochondrial membrane channel (Figure 1.6B). Several studies 
have associated the overexpression of anti-apoptotic proteins (Bcl-2, Bcl-xl) or 
underexpression of Bax with cancer119-125. 
2) Reduced caspase activity 
The inhibitor of apoptosis (IAP) gene family encodes a group of structurally 
related proteins that confer protection from death inducing stimuli. To date, 
eight human IAP proteins have been identified, namely NAIP (BIRC1), c-IAP1 
(BIRC2), c-IAP2 (BIRC3), X-linked IAP (XIAP, BIRC4), Survivin (BIRC5), 
Apollon (BRUCE, BIRC6), Livin/ML-IAP (BIRC7) and IAP-like protein 2 
(BIRC8). All IAPs contain at least one evolutionary conserved Baculovirus 
Inhibitor of Apoptosis Repeat (BIR) binding domain126-128 (Figure 1.7A). This 
motif which was first identified in the genome of the baculoviruses, is essential 







Figure 1.7 The Inhibitor of Apoptosis (IAP) family. A) Members of the 
IAP family of proteins bind and neutralises caspases. They contain at least 
one Baculovirus Inhibitor of apoptosis Repeat (BIR) binding domains. B) 
XIAP begins with BIR1 domain at the amino terminus and terminates with 
RING domain at the carboxyl terminus. The active-site substrate pockets 
of caspase 3 are shown as yellow dots. The catalytic machinery is between 
the S1 and S1’ pockets. Docking of the ‘hook’ and ‘sinker’ regions of XIAP 
inhibits caspase 3. BIR domain ensures proper alignment and stabilises the 
structure. Adapted from Obexer & Ausserlechner, 2014; Salvesen & 
Duckett, 2002128, 129. 
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IAPs act as endogenous inhibitors of caspases by keeping active caspases away 
from their substrates or by promoting their degradation130. The available 
structural information proposed that inhibition is due to an interaction between 
caspase 3 and XIAP at the region between BIR1 and BIR2 of XIAP. The active 
site of caspase 3 docks onto this domain (“sink” and “hook’) to sterically hinder 
substrate access to the caspase. The BIR domain has an important role in 
ensuring proper alignment and stabilization of the caspase-IAP structure129, 131 
(Figure 1.7B). Emerging evidence from many studies support the notion that 
aberrant expression or dysregulation of endogenous IAPs provide cancer-prone 
cells the means of bypassing apoptotic triggers and hence, to proliferate 
independently of exogenous survival factors132-140. The overexpression of IAPs 
has been associated with poor prognosis and chemo-resistance in many 
cancers110, 135, 141-143.  
Of the eight IAPs identified, survivin has attracted the most attention due to its 
differential expression in many tumours as compared to normal differentiated 
adult cells144-146. In this study, the expression of survivin in RCC will be 
investigated. 
As mentioned earlier, initiator caspases (caspase-2, -8, -9 and -10) initiates the 
apoptotic pathway, while effector caspases (caspases-3, -6 and -7) are involved 
in the breakdown of cellular components during the execution phase of 
apoptosis. Studies have shown that down-regulation of their proteolytic activity 
lead to uncontrolled cell proliferation, impairment of apoptosis and enhanced 




3) Impaired death receptor signaling 
Death receptors and their ligands play a key role in the extrinsic pathway of 
apoptosis. During tumourigenesis, cancer cells acquire a number of 
abnormalities which assist in the evasion of apoptosis. These aberrations 
include inactivation of death receptor function, reduced expression of death 
ligands or receptors and/or increased expression of decoy death receptors that 
do not possess a death domain. Several studies have indicated that these led to 
a reduction in apoptosis and the acquisition of resistance to the cytotoxicity of 
chemotherapeutic agents151-155. 
 
4) Deregulated pathways 
p53 
The p53 tumour suppressor protein functions as a transcription factor156 and has 
been described as the master guardian of the genome105. It is encoded by the 
tumour suppressor gene TP53 located at the short arm of chromosome 17 
(17p13.1) and is named after its apparent molecular weight of 53kDa when 
analysed by SDS-PAGE157. Since its discovery, many studies have described its 
involvement in cell cycle regulation and apoptosis. The cytostatic and pro-
apoptotic capabilities of p53 play an important role in maintaining genomic 
stability, inhibiting tumour development and blocking angiogenesis158-160. It can 
activate the DNA damage response pathway when it detects genomic damage, 
arrest growth by suspending the cell cycle until DNA repair is completed and 
initiate apoptosis if the damage proves to be irreparable. The International 
Cancer Genome Consortium has established that the alleles of p53 are 
frequently mutated or inactivated in more than 50% of human tumours, with a 
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frequency of 10-15% in kidney cancer. The activity of p53 may also be 
compromised when the key molecules that lie upstream or downstream of p53 
in the p53 inter-connecting pathways are disabled, such as inactivation of 
positive regulators or over-activation of negative regulators161, 162. These affect 
the expression of p53 target genes and their protein activity which includes p53 
antagonists (MDM2 induces p53 ubiquitination), growth arrest genes (p21Cip1 
inhibits cyclin dependent kinases), DNA repair genes (p53R2 biosynthesized 
DNA precursors), regulators of apoptosis (Bax, Puma, Noxa, Apaf-1) and anti-
angiogenic proteins (thrombospondin is an antagonist of angiogenesis). 
Examples are given in parentheses. In the absence of a functional p53 response 
system, cancer cells are better able to tolerate hypoxia, extensive DNA damage 
and profound dysregulation of growth control. Many studies have associated the 
defects in p53 activity with the progression of cancer and responsiveness to 
therapy163-167. 
 
The NF-κB family 
NF-kappaB (NF-κB) is a family of five structurally-related and highly regulated 
inducible transcription factors. All share in common a highly conserved DNA-
binding/dimerization domain called the Rel homology domain (RHD) at their 
N-termini. RelA (p65), RelB, and c-Rel contain a transactivation domain (TAD) 
at their C-termini. TAD is important as it is required for interacting with the 
basal transcription complex including many co-activators of transcription. p105 
and p100 are synthesized as large precursors and undergo selective degradation 
of their ankyrin repeats at the C-terminal region to generate mature NF-κB 
subunits, p50 and p52 respectively. p50 and p52 lack TADs and have been 
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proposed as transcriptional repressors when bound to κB elements as 
homodimers168, 169. In mammalian cells, NF-κB usually forms a heterodimer, 
with p65 (Rel A) and p50 (NF-κB1) being the most common and best 
characterised, in particular p65 NF-κB which contain a TAD domain170-172. 
Different NF-κB complexes have different DNA-binding specificities which in 
turn regulate the binding to various κB elements within each gene promoters 
and enhancers. Because of the lack of TAD, p50 is proposed to have a role in 
DNA binding and its phosphorylation has been cited as an essential event for 
NF-κB-DNA binding to occur169. 
The activation of the canonical NF-κB pathway is stimulated by a broad range 
of stimuli and relies predominantly on p65/p50 NF-κB heterodimer, whereas 
the non-canonical NF-κB pathway is triggered by specific TNF receptor family 
members and relies on the inducible processing of p100 instead of degradation 
of IκBα to activate the RelB/p52 NF-κB complex. Both pathways has been 
shown to regulate many genes that facilitate inflammatory responses, cell 
survival and apoptosis173-179. These include pro-survival genes (IAPs, TRAF, 
Bcl-xl), inflammatory genes (VEGF), chemokines (IL-8) and cell cycle 
regulatory genes (cyclin D1)173, 174. A number of studies have also demonstrated 
the regulation of the pro-survival IAP protein survivin by the NF-κB signaling 
pathway180-183. 
The role of NF-κB signaling in the mode of action of YM155, the drug that is 
investigated in this thesis will be expounded in Chapter 5.  A short review of 
the signaling pathway is provided in the following paragraphs by way of an 






Figure 1.8 The canonical NF-κB signaling pathway. The NF-κB family of 
transcription factors function as heterodimers and are sequestered in the 
cytoplasm by IκB. Following tumour necrosis factor receptor (TNFR) 
activation, TNFR-associated factors (TRAFs) are recruited to the receptor. 
TRAFs are ubiquitin ligases which self-ubiquitinates to facilitate the 
activation of IKK. IKK rapidly phosphorylates IκBα and targets it for 
proteasomal degradation, thereby liberating p65/p50 NF-κB heterodimer. 
NF-κB translocates to the nucleus where it activates a broad constituency 





Figure 1.8 provides an annotated scheme of the NF-κB canonical pathway. NF-
κB is sequestered in its inactive state to the cytosol by the polypeptide IκB 
(Inhibitor of NF-κB). In response to a diverse array of signals, IκBα is 
phosphorylated and thereby tagged for rapid destruction. As a result, NF-κB is 
liberated and migrates to the nucleus where it activates the expression of a large 
number of genes (up to 500, including itself). The kinase (IκB kinase or IKK) 
that tags IκBα for destruction is stimulated by signals initiated by TNF-α, 
interleukin-1β, lipopolysaccharides, reactive oxygen species (ROS), anti-cancer 
drugs and gamma-radiation. IKK is activated when TNF-α interacts with its 
receptor TNFR (TNF-α receptor), leading to the activation of an atypical protein 
kinase C (aPKC) which is in complex with the TNF receptor associated factor 
(TRAF) family of proteins. The removal of the K63-linked polyubiquitin chain 
from TRAF2 by cylindromatosis (CYLD) leads to the inhibition of the IKK 
complex. Alternatively, activation of the IKK complex may arise from the loss 
of biallelic VHL and accumulation of HIF1-α, which is a common event in clear 
cell RCC. HIF1-α accumulation induces expression of TNF-α, with subsequent 
activation of the EGFR/PI3K/AKT/IKK/NF-κB signaling cascade184. 
The deregulation of the NF-κB signaling cascade is causally linked to several 
human diseases including cancer171, 185-188. In the last decade, there is mounting 
evidence to support a role for NF-κB in renal oncogenesis. Several independent 
investigators have observed an increase in NF-κB expression and activity in 
human RCC samples189-193. Constitutive activation of NF-κB increases the 
expression of many downstream oncogenic targets and subsequent RCC 
progression. Thus, agents targeting NF-κB may have therapeutic potential. 
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p53 and NF-κB are transcription factors that interact and play key roles in the 
regulation of cell death and cell viability. Both factors functionally regulate each 
other and are co-ordinately induced in response to cellular stress, such as DNA 
damage. Extensive crosstalk between the two signal transduction pathways 
allow low levels of DNA damage to induce cell cycle arrest and DNA repair, 
whereas extensive levels of DNA damage will lead to apoptosis. It was reported 
that p65 NF-κB transactivation is regulated by the CKI p21 whereby NF-κB 
activation occurs simultaneously upon the induction of p21194. p21 is one of the 
principal target genes of p53 and this induction of p21 may have stimulated the 
activity of NF-κB. Since activation of p53 and inhibition of NF-κB promotes 
apoptosis, agents that simultaneously target both pathways could be 
therapeutically exploited as anticancer agents195. Many aspects pertaining to the 
intricate interplay between p53 and NF-κB remain to be elucidated. Tengaonkar 
and co-workers reported a decrease in p53 activity upon NF-κB activation196 
whereas others noted that the inhibition or loss of NF-κB activity abrogated p53-
induced apoptosis197. Another report maintained that the pro-apoptotic function 
of NF-κB involved stabilization of p53198.   
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1.2.4 Targeting apoptosis in cancer treatment 
Functional defects in the apoptotic pathways can be exploited as therapeutic 
targets for cancer.  Novel therapeutics may reactivate the apoptotic signaling 
pathway and eradicate malignant cells that rely on the defective apoptotic 
machinery to stay alive. Over the past decade, many studies have shed light into 
the potential of targeting apoptosis as a therapeutic approach for cancer 
treatment199-204. Reactivation of the apoptotic pathway is accompanied by 
sensitivity of resistant cancer cells to conventional chemo- and radio-therapy, 
raising hopes for the better therapeutic outcome for patients with advanced 
cancers. Some of these drugs and treatment strategies are highlighted in the 
Table 1.7. 
 
1.2.4.1 Targeting the Bcl-2 family 
Therapeutic agents targeting the Bcl-2 family aim at silencing or inhibiting the 
expression/activity of the anti-apoptotic members. These inhibitory agents 
include small molecule inhibitors that exert their effect on the gene or protein 
expression205, 206 and those that interfere directly or indirectly with protein 
activities207, 208. A subset of these small molecules belongs to a class of drugs 
known as the BH3 mimetics, which mimic the binding of the BH3-only proteins 
to the hydrophobic groove of anti-apoptotic proteins of the Bcl-2 family209. 
Silencing of the anti-apoptotic genes has led to greater sensitivity to 







Target Agent Treatment Strategy 
Bcl-2 family   
  Oblimersen sodium Antisense
  Sodium butyrate, depsipeptide, fenretinide, flavopiridol Small molecule inhibitor -                Affect Bcl-2 gene/protein expression
  Gossypol, Obatoclax and HA14-1 Small molecule inhibitor -                Interfere directly or indirectly with 
Bcl-2 protein activities 
Bcl-2, Bcl-xL and Bcl-W ABT-737 BH3 mimetics
Mcl-1 ATF4, ATF3 and NOXA BH3 mimetics
Bcl-2 Bcl-2 specific siRNA RNA interference
Target Agent Treatment Strategy 
p53   
  Retroviral vector with wild-type p53 gene Gene therapy
  Oncolytic adenovirus (ONYX-015) Gene therapy -                                   Replicate and lyse tumour cells 
deficient in p53
  Phikan083 Stabilizing agent -                             Preferentially binds mutated 
(Y220C) p53 over wild-type p53  
  CP-31398 Stabilizing agent -                             Stabilizes active conformation of 
p53 and promotes p53 activity 
  Nutlins Small molecule MDM2 antagonist - Inhibit p53-MDM2 interaction, 
stabilise p53 
  MI-219  Small molecule MDM2 antagonist - Inhibit p53-MDM2 interaction, 
stabilise p53 
  Tenovins Small molecule inhibitors of sirtuins
  Wild-type p53 vaccine Immunotherapy
  p53 peptide pulsed dendritic cells Immunotherapy
 
 






Target Agent Treatment Strategy 
IAPs  
XIAP, survivin XIAP specific siRNAs, survivin specific siRNAs RNA interference 
XIAP, survivin 




XIAP Xantags, TWX006, TWX024 Caspase-3 de-repressor 
XIAP Embelin and derivatives Small molecule inhibitors 
XIAP, cIAP1, cIAP2,  
livin 
AEG40826/HGS1029, LBW242, 
BV6, GT-T, SM-164, SM-122 Smac mimetics 
cIAP1 Bestatin methyl ester, Bestatin-actinonin hybrid, HAB-2(30b) cIAP1 degradation promoter 
Survivin YM155, Terameprocol Transcriptional repressor 
Survivin Shepherdin Hsp90 antagonist 
Survivin AICAR Hsp90 antagonist, AMPK agonist 
Survivin Peptides, autologous cytolytic T-cells (CTLs) Immunotherapy 
Target Agent Treatment Strategy 
Other regulators  
Caspases Apoptin, engineered small-molecule- activated protease Increase caspase 3 activity 
Caspases Active caspases Gene therapy 
Death receptors TRAIL Agonistic antibody 
NF-κB Bortezomib Proteasome inhibitor 
 
 





1.2.4.2 Targeting cell cycle regulator p53 
The objective of p53-based anti-cancer treatment strategies is to trigger the 
elimination of malignant cells by inducing apoptosis. This can be achieved via 
gene therapy, drug therapy and immunotherapy. In p53 gene therapy, wild-type 
p53 gene can be introduced into the tumour cells using a retroviral vector or 
p53-deficient cells can be eliminated using engineered viruses213-215. In p53 
drug therapy, small molecules can restore p53 wild-type functions in p53 mutant 
cells, stabilize p53 by disrupting the MDM2-p53 interaction or function as p53 
activators216-218. In p53 immunotherapy, clinical trials with viral-, dendritic cell-, 
short peptide- and long peptide- based vaccines have reported a stabilisation of 
the disease219, 220. 
 
1.2.4.3 Targeting other apoptosis regulators 
These include activators of caspases221, gene transfer of active caspases222, 223, 
agonistic antibodies (eg. TRAIL)224 that direct against the death receptors (eg. 
DR4) and inhibitors of NF-κB signaling pathway (eg. bortezomib). 
 
1.2.4.4 Targeting IAPs 
As IAPs play a fundamental role in the regulation of apoptosis, considerable 
interest has focussed on its potential as therapeutic targets in cancer. IAPs may 
be targeted by antisense oligonucleotides, short interfering RNA (siRNA) 
molecules and small molecule antagonists225, 226. In line with the thrust of this 
thesis which is centred on a small molecule survivin suppressor (YM155), the 
following paragraph will focus on methods at suppressing survivin activity. 
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In spite of the potential of survivin as a cancer target, a few survivin antagonists 
have been reported. To date, only three compounds have been investigated as 
anti-cancer agents. These include YM155227, 228, terameprocol229 which directly 
target survivin by inhibiting its promoter activity and a peptidomimetic, 
shepherdin which destabilises the survivin-Hsp90 complex230. YM155 is the 
most widely studied survivin suppressor and it will be reviewed in Section 1.3.6. 
Survivin antisense oligonucleotides231-233 and siRNA234-236 have been 
investigated but effective targeted delivery in vivo remains challenging. Gene 
therapy by using plasmid/viral vectors to deliver dominant-negative survivin 
mutants237, 238 or upregulating the expression of cytotoxic genes with a survivin 
gene promoter239 has been considered. Survivin immunotherapy exploits the 
differential expression of survivin in cancer cells as compared to normal 







1.3 Survivin and YM155 
1.3.1 Structure of survivin 
Survivin, discovered in 1997, is a 16.5kDa protein which in humans is encoded 
by the BIRC5 gene located on chromosome 17q25 (Figure 1.9). Structurally, it 
is the smallest member of the IAP family of proteins and contains a single 
baculovirus IAP repeat (BIR) domain at the N-terminal and an extended –
COOH alpha-helical coiled region at the C-terminal in a dimeric arrangement144. 
A single copy of the survivin gene gives rise to three different isoforms of the 
protein due to three alternatively spliced survivin transcripts240. These include 
wild-type survivin (142 amino acids), survivin-2B (165 amino acids) and 
survivin-deltaEx3 (137 amino acids). The survivin-2B transcript and survivin-
deltaEx3 are generated by insertion of an alternative exon 2 and removal of exon 
3 respectively. The splicing events lead to variations in the corresponding 
protein structure and hence alter their ability to inhibit apoptosis. Retention of 
the alternative exon 2 in survivin-2B interrupts the essential BIR domain and 
results in markedly reduced anti-apoptotic activity of this isoform. In the case 
of survivin-deltaEx3, removal of exon 3 also interrupts the BIR domain but anti-
apoptotic activity of this isoform is conserved240. Loss of exon 3 also leads to a 
frame shift in exon 4 and generates a unique COOH-terminal that enables 
survivin-deltaEx3 to reside predominantly in the nucleus, unlike survivin and 
survivin-2B which are primarily cytoplasmic. The differential subcellular 













1.3.2 Regulation of survivin 
Many upstream factors control the expression of survivin242. One of them is the 
cell cycle regulator p53, which acts directly by repressing the transcription of 
the survivin gene243-245, or indirectly by antagonising the activation of 
transcription factor specificity protein 1 (Sp1) on the survivin promoter246. 
Under conditions of cellular stress, cross talk between p53 and NF-κB facilitates 
repair and regulates mitosis via the induction of survivin. However, in the event 
of persistent damage, p53 initiates apoptosis to prevent oncogenic 
transformation and chemoresistance245, 247, 248.  
Other factors include signal transducer and activator of transcription-3 (STAT-
3)249 and nuclear β-catenin (positively regulates survivin), T cell factor 4 (TCF4) 
in WNT-induced signaling (positively regulates survivin)250, and activation of 
forkhead transcription factor FOXO3 by elevated intracellular reactive oxygen 
species (ROS) (negatively regulates survivin)251. In endothelial cells, vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (FGF) and 
angiopoietin-1 have been shown to upregulate survivin during angiogenesis, 
thereby increasing cellular integrity and protecting endothelial cells from 
apoptosis inducing stimuli252, 253. Epigenetic regulators, such as DNA histone 
methyltransferase G9a, methyltransferase-1 (DNMT1), HDAC1 and 
heterochromatin protein-1 (HP1), have been shown to inhibit the expression of 
the survivin gene254-257. 
The expression of survivin is affected by cell cycle progression258. Survivin 
increases during G1 and peaks during the G2-M phase. These changes are 
controlled largely, but not exclusively, at the gene transcription level and 
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involve the cell-cycle-dependent element/cell-cycle gene homology region 
(CDE/CHR) boxes located at the survivin promoter259-261. Post-translational 
modifications play an essential role in regulating the levels of survivin. Mitotic 
phosphorylation at threonine 34 of survivin by cyclin dependent kinase 1 
(CDK1)-cyclin B1 increases survivin stability in the G2-M phase of the cell 
cycle and promotes progression of mitosis262. Thr34 phosphorylation stabilises 
the interaction between survivin and its bound caspase, enabling progression of 
the cell cycle. Failure to phosphorylate Thr34 leads to subsequent caspase 9-
dependent apoptosis during cell division263. Survivin is a relatively short-lived 
protein (T1/2: 30 min). XIAP associated factor (XAF1) targets survivin and 
promotes ubiquitin-dependent proteasomal degradation by activating the 
ubiquitin ligase activity of XIAP264, 265.  
 
1.3.3 The role of survivin in normal tissue and development 
In normal tissue and development, there are two main established functions of 
survivin, namely regulation of cell division and inhibition of apoptosis.  
The synthesis and degradation of survivin in normal tissues are tightly 
controlled. Upon expression at mitosis, survivin functions at the metaphase and 
anaphase and its localisation to different components of the mitotic apparatus 
reflects its importance in mitotic regulation. There are two main subcellular 
pools that have been proposed as regulators of spindle formation. The first pool 
consists of a direct association between survivin and polymerised tubulin. It 
regulates the microtubule dynamics through the involvement of centrosomes, 
microtubules of metaphase and anaphase spindle and remnants of the mitotic 
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apparatus–mid bodies266, 267. The second pool comprised up to ~20% of the total 
cellular survivin and is localised to the kinetochores of metaphase 
chromosomes268. In this pool, survivin functions as a subunit of the 
chromosome passenger complex, which mediates proper chromosome 
segregation and cytokinesis by forming a complex with regulators of 
cytokinesis such as Aurora B kinase, INCENP and Borealin/Dasra269-273. To 
ensure proper alignment of chromosomal passenger proteins to kinetochores 
and stabilisation of microtubules, the expression of these two pools of 
microtubule- and kinetochore-associated survivin are differentially regulated 
with distinct patterns of phosphorylation as they progress through different 
phases of the cell cycle268. 
Inhibition of apoptotic cell death has been associated with the overexpression 
of survivin144, 244, 274-277 and increased apoptosis has been observed in the use of 
survivin molecular antagonists such as siRNA, antisense, dominant negative 
mutants, small molecule inhibitors or ribozymes278-282.  
The question as to how survivin inhibits apoptosis has been a subject of 
controversy129, 283. Survivin was initially thought to bind and promote 
degradation of active caspases, like other members of the IAP family284. Yet, 
despite several reports of the physical proximity between survivin and 
caspases285, 286, a physiologically relevant inhibition of caspase activity in vitro 
could not be demonstrated287-289. This is largely due to the fact that survivin 
lacks the caspase binding ‘hook and sinker’ regions found in other IAPs. Instead, 
there is accumulating evidence to show that survivin may have a more selective 
role in blocking mitochondrial-dependent apoptosis compared to other IAPs. 
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Some of these selective antagonistic mechanisms are highlighted here. Survivin 
associates with a co-factor (hepatitis B X-interacting protein) and inhibits 
initiator caspase-9 but not executioner caspases-3 and -7263, 290. Its association 
with Smac/DIABLO also helps to increase the availability of other IAPs to 
inhibit caspase activation291. In addition, synergistic inhibition of caspase 9 
activation was observed when survivin associates with XIAP via their 
conserved BIR domain to increase the stability of XIAP292.  
During embryonic development, survivin is highly expressed and it is essential 
for normal tissue homeostasis and differentiation293. This gene is quiescent in 
majority of the terminally differentiated cells and its expression was first 
detected in a restricted number of normal adult tissues such as the thymus, 
placenta, CD34+ bone marrow stem cells, basal colonic epithelium and gastric 
mucosa144, 294-296. Subsequently, more sensitive methods revealed that survivin 
is expressed in many adult tissues, albeit at levels lower than cancer cells. 
 
1.3.4 The role of survivin in cancer 
Overexpression of survivin is associated with tumourigenesis and widely held 
as a poor prognosis in many types of cancers297-299. The role of survivin in 
cancer has attracted considerable attention from the scientific community for 
several reasons. First, genome wide studies have confirmed that survivin is 
differentially expressed in most human solid tumours as opposed to 
differentiated normal tissues284 which may imply that alterations in survivin 
gene regulation occur during tumourigenesis144. The two alternatively spliced 
isoforms of survivin which were postulated to play different roles in the 
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regulation of apoptosis, have also been reported to be differentially expressed 
in tumours, with the loss of survivin-2B expression in the later stage of cancer 
development145, 300.  
Second, survivin counteracts the pro-apoptotic stimulus and provides tumour 
cells with a selective growth advantage to proceed through the cell division. 
Survivin is associated with more aggressive disease, increased tumour 
recurrence, shorter patient survival, reduced apoptotic index, resistance to 
conventional therapy and unfavourable outcomes140, 301-316. 
Third, the active participation of survivin in cancer progression has prompted 
intensive investigation into the molecular basis of the deregulated expression of 
survivin in cancer. In view of the association of survivin and cycle progression, 
its overexpression in cancer was initially linked to the increased number of 
proliferating cells283. However, many studies proved otherwise. The promoter 
activity of survivin is more active in malignant cells than normal cells317. 
Upregulation of cancer specific gene expression is observed when they are 
under the control of a survivin promoter, which is more active in cancer cells 
than in normal epithelial cells318. Genetic amplification of the survivin locus on 
chromosome 17q25319 and demethylation of survivin exon 1320 are reported in 
certain cancers. Survivin is transcriptionally repressed by p53 and the loss of 
p53 or overexpression of survivin antagonises p53-induced cell death243, 321. 
Taken together, the strong expression of survivin in virtually every human 
cancer studied to date indicates that alterations in survivin gene regulation occur 
commonly during tumourigenesis, which makes it a useful prognostic 
biomarker and an attractive target for therapeutic intervention. Furthermore, 
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survivin is a multifunctional protein that intersects multiple pathways required 
for tumour cell proliferation and viability. In mammalian cells, survivin is 
responsible for the control of mitosis by ensuring proper chromosomal 
alignment and chromatin-associated spindle formation. It confers stability via 
suppression of microtubule dynamics. In the regulation of apoptosis, survivin 
sequesters pro-apoptotic Smac away from XIAP, activates multiple signaling 
pathways, synergistically inhibits caspases-3 and -9 to suppress apoptosis, 
promotes tumour-associated angiogenesis and accelerates tumour progression. 
In counteracting the cellular stress response, survivin associates itself with 
various molecular chaperones such as Hsp90 to maintain stability, folding and 
subcellular trafficking of various proteins227. Pursuing the nodal functions of 
survivin in cancer might lead to the development of global pathway inhibitors 
with unique therapeutic potential. 
 
1.3.5 Survivin and RCC 
Genomic profiling studies of RCC revealed that the expression of survivin was 
inversely associated with cancer-specific survival in clear cell RCC322. A 
comparison of  aberrant expression in aggressive and non-aggressive forms of 
clear cell RCC confirmed that high expression levels of survivin protein were 
significantly associated with more aggressive disease and a shorter overall 
patient survival323-326. Clinically, survivin can be a useful predictor or 
prognostic marker for RCC progression, recurrence and treatment response327-




A preliminary study  on a patient derived RCC murine xenograft, treatment with 
sorafenib effectively inhibited VEGFR-2 and PDGFR-β with concurrent and 
significant down-regulation of survivin332. The extent to which survivin was 
inhibited paralleled that of tumour growth inhibition, suggesting that survivin 
inhibition could be one of the factors mediating the clinical effects of sorafenib. 
This observation raises the possibility of using survivin as a biomarker to predict 
treatment outcomes for RCC, in the same way that tyrosine kinase mutation 
status is used to decide on EGFR inhibitor therapies for non-small cell lung 
cancer. In another pilot study (unpublished data), RNA expression microarray 
analyses on clinical samples showed that overall survival probability of patients 
with high expression of survivin were lower than those with low expression of 
survivin, further supporting the potential of survivin as a biomarker of patient 
survivability in clear cell RCC. With this background, survivin has emerged as 
a promising molecular target for the therapeutic treatment of RCC.  
 











YM155 (sepantronium bromide) was discovered in the laboratories of Astellas 
Pharma in 2007228. A high throughput screening technique using the survivin 
promoter luciferase reporter assay was employed to screen compounds for 
repression of survivin promoter activity. YM155 was identified as a suppressor 
of survivin promoter activity in human cervical epithelial carcinomas (HeLa) 
and Chinese hamster ovary (CHO) cells with a low IC50 of 0.54nM. Time- and 
dose-dependent decrease in survivin expression was observed with p53 mutant 
prostate cancer cells. Subsequently, high affinity binding of YM155 to RNA 
binding proteins interleukin enhancer-binding factor-3 (ILF3/NF110) and 
p54/nrb showed that it disrupted the association of the complex with the 
survivin promoter333, 334. YM155 was also shown to block the binding of a zinc 
finger transcription factor, Sp1 to the survivin promoter335 which could have led 
to a general anti-proliferative effect due to inhibition of cyclin D1 and induction 
of p27336. The intact positively charged dioxonaphthoimidazolium scaffold of 
YM155 was found to be essential for anti-proliferative activity337. Omission of 
the quinone moiety or the positive charge greatly diminished activity but it is 
uncertain if these features are essential for inhibiting the posttranslational 
modifications of survivin (eg. phosphorylation of Thr34 by CDK1-cyclinB1). 
 
1.3.7 Pharmacokinetics of YM155 
To optimise the use of YM155 in cancer chemotherapy, its pharmacokinetics 
(absorption, biodistribution, metabolism, excretion) has been investigated. The 
organic cation transporter 1 (OCT1/SLC22A1) in hepatocytes and OCT2 
(SLC22A2) in renal proximal tubules were found to facilitate the cellular uptake 
of YM155, but these transporters were not required for the uptake of YM155 
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into cancer cell lines338, 339. Recently, an uncharacterised member of the 35F 
family of solute carrier proteins (SLC35F2) was identified to be an important 
flux modulator for YM155. SLC35F2 is frequently overexpressed in several 
malignancies and its expression correlates with YM155 sensitivity across a 
panel of cancer cell lines340. This establishes SLC35F2 as a highly relevant 
biomarker for patient stratification in future clinical evaluation of YM155.  
A study on nude mice bearing PC-3 xenografts showed that labelled YM155 
was highly distributed to tumours with concentrations approximately 20-fold 
higher than those in the plasma228. Besides tumours, YM155 was preferentially 
distributed to the kidneys, liver and caecum. YM155 has poor oral 
bioavailability when given orally and when given by a bolus IV infusion, its 
plasma half-life was found to be short341, 342. Continuous IV infusion was 
required to achieve adequate plasma levels. Encapsulation of YM155 in 
polyethylene glycol-coated liposomes succeeded in prolonging plasma half-life 
with retention of antitumor activity in a xenograft model. However liposomal 
YM155 accumulated in the kidneys343.  
YM155 was hardly metabolized by the hepatocytes and was excreted 
unchanged via the bile and urine form344. Renal excretion predominates and 
dose adjustment may be necessary for patients with moderate renal 
impairment345-348. Among the ATP-binding cassette (ABC) transporters, the 
efflux transporter P-glycoprotein [P-gp; multidrug resistance protein-1 (MDR1)] 





1.3.8 Efficacy of YM155  
YM155 is a small molecule that selectively inhibits survivin gene transcription 
and protein expression in several tumour cell lines. In vitro, it showed marked 
anti-proliferative activity on a broad spectrum of tumour cell lines with IC50 in 
the nanomolar range. In preclinical models, it induced tumour regression in 
several tumour xenograft animal models228, 350. Phase I and II clinical trials of 
YM155 reported potent anti-cancer activity and impressive responses, with 
tumour shrinkage and durable remissions in patients with large cell non-
Hodgkin’s lymphoma, advanced prostate cancer and non-small cell lung 
cancer347, 351. Importantly, these studies showed a favourable toxicity profile 
with minimal and rapidly reversible side effects352. A detailed summary of in 
vitro, murine xenograft and clinical studies conducted with YM155 alone and 
in combination with other drugs have been reported353.  
 
1.3.9 Multi-targeting effects of YM155 
There is mounting evidence that YM155-induced effects are not solely due to 
the inhibition of survivin. In leukaemia cells, YM155 reduces the gene 
transcription of Mcl-1 and its protein expression, leading to activation of 
caspase 8 and induction of apoptosis354, 355. In pancreatic adenocarcinoma cells, 
YM155 reduces phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), 
extracellular signal-regulated kinase (ERK), STAT3 and evoke the 
ubiquitination and proteasomal degradation of EGFR, survivin, XIAP, but not 
Bcl-xl or Mcl-1356. In a transcriptome analyses of YM155-treated Wilms tumour 
cells, YM155 significantly up-regulated 32 genes such as caspase 7, caspase 9, 
DIABLO, p21, FOXO3, BIRC3 and BIRC8 and down-regulated 54 genes such 
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as Bcl-2357. In glioblastoma cells, YM155 decreases the expression of the 
oncogene securin which is highly expressed in brain cancer cells358, 359. In 
prostate cancer cells, treatment with YM155 induced two markers of DNA 
damage, γH2A.X and pKAP1 at concentrations lower than those required to 
inhibit survivin360-363. This led to the proposal that YM155 acts primarily by 
inducing DNA damage and that any effect on survivin is a secondary event 
caused by the general deactivation of gene expression brought about by DNA 
damage. In another study involving Merkel cell carcinoma xenograft, YM155 
disrupted DNA synthesis and halted cell growth, but growth resumed when 
treatment terminated, indicating that YM155 may be cytostatic rather than 





1.4 Aims   
In the light of the preceding literature review, it is apparent that survivin is a 
potential molecular target whose intervention may lead to the suppression of 
tumour growth, in particular that of clear cell RCC. It may also be useful as a 
predictive biomarker for patient survivability and treatment modalities, as 
suggested in preliminary studies332. In order to validate this hypothesis, the 
inhibition of survivin would be required to affirm the role of survivin in RCC 
pathogenesis. To this end, the small molecule suppressor of survivin, YM155, 
will be deployed.  
In this study, the initial step would be to elucidate the effect of survivin gene 
silencing using siRNAs on RCC cell growth and survival. This would provide 
insight into the molecular mechanisms by which survivin is regulated in RCC. 
Once established, the next step would be to investigate the effect of YM155 on 
a panel of RCC cells and to determine if it acts exclusively by inhibiting survivin. 
Current literature suggests that YM155 is multi-targeting. This is not 
necessarily a disadvantage and a detailed evaluation of the mechanistic 
pathways intercepted by YM155 would address the current gaps in knowledge 




The aims of this thesis are as follows: 
 
1. To investigate the role of survivin in RCC in vitro and the efficacy of a 
small molecule inhibitor of survivin, YM155 on a panel of RCC cell 
lines 
 
2. To elucidate the possible mechanism(s) of action of YM155 on RCC 
and how it may intercept the progression of the disease 
 
3. To develop new and more effective therapeutic strategies by 
combinations of YM155 with sorafenib (current FDA-approved drug for 
treatment of metastatic RCC) or bortezomib (proteasome inhibitor) and 
perform in vivo assessment of YM155 on patient-derived RCC xenograft 






Materials and methods 
 
2.1 Cell Culture 
2.1.1 General Techniques  
2.1.1.1 Recovery of cryo-preserved cells 
Tissue culture flasks were prepared in advance by adding 10mL of warmed 
complete culture medium containing 10% heat-inactivated fetal bovine serum 
(FBS). A vial of cryo-preserved cells was retrieved from liquid nitrogen and 
maintained in dry ice until it is ready for thawing. Before thawing the cryo-
preserved cells, excess pressure that may have built up in the vial was released 
by opening the lid by a quarter or half turn and then resealing. Cells were thawed 
rapidly in a 37°C waterbath, swirling the tube constantly to ensure even thawing. 
As soon as the cells have thawed completely, they were transferred to the 
prepared culture flasks with a sterile, disposable Pasteur pipette. In order to 
ensure even distribution of cells, flasks were gently swirled in a cross-shaped 
pattern several times in each direction. Finally, the flasks were placed at 37°C 





2.1.1.2 General growth conditions 
Cells were grown in tissue culture incubators in a humidified atmosphere of 5% 
CO2, 95% filtered atmospheric air, and maintained at a temperature of 37°C. 
Cell were cultured in sterile, tissue-culture grade polystyrene, non-pyrogenic 
plastic ware including flasks with vented caps (25cm2, 75cm2 and 175cm2), 
dishes (60x15mm, 100x20mm and 150x25mm) and plates (96-well, 24-well 
and 6-well ). Cells were grown in 5mL, 15mL and 25mL media in 25cm2, 75cm2 
and 175cm2 flasks respectively, and 5mL, 10mL and 20mL media in 60x15mm, 
100x20mm dishes and 150x25mm dishes respectively, and 200µL, 1mL and 
3mL (per well) media in 96-well, 24-well and 6-well plates respectively. 
 
2.1.1.3 Sub-culturing 
Cells were split at weekly intervals – in ratios ranging from 1 in 5 to 1 in 20. 
Sub-culturing was carried out when cells reached ~90% confluence. Media, 
PBS, and trypsin EDTA solution were warmed in a 37°C water bath for 15 to 
30 minutes prior to use. The medium was removed from all plates followed by 
washing with PBS. Next, 100µL to 3mL of trypsin EDTA was added to the 
flasks, dishes or plates to effect cell detachment. After incubation at 37°C and 
5% CO2 for approximately 2 to 5 minutes, flasks, dishes or plates were gently 
tapped on their sides to dislodged cells that were still attached. Upon complete 
detachment, 500µL to 10mL of medium was added to dilute the trypsin EDTA. 
The cell suspension was transferred to a 15mL or 50mL centrifuge tube, and 
centrifuged at 1200rpm for 5 minutes. Tissue culture flasks, dishes or plates 
were concurrently filled with the appropriate volume of medium. The cell pellet 
was re-suspended in 2 to 10mL of fresh medium and re-seeded in appropriately 
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size flasks, dishes or plates in volumes that would give the desired cell 
confluence. After seeding, plates were gently swirled in a cross-shaped pattern 
to evenly distribute the cells and then placed in the incubator at 37°C with 5% 
CO2. 
 
2.1.1.4 Preparation of cell stocks (cryopreservation) 
Established cell lines were recovered according to Section 2.1.1.1 and passaged 
three times according to Section 2.1.1.3. Once cells had reached passage three, 
cells stocks were prepared for cryopreservation. Cells were washed and 
disaggregated as described in Section 2.1.1.3. While cells were being 
centrifuged at 1200rpm, the freezing medium was prepared. This contained 10% 
dimethylsufloxide (DSMO) and 40% foetal bovine serum, and 50% growth 
medium. Cells were re-suspended in an appropriate volume of freezing medium 
such that the final concentration was 2 million cells per mL. Cells in freezing 
medium were dispensed into 2mL round-bottomed cryogenic vials. Vials were 
frozen down overnight at 1°C/min to -80°C in an isopropanol-bath freezing 
container (“Mr Fosty”). The following day, vials were stored into a liquid 
nitrogen dewar. 
 
2.1.2 Cell lines  
RCC786.0, ACHN and A498 were obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA).  Two human clear cell RCC cell lines, 
786.0/EV and 786.0/VHL were obtained from Cancer Research UK 
Laboratories, Clare Hall, Hertfordshire, UK. Three patient-derived RCC cell 
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lines, NCC010, NCC035 and P.RCC were obtained from NCCS-VARI 
Translational Research Laboratory, National Cancer Centre Singapore. All cells 
were cultured in high glucose Dulbecco’s Modified Eagle Medium (DMEM) 
containing L-glutamine, sodium pyruvate, 10% FBS and 100U 
Penicillin/Streptomycin (Gibco, Waltham, MA, USA). RCC786.0/EV and 
RCC786.0/VHL.HA had been stably transfected with empty vector or HA-
tagged Wild Type von Hippel-Lindau (VHL) respectively. Clones V4.1, B1.3, 
B1.6 and B2.5 stably transfected with empty vector or survivin expression 
vector, were derived from RCC786.0. For these stable clones, the growth 
medium was further supplemented with 0.5mg/mL G418 (Gibco, Waltham, MA, 
USA). Clones N1.1 and m2.13, also from RCC786.0, were stably transfected 
with non-targeting or survivin miRNA respectively. They were grown in media 
which have been supplemented with 10µg/mL blasticidin (Gibco, Waltham, 
MA, USA). All RCC cells are of the clear cell histological subtype, with the 
exception of P.RCC, which is of the papillary subtype. RCC786.0, 
RCC786.0/EV, A498, NCC010 and NCC035 lack a functional pVHL due to a 
mutation in the VHL gene. Isogenic RCC786.0/VHL.HA contains wild type 
pVHL which were re-expressed365 whereas ACHN and P.RCC do not carry a 
VHL mutation. All cells were grown in a humidified atmosphere of 5% CO2 and 
95% filtered atmospheric air and maintained at a temperature of 37oC. These 





2.2 Tissue specimens 
Clinical specimens were obtained from patients with renal cancer and had 
undergone nephrectomy. Sample collection was carried out with informed 
consent from patients and approval from the Institution Review Board of the 
Singapore General Hospital. Approval was also granted by the hospital’s 
Institutional Animal Care and Use Committee for in vivo experiments on mice. 
These experiments adhered strictly to the guidelines described for the welfare 
and use of animals in cancer research by Workman et al366. Specimens from 
nephrectomy were obtained intraoperatively. The diagnoses of RCC were 
confirmed by histology for all cases.  
 
2.2.1 Tissue microarray 
Tissue microarray (TMA) was first described by Kononen et al. (1998) and it 
consists of paraffin blocks in which up to 1000 separate tissue cores are 
assembled in array fashion to allow multiplex histological analysis367. It uses a 
novel sampling approach to produce tissues of regular size and shape that can 
be more densely and precisely arrayed. A tissue microarray (TMA) consisting 
of 302 nephrectomy specimens from 1995 to 2008 was constructed. The 
expression profiles of VEGFR, EGFR, PDGFR, IGF1-R and survivin were 
analysed by immunohistochemical (IHC) staining368. Briefly, deparaffinization 
and hydration of sections were performed by subjecting them to multiple 
washings in a single solvent for 5-10 minutes before proceeding to the next, as 
per the sequence: xylene, decreasing concentrations of ethanol (100%, 95%, 
70%, 50% and 35%), water. Sections were kept in water until it was ready to 
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perform antigen retrieval. Drying will lead to non-specific binding and high 
background. Next, the antigen was unmasked by boiling in citrate, TE, EDTA 
or pepsin depending on the type of antibody used. The unmasked antigen was 
first blocked with 3% peroxidase to enhance specificity and then sequentially 
stained with primary and biotinylated secondary antibody. The substrate DAB 
was added to enable visualization of the staining intensity and the sections were 
then counterstained with hematoxylin. Lastly, the sections were dehydrated and 
cleared by multiple washings in a single solvent for 5-10 minutes before 
proceeding to the next, as per the sequence: water, increasing concentrations of 
ethanol (35%, 50%, 70%, 95% and 100%), xylene before they were mounted 
with coverslips. All incubations were carried out in a humidified chamber to 
avoid drying of the tissue. The intensity of the IHC staining was scored by two 
histo-pathologists. Statistical analysis was performed by GraphPad PRISM 
software version 5.0 (GraphPad Software Inc., San Diego, CA, USA). Pearson 
Chi square was used to evaluate significance.   
 
2.2.2 Patient-derived RCC xenograft in SCID mice  
The experiments were carried by Professor Hung Huynh of the National Cancer 
Centre Singapore using mice that are homozygous for the SCID mutation369. 
Briefly, freshly sectioned RCC tissues were placed in RPMI 1640 in an ice bath 
immediately on tumour sectioning. Thin slices of tumour tissue, taken during 
the preparation of contiguous thin slices for cryostat sections, but before the 
tissues were processed into permanent sections (paraffin-embedded sections), 
were weighed, diced into 2–3mm3 pieces, and washed three times with RPMI 
1640 medium. They were minced finely to give tissue fragments that could 
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passed through an 18-gauge needle, then mixed 1:1 (V/V) with Matrigel to give 
a total volume of 0.2mL per injection. The tissue mixture was subcutaneously 
injected to the right flank of 8 to 10 weeks old male SCID mice. For each tumour, 
five mice were used. Mice were monitored for general well-being and tumour 
size was measured at least twice weekly for 5 months. For serial transplantation, 
tumour-bearing animals were killed by CO2 exposure. Animals were placed in 
ice water bath for 2 min. They were then dipped in and out of 10% Clorox 
solution for 2 min, washed in four changes of ice water, placed in 70% ethanol, 
and transferred to a laminar flow hood for dissection. Tumours were minced 
under sterile conditions and tissue fragments that passed through an 18-gauge 
needle were mixed with Matrigel for serial transplantation in successive SCID 
mice. 
 
2.3 Procedures for handling DNA 
2.3.1 General techniques 
All solutions used for preparation and manipulation of DNA were made with 
nuclease-free water unless otherwise stated. Tubes and disposable tips were 
autoclaved before use. DNA was suspended in TE buffer (Axil Scientific, 
Singapore) and routinely stored at –20°C. 
 
2.3.2 Total DNA preparation 
The DNeasy® kit (Qiagen, Hilden, Germany) was used according to 
manufacturer’s recommendations to obtain high quality total DNA for 
downstream applications. Cells grown in monolayer were washed with PBS and 
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disaggregated with trypsin-EDTA. After centrifugation, pellets of 1 to 5 x 106 
cells were re-suspended in PBS containing proteinase K and RNaseA 
(100mg/mL). Following incubation (2 minutes) at room temperature, Buffer AL 
was added and the sample was mixed thoroughly by vortexing before another 
10 minutes of incubation at 56oC. Next, absolute ethanol was added with mixing 
and the mixture was pipetted into a spin column. After centrifugation (8000 rpm, 
1 minute), the silica bound DNA was washed once with Buffer AW1 
(containing ethanol), washed again with Buffer AW2 (containing ethanol) and 
the column was centrifuged to dry the membrane. Total cellular DNA was 
eluted from the column with 50-100μL of Buffer AE. The concentration was 
assessed by spectrophotometry (Section 2.3.3) and purity was determined from 
the ratio of absorbance at 260nm versus 280nm. Generally this method yielded 
approximately 20-40μg of DNA with an A260/280 ratio of 1.7-1.9 (acceptable 
range for purified DNA) from 2 to 4 x 106 cells. DNAs were stored at –20°C.  
 
2.3.3 Spectrophotometric quantitation of nucleic acids 
Both DNA and RNA were quantified by measuring the UV absorbance at 
260nm using the ND-1000 spectrophotometer (Nanodrop Technologies, 
Wilmington, DE, USA) supported by the NanoDrop version 3.0.1 software. The 
ND-1000 was cleaned before each measurement with distilled water. A 1μL 
sample of distilled water was placed on the sample pedestal before initialising 
the machine, as suggested by the manufacturer. A fresh 1μl sample of distilled 
water or appropriate diluent was used to blank the ND-1000 prior to 
measurement. The sample pedestal was wiped after each measurement with a 
clean Kim Wipe (Kimberly-Clark, West Malling, Kent, UK). A 1μL aliquot of 
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DNA or RNA solution was pipetted onto the sample pedestal to obtain a reading. 
All readings were saved or printed out and stored for reference. DNA was 
quantified using the DNA-50 presets and RNA was quantified using the RNA-
40 presets. Assuming the weight of a nucleotide pair is 660Da, the following 
formula was used: 1 unit OD260 was equivalent to 50μg/mL for double-stranded 
DNA, 33μg/mL for oligonucleotides of twenty bases and 40μg/mL for RNA. 
 
2.3.4 Expression constructs 
2.3.4.1 microRNA expression vector targets survivin mRNA transcripts 
Artificial microRNA (miRNA) hairpins that are highly effective and specific at 
knocking down the target survivin mRNA sequence were designed using the 
BLOCK-iT™ RNAi Designer (Thermo Fisher Scientific, Waltham, MA, USA). 
They were synthesized in the form of pre-miRNA that are ready to anneal and 
clone into expression vectors according to manufacturer’s instructions. The 
expression vector pcDNA™6.2-GW/EmGFP-miR allows expression of these 
engineered pre-miRNA under the control of the strong, Pol II human CMV 
(cytomegalovirus) promoter and Herpes Simplex virus (HSV) thymidine kinase 
(TK) polyadenylation signal370. The vector backbone contains a blasticidin 
resistance gene to allow selection in E. coli and subsequent generation of cell 
lines stably expressing miRNA using mammalian cells. The EmGFP (Emerald 
Green Fluorescent Protein) incorporated in the vector allows tracking of the 
miRNA expression and provides strong correlation of EmGFP expression with 
the knockdown of the target gene. Briefly, single stranded lyophilized DNA 
oligos (pre-miRNA) were re-suspended in TE buffer, annealed to form double 
stranded oligos by incubating the annealing mixture (oligos, annealing buffer 
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and H2O) at 95oC, 4 minutes, followed by cooling to room temperature for 10 
minutes. The double stranded oligo mixture (50µM) was further diluted to 
10nM before ligation with the pcDNA 6.2-GW/EMGFP-miR (Invitrogen, 
Waltham, MA, USA) expression vector. The ligation reaction mixture of 
ligation buffer, linearized vector, oligo, H2O and T4 DNA ligase (1U/µL) was 
prepared and ligation was performed by gently pipetting the mixture up and 
down, followed by 5 minutes incubation at room temperature.  
 
2.3.4.2 Survivin expression vector 
The full length survivin expression construct (survivin-tGFP) was obtained 
from OriGene (OriGene Technologies, Rockville, MD, USA). The CMV 
promoter and a Kozak consensus sequence in the vector were responsible for 
driving protein expression in mammalian cells. This expression vector carries 
the survivin cDNA which is tagged with a turbo green fluorescent protein 
(tGFP). tGFP (excitation/ emission max = 482/502nm) is intended for 
applications where fast appearance of bright fluorescence is crucial. Such 
expression clones are the best suited for monitoring protein expression, 
localization, translocation and co-localization with other protein(s). The vector 
backbone contains an ampicillin resistance gene to allow selection in E. coli and 
a mammalian selectable marker for geneticin (G418) resistance to enable 
generation of stable cell lines that constitutively expressed survivin. The empty 
vector pCMV-AC-GFP (OriGene Technologies, Rockville, MD, USA) was 





2.3.4.3 NF-κB and Renilla luciferase reporter vector 
A luciferase reporter vector driven by NF-κB response elements, 
pGL4.32[luc2P/NF-κB-RE/Hydro] and a thymidine kinase promoter - Renilla 
luciferase reporter plasmid, pGL4.74[hRluc/TK] were purchased from Promega 
(Promega Corporation, Fitchburg, WI, USA). The pGL4.32[luc2P/NF-κB-
RE/Hygro] vector contains five copies of an NF-κB response element (NF-κB-
RE) that drives transcription of the luciferase reporter gene luc2P (Photinus 
pyralis). Luc2P is a synthetically-derived luciferase sequence with humanized 
codon optimization designed for high expression and reduced anomalous 
transcription. The pGL4.74[hRluc/TK] vector encodes the luciferase reporter 
gene hRluc (Renilla reniformis) and a HSV-TK promoter which was used as an 
expression control or a co-reporter vector to check for transfection efficiency. 
The vector backbone contains an ampicillin resistance gene to allow selection 
in E. coli and a mammalian selectable marker for hygromycin resistance.  
 
2.3.5 Transformation of bacteria and amplification of transformants 
One Shot® TOP10 Chemically Competent E. coli (Invitrogen, Waltham, MA, 
USA) were used for transformation of DNA by heat-shock. Briefly, 10ng 
plasmid was mixed with 50µL competent bacteria. The cells were chilled on ice 
for 30 minutes, heat shocked at 42°C for 30 seconds and replaced on ice for 2 
minutes. Bacteria were then mixed with 250µL of SOC medium (Invitrogen, 
Waltham, MA, USA) and agitated (200rpm) horizontally for 1 hour at 37°C in 
an orbital shaker. Bacteria were then plated on LB-agar plates containing 
antibiotics (100µg/mL blasticidin for microRNA vector, 100µg/mL 
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carbenicillin for survivin vector and luciferase reporter vector) and incubated 
overnight at 37°C. Antibiotics-resistant colonies were picked and inoculated in 
LB containing the appropriate antibiotics at 37°C overnight with shaking. 15% 
Glycerol was added to the transformants and stored as stock clones at -80°C. 
 
2.3.6 Oligonucleotide preparation 
Oligonucleotides designed by Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/) to 
be used as primers (Table 2.1) for polymerase chain reaction (PCR), quantitative 
real-time PCR (qRT PCR) and sequencing were synthesized by Integrated DNA 
Technologies ( Integrated DNA Technologies Inc, Coralville, IA, USA) and 
supplied in lyophilised form. Lyophilised oligonucleotides were resuspended in 
TE buffer to produce a stock concentration of 100μM. This stock was further 
diluted to a working concentration of 10μM for PCR and qRT PCR and 3.3µM 
for sequencing. The Taqman probes (Table 2.2) for qRT PCR were produced 
by Applied Biosystems (Thermo Fisher Scientifc, Waltham, MA, USA) as 
ready-to-use and stored at -20°C. 
 
2.3.7 Preparation of plasmid DNA 
For the generation of large quantities of plasmid DNA (0.5–2mg), the 
PureYield™ Plasmid Maxiprep (Promega Corporation, Fitchburg, WI, USA) 
was used according to the manufacturer’s instructions. Briefly, a single 
antibiotic resistant colony was picked from a streaked agar plate and inoculated 





Name Forward Primer Reverse Primer 
miRNA primer site GGCATGGACGAGCTGTACAA CTCTAGATCAACCACTTTGT 
BIRC5_1_External CCCAGCTCCAGAAGTGACTC ACTGGGCCACTACCGTGATA 
BIRC5_1_Internal AACACCCTGTTCCAAAGCAG GGGCCACTACCGTGATAAGA 
BIRC5_2_External AGATGGCTTTCAGCAAAGGA GACTCCCTACAGCCACAAGC 
BIRC5_2_Internal GGGCTTATCAGACACCAACC TAACACGCTCACATCCATCC 
IL8_External CATCAGTTGCAAATCGTGGA GAAGCTTGTGTGCTCTGCTG 
IL8_Internal TCGTGGAATTTCCTCTGACA GTTTGTGCCTTATGGAGTGCT 
 
Table 2.1. Primer sequences for PCR, qRT PCR and sequencing analysis. 
 
 
Gene Symbol Assay ID Context Sequence 
BIRC5 Hs00153353_m1 CCAAGAACAAAATTGCAAAGGAAAC 
CYLD Hs00211000_m1 CGGGATGGTGGTCAGAATGGCTTCA 
FOXO1 Hs01054576_m1 GGCTGGAAGAATTCAATTCGTCATA 
ID1 Hs03676575_s1 CCCAACGCGCCTCGCCGGATCTGAG 
IL8 Hs00174103_m1 GTGTGAAGGTGCAGTTTTGCCAAGG 
RelA Hs00153294_m1 AGTACCTGCCAGATACAGACGATCG 
ACTB Hs99999903_m1 CCTTTGCCGATCCGCCGCCCGTCCA 
GAPDH Hs02758991_g1 GACTCATGACCACAGTCCATGCCAT 
 





The starter culture was diluted 1:500 with 500mL LB containing the appropriate 
antibiotics, agitated overnight on an orbital shaker at 37°C cell proliferation and 
harvested the following day by centrifugation (6000 x g, 15 minutes, 4°C). The 
cell pellet was resuspended in 12mL of cell resuspension solution, after which, 
12mL of cell lysis solution was added, the mixture was then gently mix by 
inverting 3–5 times and incubated for 3 minutes at room temperature. Next, 
12mL of Neutralization Solution was added to the lysed cells and the suspension 
was mixed by gently inverting the tube 10–15 times. The lysate was then 
centrifuged at 14,000 × g for 20 minutes at room temperature in a fixed-angle 
rotor. The clear sample was poured into a stack column and maximum vacuum 
was applied. 5mL of endotoxin removal wash and 20mL of column wash were 
added to the binding column before the membrane was left to dry by applying 
vacuum for 5 minutes. 1mL of nuclease-free water was added and this 
transfection ready plasmid DNA was stored for DNA quantitation (Section 
2.3.3), agarose gel and sequencing analysis to confirm the presence, correct 
orientation and sequence of the oligo insert. 
 
2.3.8 Polymerase Chain Reaction (PCR) 
PCR was developed by Mullis in 1983371 and is used to amplify a single or more 
copies of DNA across several orders of magnitude to generate thousands to 
millions of copies of a specific DNA sequence. The HotStarTaq DNA 
Polymerase (Qiagen, Hilden, Germany) used in this study is a modified form of 
the recombinant 94kDa Tag DNA polymerase and is useful in preventing the 
formation of misprimed products and primer–dimers at low temperatures. In 
general, the reaction master mix consisted of 1µL 10X PCR buffer containing 
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1.5mM MgCl2, 1µL deoxynucleotides mix of 2mM each, 1µL 10µM forward 
primer, 1µL 10µM reverse primer, 0.2µL Taq (5U/µL), and an appropriate 
volume of H2O (depending on volume of DNA template) to make up a final 
reaction volume of 20µL. The master mix was dispensed into PCR tubes and an 
appropriate amount of DNA template (<1µg/100µL reaction) was added. The 
optimised cycling program included an initial 15 minute, 95°C incubation step 
to activate the HotStarTaq DNA polymerase and a 3-step cycling involving 
denaturation (30 seconds, 94°C), annealing (45 seconds, 55°C or depending on 
Tm of primers) and extension (60 seconds, 72°C), The total number of cycles 
ranged from 25-35. A final extension step of 10 minutes at 72°C will complete 
the program. When the amount of starting DNA template was low, a nested PCR 
was performed to reduce non-specific binding. Two sets of primers were used 
in two successive runs of PCR. The second set (internal primers) was used to 
amplify a secondary target within the first run product. 
 
2.3.9 Gel electrophoresis of nucleic acids 
Gel electrophoresis is a technique used in the separation and analysis of 
macromolecules (DNA, RNA and proteins) and their fragments, based on their 
size and charge. An electric field is applied to move the negatively charged 
nucleic acid molecules through a matrix of agarose in 0.5X Tris-Borate-EDTA 
(TBE) running buffer, pH 8.3 (Axil Scientific, Singapore). The amount of the 
agarose gel used depends on the size of the target fragments to be resolved and 
typically range from 1% to 3%. An intercalating agent such as ethidium bromide 
or gel red was used as a nucleic acid stain because of their fluorescent properties. 
Samples were electrophoresed in parallel with a standard molecular (DNA or 
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RNA) size marker or ladder to enable identification of the approximate size of 
the unknown sample. The nucleic acid fragments were visualised under UV 
light and the gels were photographed and digitalised using the Gel Doc System 
(Bio-Rad Laboratories, Hercules, CA, USA).  
 
2.3.10 DNA sequencing 
DNA sequencing is the process of determining the precise order of nucleotides 
within a DNA molecule. The development of fluorescence-based sequencing 
methods using an automated DNA sequencer372 has increased the speed and 
reduced the costs of  sequencing DNA373. In this study, 200ng of plasmid DNA 
was sequenced using the Big Dye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystems, Waltham, MA, USA) as per manufacturer instructions. 
Briefly, a reaction mixture of 2µL sequencing buffer, 1µL big dye terminator, 
0.5µL forward or reverse primer, 2µL DNA template, 4.5µL H2O in a final 
volume of 10µL, was prepared and subjected to an initiation denaturation of 
96°C for 1 minute, followed by 28 cycles of a 3-step cycling process consisting 
of 96°C for 10 seconds, 50°C for 5 seconds, 60°C for 4 minutes, after which the 
mixture was rapid cooled to 4°C. The sequenced reaction mix was subsequently 
purified using 3M sodium acetate, 100% ethanol, 70% ethanol, dried and 
resuspended in formamide before analysis on the ABI 3100 Genetic Analyser 





2.4 Procedures for handling RNA 
2.4.1 General techniques 
All solutions were prepared using nuclease-free, DEPC-treated water (Ambion, 
Waltham, MA, USA). Work surfaces were cleaned with absolute ethanol and 
RNaseZap (Ambion, Waltham, MA, USA) and all filter-tips and tubes used 
were RNase-free. 
 
2.4.2 Total RNA preparation 
The RNeasy® kit (Qiagen, Hilden, Germany) was used according to 
manufacturer’s recommendations to obtain high quality total RNA for RT PCR 
reactions. Cells grown in monolayer were washed with PBS and disaggregated 
with trypsin-EDTA. After centrifugation, pellets of 106-107 cells were lysed in 
Buffer RLT containing β-mercaptoethanol (Sigma-Aldrich Corporation, St. 
Louis, MO, USA). The resulting highly viscous lysate was homogenised by 
passage through a 20-gauge needle at least 5 times. Thereafter, 1 volume of 70% 
ethanol was added to the lysate after which it was applied onto a silica-
membrane column. After centrifugation, the silica-bound RNA was washed 
once with Buffer RW1, incubated with DNase I for 15 minutes at room 
temperature to remove contaminating DNA, washed again with Buffer RW1 
and twice with Buffer RPE (containing ethanol). Total cellular RNA was eluted 
from the column with 30-50μl of RNase-free water. The concentration was 
assessed by spectrophotometry (Section 2.3.3) and purity was determined from 
the ratio of absorbance at 260nm versus 280nm. Generally this method yielded 
approximately 20-40μg of RNA with an A260/280 ratio of 1.8-2.0 (acceptable 
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range for purified RNA) from 2-4 x 106 cells. An assessment of the RNA 
integrity was performed by running a 1% agarose gel (Section 2.3.9). The upper 
ribosomal band (28S) should be about twice as intense as the lower band (18S).  
Messenger RNA (mRNA) was detected between the 2 ribosomal bands, often 
as a faint smear. RNAs were stored at –80°C.  
 
2.4.3 Reverse transcription of RNA 
Complementary DNA (cDNA) was synthesized by reverse transcribing total 
RNA using the SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, 
Waltham, MA, USA) according to the manufacturer’s instructions. Briefly, a 
reaction master mix was prepared, which comprised of 4μl of 5X Vilo reaction 
mix, 2μl of 10X Superscript Enzyme mix and an appropriate volume of RNA 
sample and DEPC water. Generally, the kit can reverse transcribe up to 2.5μg 
of total RNA and DEPC-treated water was added to the reaction mix to a final 
volume of 20μl. Reactions were gently mixed, placed in a Veriti Thermo Cycler 
(Applied Biosystems, Waltham, MA, USA) and incubated at 25°C for 10 
minutes, 42°C for 60 minutes. The reaction was terminated at 85°C for 5 
minutes and the cDNA was stored at -20°C until further analysis. 
 
2.4.4 Quantitative real-time PCR (qRT PCR) 
qRT PCR monitors the amplification of a targeted DNA molecule during the 
PCR in real-time. There are two main methods for the detection of PCR 
products in real-time PCR. The first method requires non-specific fluorescent 
dyes such as SYBR green that intercalate with any double-stranded DNA. The 
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second method (TaqMan) relies on sequence-specific probes consisting of 
oligonucleotides that are labelled with a fluorescent reporter (FAM™) and 
permits the detection only after hybridization of the probe with its 
complementary sequence. qRT PCR was performed using primers and specific 
Taqman DNA probes as previously described (Table 2.1 and Table 2.2). The 
analysis was performed on the AB7500 Fast real-time PCR System (Applied 
Biosystems, Waltham, MA, USA) using Express SYBR® GreenER™ qPCR 
SuperMix Universal (Invitrogen, Waltham, MA, USA) or TaqMan® Fast 
Advanced Master Mix (Applied Biosystems, Waltham, MA, USA).  
For the first method, a reaction mix of 7.5μl SuperMix Universal, 0.03µL ROX, 
0.75µL forward primer (10µM), 0.75µL reverse primer (10µM), 2µL genomic 
DNA template and 3.97µL H2O in a total volume of 15μl was prepared. 
Conditions for this first qRT PCR reaction method were 50°C for 2 minutes, 
95°C for 2 minutes and then 40 cycles, each consisting of 30 seconds at 94°C, 
45 seconds at 55°C and 45 seconds at 72oC. Following that, a 
melting/dissociation curve was run to check primers specificity. The reaction 
efficiency of each gene and the amount of DNA in each unknown sample was 
extrapolated from standard curves for each PCR reaction, by making 10-fold 
serial dilutions covering the concentration range equivalent to 10 to 0.001ng 
DNA.  
For the second method, a reaction mix of 7.5µL 2X TaqMan Master Mix, 
0.75µL 20X Taqman probe, 1.5µL cDNA template and 5.25µL RNase-free 
water in a total reaction volume of 15µL was prepared. Conditions for this 
second qRT PCR reaction method were 2 minutes at 50°C, 20 seconds at 95°C 
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and then 40 cycles, each consisting of 3 seconds at 95°C and 30 seconds at 60°C. 
The housekeeping genes were glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and β-actin (ACTB). To quantify the expression level of the gene of 
interest (GOI), the comparative method was used374, 375. This method assumes 
that the amplification efficiencies of the GOI and the housekeeping genes are 
near to 100 percent. First, the difference between the Ct values (ΔCt) of the GOI 
and the housekeeping gene was calculated for each experimental sample. Then, 
the difference in the ΔCt values between the experimental and control samples 
ΔΔCt was calculated using the following equation.  
ΔΔCt = ΔCt (GOItreat ‐	GAPDHtreat) ‐ ΔCt (GOIcontrol ‐	GAPDHcontrol)  
where Ct is the threshold cycle  
The fold change in expression of the GOI between the two samples is given by 
2(-ΔΔCt).  
 
2.4.5 Microarray Analysis 
Microarray analysis was performed on control (0.1% DMSO) and cells treated 
with 40nM YM155 or 80nM YM155 for 24h and 48h. Total RNA were isolated 
and subjected to spectrophotometric measurements (BioSPEC-Mini, Shimadzu 
Corporation, Kyoto, Japan) using capillary electrophoresis (Agilent 2100 
Bioanalyzer; Agilent Technologies, Santa Clara, CA, USA) to evaluate its 
quality (RIN)376. Only high quality RNA samples were used for microarray 
analysis. The samples were processed according to the Affymetrix 3’ IVT 
Express protocol and Origen Lab’s Standard Operating Procedures (SOP) for 3’ 
IVT Express analysis. Briefly, 100 ng of total RNA was reverse transcribed to 
produce cDNA, which was subsequently used as a template to create biotin-
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labeled aRNA (amplified RNA). The aRNA was then fragmented and 
hybridized to Affymetrix PrimeView Human Gene Expression Arrays 
(Affymetrix Inc, Santa Clara, CA, USA) for 16 hours at 45oC with rotation at 
60 rpm. The RNA samples were processed using the same reagent kit. Arrays 
were then washed and stained using the FS450_0002 fluidics protocol on 2 
fluidics station and scanned using an Affymetrix 3000 7G scanner. The scanned 
images were inspected for hybridization efficiency. CEL files were generated 
from AGCC (GeneChip Command Console Software) and the array quality 
controls (QCs) including housekeeping genes ratio (3’/5’), hybridization 
controls, poly-A controls were checked to ensure that they fell within the 
acceptable range.  
The CEL files of the various samples were then exported to the Partek Genomics 
Suite V6.3 (Partek Inc, St Louis, MI, USA), an advanced statistical analysis and 
data visualization software designed for large data sets 
(http://www.partek.com/pgs). The raw expression values obtained were pre-
processed using the RMA (Robust Multi-chip Average) method377. To facilitate 
analysis of expression at the “gene-level”, normalized signal intensities of 
multiple probes on different exons were summarized into an expression value 
of all transcripts from the same gene. Comparisons of differential gene 
expression between treatment concentration, duration, as well as the effects of 
batch (Scan Date) were measured with 2-way analysis of variance (ANOVA). 
To deal with the multiple testing issues derived from the fact that many tests are 
performed simultaneously, P-values were adjusted to obtain strong control over 
the “false discovery rate” (FDR) using the Benjamini and Hochberg method378. 
To aid visualization of high dimensional data, a Principal Components Analysis 
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(PCA) of differentially expressed genes were performed, where each point 
represents an aggregate observation on a sample and where the distance between 
any two points is related to the similarity between the two observations/samples.  
A list of genes (p<0.05 and fold change of >2) was generated and was overlaid 
onto a global molecular network developed from information contained in the 
Ingenuity Pathway Analysis (IPA) knowledge base. For network analysis, IPA 
computed a score (p-score=-log10(p-value)) based on the list of genes that were 
submitted and associate them with a list of biological functions stored in the 
knowledge base. The score allowed the networks to be prioritized for further 
studies. A score >3 (p<0.001) indicates a >99.9% confidence that a gene 
network was not generated by chance alone. The network identified was 
presented as a graph indicating the molecular relationships between the 
differentially expressed genes/gene products. The functional analysis identified 
the biological functions and the canonical signaling pathways that were most 
significant to the input data set. The significance of the association between the 
input data set and the functions or pathways was determined based on two 
parameters: (1) a ratio of the number of genes from the data set that map to the 
function/pathway divided by the total number of genes that map to the 
function/pathway and (2) a P-value calculated using Fischer’s exact test to 
determine the probability that the association between the genes in the dataset 





2.4.6 Gene silencing by RNAi 
RNA interference (RNAi) describes the phenomenon by which short, 
homologous RNA duplexes induce potent and specific inhibition of eukaryotic 
gene expression via the degradation of complementary messenger RNA 
(mRNA). In terms of function, it is similar to the processes of post-
transcriptional gene silencing (PTGS) or co-suppression in plants379-382 and 
quelling in fungi383-385. In plants, the PTGS response is a natural defence against 
viral infection or transposon insertion386-389. In experimental settings, RNAi is 
widely used to silence genes through transfection of RNA duplexes.  
 
2.4.6.1 Transient transfection with siRNA duplexes 
In eukaryotic organisms, dsRNA is processed into 21-23 nucleotide double-
stranded short interfering RNA duplexes (siRNA) by an enzyme called Dicer, a 
member of the RNase III family of double-stranded RNA-specific 
endonucleases390, 391. Each siRNA is then incorporated into an RNA-induced 
silencing complex (RISC), an enzyme complex which targets cellular 
transcripts that are complementary to the siRNA for specific cleavage, 
degradation or translational repression392, 393. siRNA duplexes (Table 2.3) were 
supplied by Qiagen (Hilden, Germany) as annealed deprotected, HPLC purified 
lyophilised pellets and were stored at -20°C. Pellets were re-suspended in 1mL 
Qiagen (Hilden, Germany) siRNA suspension buffer (100mM Potassium 
Acetate, 30mM Hepes KOH, 2mM Magnesium Acetate, pH7.4), denatured for 
1 minute at 95°C, centrifuged for 15 seconds and incubated at 37°C for 1 hour. 
Duplexes were subsequently aliquoted, stored at -20°C and subjected to fewer 





siRNA Sense (5' to 3') Antisense (5'to 3') 
IGF1R GGAGAAUAAUCCAGUCCUATT UAGGACUGGAUUAUUCUCCAT 
Survivin GCAUUCGUCCGGUUGCGCUTT AGCGCAACCGGACGAAUGCTT 
Negative Control Proprietary - sequences not available 
 
Table 2.3. siRNA sequences for gene silencing. 
 
































Antisense Proprietary - sequence not available 
 




Based on the gene silencing technique described by Elbashir et al394, cells were 
transfected with IGF1R specific siRNAs and survivin specific siRNAs using 
Oligofectamine® (Invitrogen, Waltham, MA, USA) according to 
manufacturer’s instructions. This is a lipid-mediated transfection protocol 
which was used to introduce double-stranded siRNA into cultured mammalian 
cells. Briefly, 24 hours before transfection, cells were seeded at the appropriate 
density to ensure 40-50% density for transfection and less than 80-90% 
confluence on the day of harvest (usually 48 hours after transfection). For 
transfection in a 10cm dish, 12.3μl of Oligofectamine was incubated with 410μl 
OptiMEM® (Invitrogen, Waltham, MA, USA) serum-free medium in a tube for 
10 minutes at room temperature. Meanwhile, the 20μM siRNA stock was mixed 
with OptiMEM in a separate tube at the appropriate dilution to yield a final 
transfection concentration of 0.1-200nM duplex. For a 100nM siRNA 
transfection, 13.65μl of stock siRNA duplex was added to 1516.7μl OptiMEM. 
The lipid and duplex mixtures were then combined, incubated at room 
temperature for 25 minutes. Cell monolayers were washed twice with 10mL 
OptiMEM, 780µL OptiMEM was added to each dish and the lipid/siRNA 
complex was applied to the cells with swirling. After 4 hours of incubation at 
37°C, 273μl FBS and 10mL DMEM containing 10 % FBS were added to the 
cells. Transfected cells were grown at 37°C for 24-72 hours prior to further 
manipulation. These gene specific siRNAs were homologous to the target genes 
investigated here (survivin, IGF1R) and mediate degradation of the 
corresponding mRNA, resulting in down regulation of protein expression. 
Proprietary negative control siRNA (Qiagen, Hilden, Germany) with no known 
homology to any mammalian gene was used as the negative control.  
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2.4.6.2 Transient transfection with miRNA expression vector 
MicroRNAs (miRNAs) are endogenously expressed RNAs that trigger gene 
silencing395, 396. They are expressed in the form of small ssRNA sequences of 
~22 nucleotides in length and direct gene silencing through components shared 
with the RNAi pathway 397. miRNAs contain a hairpin structure and are usually 
found embedded, sometimes in clusters, in long primary transcripts (pri-
miRNAs) of several kilobases in length. It is driven by RNA Polymerase II, 
which is the same polymerase responsible for mRNA expression398. Briefly, 
Drosha, a nuclear RNase III, cleaves the stem-loop structure of the pri-miRNA 
to generate small hairpin precursor miRNAs (pre-miRNAs) which are ~70 
nucleotides in length399. The pre-miRNAs are exported from the nucleus to the 
cytoplasm by a nuclear transport receptor, exportin-5400, 401. Following the 
nuclear export, the pre-miRNAs are processed by Dicer into a ~22 nucleotides 
miRNA (mature miRNA) molecule, and incorporated into an miRNA-
containing RNA-induced silencing complex (miRISC)402. The mature miRNAs 
regulate gene expression by mRNA cleavage or translational repression. In 
animals, most miRNAs imperfectly complement their targets and interfere with 
protein production without directly inducing mRNA degradation 403. However, 
target cleavage can be induced artificially by altering the miRNA sequence to 
obtain complete hybridization404. The engineered miRNAs produced by the 
BLOCK-iT™ Pol II miR RNAi expression vector kit (Invitrogen, Waltham, 
MA, USA) fully complemented their target sites and cleave the target mRNA 
(Section 2.3.4.1).  
In this study, RCC cells were transfected with the miRNA expression vectors 
using Lipofectamine® Transfection Reagent (Invitrogen, Waltham, MA, USA) 
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according to manufacturer’s instructions. Briefly, 24 hours before transfection, 
cells were seeded at the appropriate density to ensure 90% density for 
transfection. A DNA lipofectamine complex of 1:2 was used. For transfection 
in a 6-well plate, 8μl of Lipofectamine was incubated with 250μl OptiMEM® 
(Invitrogen, Waltham, MA, USA) serum-free medium in a tube for 5 minutes 
at room temperature. Meanwhile, the miRNA expression vector stock was 
mixed with 250µL OptiMEM in a separate tube at the appropriate dilution to 
yield a final transfection concentration of 4µg plasmid DNA/well. The lipid and 
duplex mixtures were then combined, incubated at room temperature for 20 
minutes. Cell monolayers were washed twice with 10mL OptiMEM, 1mL 
OptiMEM was added to each well and the lipid/miRNA complex was applied 
to the cells with swirling. After 4 hours of incubation at 37°C, the lipid/miRNA 
complex was removed and 3mL DMEM containing 10% FBS were added to the 
cells. Transfected cells were grown at 37°C for 24 hours prior to further 
manipulation. Transfection efficiency was checked by visualising the green 
fluorescent protein (GFP) in the cells using inverted fluorescence microscopy.  
Initially, eight different pre-miRNA sequences targeting different exons of the 
survivin gene (RefSeq: NM_001012271.1) were selected (Table 2.4). However, 
only one of the pre-miRNA sequence, m451 showed satisfactory knockdown of 
survivin. A control plasmid (Invitrogen, Waltham, MA, USA) containing a 
proprietary insert that can form a hairpin structure and be subsequently 
processed into mature miRNA was used as a negative control as it was predicted 




2.5 Protein Analysis 
2.5.1 Lysis of adherent cells 
Adherent cells were lysed directly in M-PER Mammalian Protein Extraction 
Reagent (Pierce, Waltham, MA, USA) to ensure preservation of protein 
phosphorylation and high protein yields. Culture medium was aspirated from 
the dishes and adherent cells were washed once with ice-cold PBS. After 
carefully removing residual PBS by blotting with tissue paper, an appropriate 
amount of the extraction reagent containing Halt Protease and Phosphatase 
Inhibitors (Pierce, Waltham, MA, USA) was added directly to the cells in the 
dish (e.g. 100μl per 10cm dishes). The lysate was collected by scraping, 
transferred to a pre-chilled microcentrifuge tube on ice, vortexed vigorously and 
incubated on ice for 15 minutes. Cell debris was pelleted by centrifugation at 
13000rpm for 15 minutes at 4°C and supernatants were transferred to fresh pre-
chilled microcentrifuge tubes. Lysates were stored at -80°C. 
 
2.5.2 Protein extraction from tumour specimens 
For protein extraction from RCC xenograft tissues, specimens were washed 
with PBS, minced and homogenized using TissueLyser LT (Qiagen, Hilden, 
Germany) in T-PER Mammalian Protein Extraction Reagent (Pierce, Waltham, 
MA, USA) containing Halt Protease and Phosphatase Inhibitors (Pierce, 
Waltham, MA, USA). Samples were incubated on ice for 15 minutes, with 
vigorous vortexing for 15 seconds every 5 minutes, followed by centrifugation 
at 13000rpm at 4°C for 15 minutes. The supernatant was transferred to a fresh 
microcentrifuge tube to be stored at -80°C prior to western blot analysis. 
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2.5.3 Protein quantitation 
For routine quantitation of proteins in solution, the bicinchoninic acid (BCA) 
procedure was used (Pierce, Waltham, MA, USA). This assay is based on the 
ability of peptide bonds in proteins to reduce cupric ions (Cu2+) to cuprous ions 
(Cu+) in a temperature dependent reaction. The cuprous ions are chelated by 
bicinchoninic acid (2 molecules to one Cu+) to give a purple colored product 
(λmax 562 nm). The intensity of the absorbance is proportionate to the amount 
of protein present in the sample. Briefly, 50 parts of reagent A (alkaline solution 
of BCA) were mixed with 1 part of reagent B (cupric sulfate) and 200μL was 
added to 5-10μL protein solution in a 96-well plate. After 30-minute incubation 
at 37°C, the protein concentration was determined on a plate reader (Benchmark 
Plus Microplate Reader, Bio-Rad Laboratories, Hercules, CA, USA) at 562nm. 
The protein content of the samples was extrapolated from a standard curve 
generated using bovine serum albumin (BSA from Pierce) at 0.1-2mg/mL.  
 
2.5.4 SDS polyacrylamide gel electrophoresis (PAGE) 
This procedure was used to separate proteins according to molecular weight. 
The polyacrylamide gels were prepared according to the method of Laemmli405. 
The apparatus (Mini Protean 3) used for this procedure was from Bio-Rad. The 
8x10cm gels were made in two parts, the resolving gel and the stacking gel. The 
resolving gel was prepared with 30% acrylamide, 0.4% bisacrylamide stock 
(Bio-Rad Laboratories, Hercules, CA, USA) to give a final concentration of 5-
12% acrylamide, 0.1% sodium dodecyl sulfate (SDS) and 0.375M Tris.Cl 
pH8.8. For a 20mL gel mix, 260μL of 10% w/v ammonium persulphate (APS) 
and 24µL of TEMED (Sigma-Aldrich Corporation, St. Louis, MO, USA) were 
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added as polymerisation catalysts. For analysis of proteins in the size range 15-
40kDa and 40-180kDa, 12% and 9% acrylamide resolving gels were prepared, 
respectively. The resolving gel mix was poured between clean glass plates, 
1.5mm apart to within 2cm of the top of the gel plates. A thin layer of 
isopropanol was overlaid while the polyacrylamide was polymerised. The top 
of the gel was washed thoroughly with water prior to the addition of the stacking 
gel mix consisting of 5% acrylamide, 0.1% SDS, 0.125M Tris.Cl pH 6.8 with 
APS and TEMED to aid polymerisation. Once the stacking gel was poured, a 
1.5mm comb was inserted. Cell lysates were mixed with the appropriate 
volumes of 4x Laemmli buffer (5mL 0.5M Tris.Cl pH6.8, 4mL glycerol, 1mL 
β-mercaptoethanol, 0.8g SDS, 0.01% bromophenol blue). The samples were 
denatured at 100°C for 20 minutes and centrifuged briefly (approximately 1-2 
seconds). Typically, 20-60μg protein lysate was used for the detection of protein 
by western blotting. Electrophoresis at 70 volts was applied until the sample ran 
beyond the stacking gel, after which the proteins were resolved at 110 volts for 
one and a half hours in parallel with a molecular weight marker (Bio-Rad 
Laboratories, Hercules, CA, USA) in running buffer composed of Tris glycine 
buffer (Axil Scientific, Singapore) and 0.1% SDS. 
 
2.5.5 Western immunoblotting 
2.5.5.1 Dry transfer of proteins to nitrocellulose 
Proteins electrophoresed by SDS-PAGE were transferred onto nitrocellulose 
membrane using iBlot® Dry Blotting System, based on a dry blotting transfer 
method. The gel was removed from between the glass plates and placed onto 
the iBlot® Transfer Stack which consists of an Anode Stack and a Cathode 
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Stack. The nitrocellulose blotting membrane was placed on the anode side and 
the gel on the cathode side. Once assembled, the run was initiated for the 
transfer of proteins from the gel to the blotting membrane.  
 
2.5.5.2 Antibodies used for western immunoblotting 
Once the proteins were transferred to nitrocellulose membranes, the membranes 
were blocked in TBS containing 3% w/v BSA (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) and 0.05% Tween20 (Sigma-Aldrich Corporation, St. 
Louis, MO, USA) to reduce non-specific antibody binding. Membranes were 
blocked for 1 hour at room temperature on an orbital shaking platform. The 
membranes were cut horizontally at the appropriate molecular weight marker 
band if more than one protein was studied on the same membrane. For example, 
to assess survivin and GAPDH levels, the nitrocellulose membrane was cut at 
the 25kDa marker. The lower part of the membrane (<25kDa) was incubated 
overnight with a 1:2000 dilution of the rabbit monoclonal anti-survivin antibody 
(Cell Signaling Technology Inc, Danvers, MA, USA). The top half (>25kDa) 
was incubated overnight with a 1:5000 dilution of the anti-GAPDH antibody 
(Cell Signaling Technology Inc, Danvers, MA, USA). Other antibodies used are 
described in Table 2.5. The membranes were placed protein side up in the 
incubation container with approximately 6mL of primary antibody diluted in 
blocking buffer to ensure uniform exposure of the antibody to the entire 
membrane. The container was covered to minimise evaporation and incubated 
at 4°C overnight. The next morning, following three 10-minute washes in TBS 
containing 0.05% Tween20, the membranes were incubated with secondary 
antibody, diluted 1:2000-1:10000 in blocking buffer, for 1 hour at room 
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temperature on a shaking platform. The secondary antibody was either goat anti-
rabbit or goat anti-mouse conjugated to horse-radish peroxidase (HRP) (DAKO, 
Santa Clara, CA, USA), depending on the source of the primary antibody. The 
membrane was washed as before and proteins were visualised with Immobilon 
chemiluminescent detection reagent (Millipore, Billerica, MA, USA). This 
method utilizes HRP-induced catalytic oxidation of luminol, in the presence of 
hydrogen peroxide. Light is emitted as luminol decays from its excited state and 
this can be visualized using a photo sensor equipped with a CCD camera 
(UVIchemi Chemiluminescence Imaging System). A digital image of the 
western blot was captured, saved and digitalized. Generally, faint exposures 
were used for quantitation to minimise errors due to signal saturation. Band 
intensity was quantified using the computer program Image J 
(http://imagej.nih.gov/ij/). Typically, measured protein levels were corrected 
for variations in loading by normalising for differences in GAPDH, β-tubulin 





Antibody Size (kDa) Source Dilution Application 
Phospho-Histone H2A.X (Ser139) (20E3) 15 Rabbit 1 : 2000 W 
Histone H2A.X (D17A3)  15 Rabbit 1 : 2000 W 
Phospho-p53 (Ser15) (16G8) 53 Mouse 1 : 2000 W 
p53 (1C12) 53 Mouse 1 : 2000 W 
p18 INK4C (DCS118) 18 Mouse 1 : 2000 W 
p21 Waf1/Cip1 (12D1) 21 Rabbit 1 : 2000 W 
p27 Kip1 (D69C12) XP® 27 Rabbit 1 : 2000 W 
Phospho-Chk1 (Ser345) (133D3) 56 Rabbit 1 : 2000 W 
Chk1 (2G1D5) 56 Mouse 1 : 2000 W 
Phospho-Chk2 (Thr68) (C13C1) 62 Rabbit 1 : 2000 W 
Chk2 (1C12) 62 Mouse 1 : 2000 W 
Phospho-Rb (Ser807/811) (D20B12) XP® 110 Rabbit 1 : 2000 W 
Rb (4H1) 110 Mouse 1 : 2000 W 
E2F 70 Rabbit 1 : 2000 W 
Cyclin A2 (BF683) 55 Mouse 1 : 2000 W 
Cyclin B1 (V152) 60 Mouse 1 : 2000 W 
Cyclin D1 (92G2) 36 Rabbit 1 : 2000 W 
Cyclin D3 (DCS22) 31 Mouse 1 : 2000 W 
Cyclin E1 (HE12) 48-56 Mouse 1 : 2000 W 
CDK4 (D9G3E) 30 Rabbit 1 : 2000 W 
Phospho-CDK2 (Thr160) 33 Rabbit 1 : 2000 W 
CDK2 (78B2) 33 Rabbit 1 : 2000 W 
Phospho-cdc2 (Tyr15) (10A11) 34 Rabbit 1 : 2000 W 
cdc2 (POH1) 34 Mouse 1 : 2000 W 
Phospho-cdc25C (Ser216) (63F9) 60 Rabbit 1 : 2000 W 
cdc25C (5H9) 60,80 Rabbit 1 : 2000 W 
FoxO1 (C29H4) 78-82 Rabbit 1 : 2000 W 
 
 
Table 2.5. Antibodies used for Western blot (W), Chromatin Immunoprecipitation 
(ChIP) and Immunohistochemical (IHC-P) analysis. All antibodies were obtained 




Antibody Size (kDa) Source Dilution Application 
Phospho-NF-κB p65 (Ser536) (7F1) 65 Mouse 1 : 2000 W 
NF-κB p65 (D14E12) XP® 65 Rabbit 1:2000(W); 4µg(ChIP) W, ChIP 
Phospho-IKKα/β (Ser176/180) (16A6) 85, 87 Rabbit 1 : 2000 W 
IKKβ (D30C6) 88 Rabbit 1 : 2000 W 
Phospho-IκBα (Ser32/36) (5A5) 40 Mouse 1 : 2000 W 
IκBα (L35A5) 39 Mouse 1 : 2000 W 
CYLD (D1A10)  108 Rabbit 1 : 2000 W 
Survivin 16 Rabbit 1:2000(W);1:200(IHC) W, IHC-P 
XIAP (3B6) 53 Rabbit 1 : 2000 W 
Bcl-xl 30 Rabbit 1 : 2000 W 
Mcl-1 (D35A5) 40, 35 Rabbit 1 : 2000 W 
Phospho-Bad (Ser112) (7E11) 23 Mouse 1 : 2000 W 
Bad (D24A9) 23 Rabbit 1 : 2000 W 
Bax (D2E11) 20 Rabbit 1 : 2000 W 
Cleaved Caspase-3 (Asp175) 17, 19 Rabbit 1 : 2000 W 
Cleaved PARP (Asp214) 89 Rabbit 1 : 2000 W 
ID-1 (C-20) 15 Rabbit 1 : 2000 W 
IGF-I Receptor β 95 Rabbit 1:2000(W); 1:50(IHC) W, IHC-P 
PDGF Receptor β (28E1) 190 Rabbit 1 : 25 IHC-P 
VEGF Receptor 2 (55B11) 210, 230 Rabbit 1 : 100 IHC-P 
EGF Receptor (D38B1) 175 Rabbit 1:2000(W); 1:25(IHC) W, IHC-P 
GAPDH (D16H11) 37 Rabbit 1 : 5000 W 
β-Actin 45 Rabbit 1 : 5000 W 
β-Tubulin 55 Rabbit 1 : 5000 W 
TBP 42 Mouse 1 : 2000 W 
HA-Tag (C29F4)  35 Rabbit 1 : 2000 W 
turboGFP antibody, clone OTI2H8 26 Mouse 1 : 2000 W 
 
Table 2.5. Antibodies used for Western blot (W), Chromatin Immunoprecipitation 
(ChIP) and Immunohistochemical (IHC-P) analysis. All antibodies except ID-1 
(Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) were obtained from Cell 




2.5.6 Detection of active p65 NF-κB 
2.5.6.1 Extraction of nuclear and cytoplasmic protein fractions 
Nuclear extracts are preferred to whole cell lysates for gene regulation studies. 
NE-PER Nuclear & Cytoplasmic Extraction Reagents (Thermo Fisher 
Scientific, Waltham, MA, USA) was used to lyse and extract the nuclear and 
cytoplasmic protein fraction of cells according to manufacturer instructions. 
Briefly, culture medium was aspirated from the dishes and adherent cells were 
washed once with ice-cold PBS. After carefully removing residual PBS by 
blotting with tissue paper, an appropriate amount of ice-cold CER I containing 
protease and phosphatase inhibitors (Pierce) was added to the cells. The volume 
ratio of CER I : CER II : NER reagents was maintained at 200 : 11 : 100μl 
respectively. The lysate was collected by scraping, transferred to a pre-chilled 
microcentrifuge tube on ice and vortexed vigorously. Ice-cold CER II was 
added, vortexed, incubated on ice and vortexed vigorously again to completely 
release the cytoplasmic contents before centrifugation at maximum speed 
(15000rpm). The cytoplasmic fraction was found in the supernatant while the 
insoluble pellet contained the intact nuclei. The proteins were extracted from 
the nuclei by re-suspending the pellet in ice-cold NER containing protease and 
phosphatase inhibitors (Pierce, Waltham, MA, USA), incubation on ice for 40 
minutes, with vigorous vortexing for 15 seconds every 10 minutes. The mixture 
was centrifuged at maximum speed (15000rpm) to yield the nuclear fraction in 
the supernatant. Both nuclear and cytoplasmic fractions were quantified and 





2.5.6.2 NF-κB DNA binding activity 
The NF-κB p65 Transcription Factor Assay Kit (Thermo Fisher Scientific, 
Waltham, MA, USA) was used to measure the active/nuclear forms of p65 as it 
contained a streptavidin-coated 96-well plate with bound NF-κB biotinylated-
consensus sequence. Cells were treated with different concentrations of YM155 
(20nM, 40nM, 60nM and 80nM) with or without TNF-α for 24h. The nuclear 
fractions of treated cells were obtained as described in Section 2.5.7.1 and added 
to the above mentioned wells following manufacturer’s instructions. The active 
p65 dimers (p65/p65, p65/p50) were bound to the consensus sequences on the 
coated plate during incubation. After three washes, the plate was incubated with 
an NF-κB p65 primary antibody, washed again (three times), and treated with a 
secondary HRP-conjugated antibody. After incubation, the plate was again 
washed thoroughly (four times) to remove any unbound secondary antibody. A 
chemiluminescent substrate (SuperSignal® Technology, Waltham, MA, USA) 
was added to the wells and the resulting signal was detected with a luminometer 
(Perkin Elmer, Waltham, MA, USA). The relative NF-κB DNA binding activity 
in the nuclear extracts of treated cells was determined by comparing nuclear 
extracts obtained from untreated control cells. 
 
2.5.7 NF-κB Luciferase Reporter Assay 
RCC786.0 cells were transiently co-transfected with pGL4.32[luc2P/NF-κB-
RE/Hydro], a firefly luciferase reporter plasmid driven by NF-κB response 
elements (Promega Corporation, Fitchburg, WI, USA), and 
pGL4.74[hRluc/TK], a renilla luciferase reporter plasmid using 
Lipofectamine® Transfection Reagent (Invitrogen, Waltham, MA, USA) 
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following the manufacturers’ instructions. Similar transient transfection 
procedures were followed as described in Section 2.4.6.2. The ratio of 
pGL4.32[luc2P/NF-κB-RE/Hydro] firefly luciferase reporter plasmid to 
pGL4.74[hRluc/TK] renilla luciferase reporter plasmid in each well was 
maintained at 1.5 : 1. Twenty-four hours post transfection, the cells were treated 
with 40nM of YM155 or 0.1% DMSO in the absence or presence of TNF-α for 
24h. The cells were collected by scraping and stored as dry pellets at -80oC until 
use. Dual-Glo® Luciferase Assay System (Promega, Corporation, Fitchburg, 
WI, USA) was used to measure the luciferase activities according to 
manufacturer’s instructions. Briefly, the cell pellet was re-suspended in PBS 
and added to a 96-well white plate containing the Dual-Glo® Luciferase 
Reagent. The firefly luciferase luminescence was measured after 10 minutes 
and Dual-Glo® Stop & Glo® Reagent was added to each well. The renilla 
luminescence was measured 10 minutes later. Transcription activity of NF-κB 
was calculated as the relative firefly luciferase activity (experimental reporter) 
normalized to the renilla luciferase activity (control reporter). Changes in 
transcription activity of NF-κB of treated samples were expressed as fold 
change with respect to the corresponding control samples. 
 
2.5.8 Development of sandwich ELISA to measure Interleukin 8 (IL-
8) 
Enzyme-Linked Immunosorbent Assay (ELISA) is a useful method that uses 
antibodies and colour changes to identify an "analyte" in a liquid sample. IL-8 
is a chemokine that is secreted into the culture media by cells. The DuoSet 
ELISA Development kit (R&D Systems, Minneapolis, MN, USA) was used to 
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develop a sandwich ELISA to measure the secreted IL-8 in the culture media 
after cells were treated with increasing concentrations of YM155 (20nM, 40nM, 
60nM and 80nM) for 6h and 24h in the absence or presence of TNF-α. Briefly, 
the capture antibody was coated on the 96-well MaxiSorpTM flat bottom plate 
(Nunc, Rochester, NY, USA) overnight. Repeated rounds of aspiration and 
thorough washing was essential for good performance. The plates were then 
blocked with blocking buffer for a minimum of 1h. Thereafter, it was washed 
thoroughly, sample aliquots from culture media or standards were added to the 
wells in triplicates and incubated at room temperature for 2 hours. The washing 
steps were repeated, detection antibody was added and incubated for another 2 
hours.  Again, the washing steps were repeated, streptavidin-HRP was added 
and incubated for approximately 10-20 minutes in the dark. Once the colour of 
the standards developed to achieve a visible intensity gradient, the reactions 
were stopped with the Stop solution. The optical density of each well was 
determined on a microplate reader at 450nm. Determinations were also made at 
570nm to correct for optical imperfections in the plate. Changes in IL-8 
secretion levels of treated samples were expressed as fold change compared to 
corresponding control samples. 
 
2.5.9 Chromatin Immunoprecipitation (ChIP) 
ChIP is an experimental technique that investigates the interaction between 
DNA and proteins in the cell. In this study, ChIP-IT High Sensitivity (Active 
Motif) was used following manufacturer’s instructions with minor 
modifications. The aim of the experiment was to determine the association of 
transcription factor p65 NF-κB with their specific genomic regions (promoters 
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or other DNA binding sites) on the gene BIRC5 and IL8. RCC786.0 cells were 
treated with 40nM of YM155 or 0.1% DMSO (control) for 24h and subjected 
to cell fixation, chromatin sonication, immunoprecipitation and DNA 
purification. Rabbit IgG was used as a negative control in the 
immunoprecipitation experiments. The immunoprecipitated fraction was 
analysed by PCR (Section 2.3.8) and qRT PCR (Section 2.4.4) to determine the 
abundance of the target DNA sequence(s) relative to the input chromatin (not 
subjected to immunoprecipitation).  
 
2.5.9.1 Cell fixation 
DNA and associated proteins on the cell chromatin were crosslinked by fixation. 
Briefly, the cell fixation solution was prepared by mixing fixation buffer, 
formaldehyde and H2O, then added to the cells (15 minutes with gentle shaking), 
followed by stop solution (5 minutes with gentle shaking). Cells were washed 
with PBS and incubated with 20% trypsin-EDTA at room temperature for 5 
minutes. 10% FBS in PBS was used to inactivate the trypsin-EDTA and the cell 
monolayer was washed twice with ice-cold PBS wash buffer (provided in the 
kit), followed by PBS supplemented with protease inhibitors and PMSF. Cells 
were then collected by scraping, pelleted by centrifugation and stored at -80oC. 
Cell pellets were re-suspended in Chromatin Prep Buffer supplemented with 
protease inhibitors and PMSF, incubated on ice for 10 minutes, with vigorous 
vortexing for 15 seconds every 5 minutes and re-pelleted by centrifugation. This 
step was repeated twice. Next, the cell pellet was re-suspended in ChIP Buffer 




2.5.9.2 Chromatin sonication and Input preparation 
Fragmentation of DNA-protein complexes by sonication generated chromatin 
fragments of appropriate size for immunoprecipitation and subsequent DNA 
analysis. Sonication of chromatin was performed on an ice-bath and conditions 
for sonicating fixed chromatin of RCC786.0 cultured cells were optimised (25% 
amplitude, 10 pulses of 30 seconds each, with a 30-second rest between each 
pulse). Cellular debris was pelleted by maximum centrifugation. A small 
portion of the chromatin preparation was used to generate the Input DNA for 
analysis of shearing efficiency and quantitation while the rest was stored in -
80oC for immunoprecipitation. To prepare the input DNA, TE buffer and RNase 
was added, vortexed to mix and incubated at 37oC for 30 minutes. Proteinase K 
was added to remove associated proteins, vortexed again, incubated in a 
thermocycler at 55°C for 30 minutes and then 80°C for 2 hours. Precipitation 
Buffer, Carrier (provided in the kit) and absolute ethanol was then added, 
vortexed and the mixture chilled at -80°C for 30 minutes to overnight. DNA 
was pelleted by maximum centrifugation, washed with 70% ethanol and 
centrifuged at maximum speed. Pelleted DNA was left to dry for 10-15 minutes 
and DNA Purification Elution Buffer was added to generate the Input DNA. 
The DNA concentration of each chromatin preparation was determined using 
the Input DNA. Following that, 500mM NaCl was added to 500ng of input DNA 
and the samples were placed in a thermocycler at 100°C for 20 minutes, after 
which the temperature was decreased to 50°C for 1 minute. The mixture was 
then cooled to room temperature for 5 minutes before being applied to a 1.5% 
agarose gel for shearing efficiency analysis. DNA should appear as a smear 




The crosslinked chromatin fragments associated with the transcription factor 
p65 NF-κB were selectively immunoprecipitated using the p65 NF-κB antibody. 
10µg of sheared chromatin was added to ChIP buffer containing protease 
inhibitor cocktail, 4µg antibody and 5µL blocker mix. The mixture was 
incubated on an end-to end rotator overnight at 4oC. Next, protein G agarose 
beads were washed twice with TE, added to the ChIP reaction mixture and 
incubated on the rotator for 3 hours at 4oC. The entire reaction was then 
transferred to a ChIP filtration column, flow through was allowed to occur by 
gravity, washed with Wash Buffer for a total of 6 times before centrifugation to 
remove residual buffer. Elution Buffer AM4 was added to elute the bound ChIP 
DNA. 
 
2.5.9.4 ChIP DNA purification 
The protein associated DNA fragments were purified. Enrichment of specific 
DNA sequences represented regions on the genome that were associated with 
the transcription factor p65 NF-κB. Proteinase K was added to remove the 
associated protein, vortexed to mix and heated in a thermocycler at 55°C for 30 
minutes and the temperature was increased to 80°C for 2 hours. DNA 
Purification Binding Buffer was added, pH adjusted with 3M Sodium Acetate 
until a bright yellow was observed and the sample was loaded onto the 
purification column. After centrifugation, the column was washed with DNA 
Purification Wash Buffer containing ethanol. Maximum centrifugation speed 
(15000rpm) was applied to remove any residual Wash Buffer from the column. 
DNA Purification Elution Buffer was added to elute the purified DNA from the 
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column and stored at -20°C for PCR (Section 2.3.8) and qRT PCR (Section 
2.4.4) analyses. 
 
2.6 Generation of stable cell lines 
2.6.1 Determination of Antibiotic Sensitivity 
To enable the selection of stably transfected cells with survivin knockdown or 
survivin over-expression, the minimum concentration of antibiotics (blasticidin 
or geneticin G418) required to kill the un-transfected cells was determined. 
RCC786.0 cells were exposed to varying concentrations of blasticidin (0, 2, 4, 
6, 8, 10 µg/mL) or geneticin (0, 100, 200, 300, 400, 500 µg/mL) for the selection 
of survivin knockdown or survivin overexpressed cells respectively. The 
selection media was replenished every 3-4 days and the percentage of surviving 
cells was observed. The concentration of antibiotics required to kill the cells 
within 10-14 days was determined to be 10µg/mL blasticidin and 500µg/mL 
geneticin. 
 
2.6.2 Stable transfection and selection of survivin knockdown or over-
expressed cells 
Transient transfection of RCC786.0 cells was performed using miRNA 
expression vector to knockdown survivin (Section 2.4.6.2) and similar 
procedures were followed using survivin expression vector (Section 2.3.4.2) to 
constitutively over-express survivin. Following analysis of transfection 
efficiency through the detection and capturing of GFP expression, the 
transfected cells were trypsinized, diluted and re-plated in larger-sized culture 
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vessels containing fresh medium and the appropriate concentration of 
blasticidin or geneticin. The selection medium was replaced with fresh medium 
containing antibiotics every 2-3 days. After 10-14 days of exposure to the 
antibiotics, the cells that remained viable retained the expression plasmid stably 
integrated in the genome of the targeted cells. A mock transfection was 
performed in parallel as a control to ensure the cells were dying. The resistant 
cells were then left to grow for a longer duration until individual antibiotic-
resistant colonies can be identified with the naked eye. At least 10 antibiotic-
resistant colonies per construct were picked and expanded into larger culture 
vessels. The antibiotic resistant clones were analysed by checking for the 
presence of the GFP and isolating of the genomic DNA (Section 2.3.2) for DNA 
sequencing (Section 2.3.10) to confirm the presence and correct sequence of the 
GOI. The cells were also lysed for isolation of RNA (Section 2.4.2) and protein 
(Section 2.5.1) to analyse the target mRNA (Section 2.4.4) and protein 
expression (Section 2.5.5). The relative expression was obtained by comparing 
with un-transfected cells and cells stably transfected with the vector alone. The 







2.7 Treatment of RCC cells and xenografts 
2.7.1 Chemical compounds/Drugs 
Four chemical compounds were used in this study and were obtained from 
Shanghai BioChemPartner, PRC. YM155 (survivin inhibitor), 9-aminoacridine 
(NF-κB inhibitor), sorafenib (tyrosine kinase inhibitor) and bortezomib 
(proteasome inhibitor) were diluted in DMSO to yield stock solutions of 10-
50mM which were aliquoted and stored at 4oC. The stock solutions were diluted 
with culture medium to yield the desired concentrations when required. 0.1% 
DMSO in media was used in place of the chemical inhibitors as a control. 
 
2.7.2 TNF-α stimulation 
For TNF-α stimulation, cells were exposed to 20ng/mL TNF-α (Promega 
Corporation, Fitchburg, WI, USA) for 30 minutes. After which the cells were 
treated with various concentrations of the chemical compounds (Section 2.7.1). 
Cells were then lysed for protein analysis (Section 2.5.5). 
 
2.7.3 In vitro drug combination 
Growth inhibitory IC50 of each drug was calculated (Section 2.8.2). Two drugs 
(A, B) were combined in the following ways i) 0.5x IC50 of A was combined 
with either 0.5x IC50 or 1x IC50 of B. ii) 1x IC50 of A was combined with either 
0.5x IC50 or 1x IC50 of B. RCC786.0 was treated with each combination of A 
and B for 72h at 37oC. Cell proliferation assay was carried out using MTS 
(Section 2.8.2). To evaluate the interaction between A and B, the method of 
Chou and Talalay406 was used.  
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The combination index (CI) value for each combination of x% inhibition was 
calculated as: 
 
where D1 indicates the dose of A in the combination, D2 indicates the dose of B 
in the combination, DX1 and DX2 represent the dose of A and B respectively 
giving rise to x% inhibition when used alone. Chou and Talalay defined 
synergism as a more than expected additive effect, and antagonism as a less than 
expected additive effect. Their equation determines the additive effect (CI=1) 
rather than synergism or antagonism for mutually non-exclusive drugs that have 
totally independent modes of action. Thus, they proposed that a CI less than 
0.90 indicates a synergistic interaction; CI between 0.90 and 1.10 indicates an 
additive effect; and CI more than 1.10 indicates antagonism406.  
The dose-reduction index (DRI) is a measure of how many times the dose of 
each drug in a synergistic combination is reduced at a given effect level (x% 
inhibition) compared with the dose of each drug alone. For a combination of 
drugs A and B, DRI1 of A = (DX1) / D1 and DRI2 of B = (DX2) / D2. DX1, DX2, 
D1 and D2 are defined in the preceding paragraph. When both drugs do not have 
overlapping toxicity towards the host, then DRI > 1 may be beneficial; although 
it does not necessary indicates synergism. If one of the two drugs has no effect 
by itself or the IC50 could not be accurately obtained, then 
synergism/antagonism cannot be determined. Instead, potentiation or inhibition 
can be determined. 
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2.7.4 In vivo drug treatment 
Drug treatment was performed by Professor Hung Huynh to assess the efficacy 
of YM155 alone or in combination with Sorafenib in patient-derived RCC 
xenografts in SCID mice (Section 2.2.2). Treatment was initiated when the 
average tumours size was approximately 200 mm3 (about two weeks post 
implantation). Briefly, to determine the effects of various doses of YM155 on 
the inhibition of tumour growth in RCC xenografts implanted in SCID mice, 
xenograft-bearing mice (10 per group) were administered (intra-peritoneal) with 
vehicle (PBS) or YM155 at doses 1, 2 or 3 mg/ kg BID for a total duration of 
15 days. This treatment doses were with reference to current literatures407, 408 on 
the in vivo studies of YM155 in tumour xenograft model with minor 
modifications to the administration route and frequency. Sorafenib was well 
studied in xenograft-bearing mice332, 369, 409. In these studies, RCC xenograft-
bearing mice were administered orally with vehicle and Sorafenib (10mg/kg, 
20mg/kg and 40mg/kg QD) daily for a total duration of 3 consecutive weeks. 
This treatment doses were with reference to current literatures332, 410 on the in 
vivo studies of Sorafenib in tumour xenograft model. Hence, there was no need 
to determine the effects of various doses of Sorafenib on the inhibition of tumor 
growth in primary RCC xenografts implanted in SCID mice. To determine the 
effects of combination of YM155 and Sorafenib on the inhibition of tumour 
growth in RCC xenografts implanted in SCID mice, xenograft-bearing mice 
were administered via intra-peritoneal (YM155) or oral (Sorafenib) with vehicle, 
YM155 alone (2mg/kg BID), Sorafenib alone (10mg/kg QD) and a combination 
of YM155 (2mg/kg BID) and Sorafenib (10mg/kg QD) for a total duration of 
15 days. Growth of established xenografts was monitored at least twice weekly 
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by measuring the tumour length (a) and breadth (b) with Vernier calipers. 
Tumour volume was calculated from (a−b2)/2. Animals were killed at 12h after 
the last treatment dose, body and tumour weights were recorded and tumours 
were snapped frozen in liquid nitrogen and stored at -80oC for further analyses. 
 
2.8 Cell Proliferation Assays 
2.8.1 Clonogenic survival assay 
To assess the ability of adherent cells to survive and replicate,  clonogenic 
survival assays were performed as described411. Forty-eight hours after siRNA 
transfection, cells were disaggregated and seeded in 10-cm dishes (in triplicates) 
at 1000-1500 cells/dish. The cells were incubated at 37°C, 5% CO2 for 10-14 
days until discreet colonies were observed. Cell colonies were fixed in 
methanol:acetic acid (3:1) and stained with Giemsa Methylene Blue (Merck). 
Visible colonies were manually counted. The remaining transfected cells were 
pelleted by centrifugation at 13000rpm at 4°C, washed with ice-cold PBS, lysed 
with protein extraction reagent and subjected to western immunoblotting 
(Section 2.5.5) to assess IGF1-R and survivin levels. 
 
2.8.2 MTS assay 
In vitro cell viability was assessed by MTS assay using the CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (Promega Corporation, 
Fitchburg, WI, USA). The assay is based on the ability of mitochondrial 




tetrazolium; MTS] to a purple product called formazan.  Cells use NADPH or 
NADP produced from normal cellular activity to achieve this reduction.  When 
cells are not viable, the reduction does not occur due to insufficient 
NADPH/NADP.  Thus less formazan is formed in non-viable cells. The amount 
of formazan is monitored by its absorbance in the visible range (490 nm). 
Besides MTS, the kit contains phenazine methosulfate (PMS) which functions 
as an intermediate electron carrier to couple the production of NADH/NADPH 
to the reduction of MTS. The assay measures the mass of viable cells in 
proliferation, using a colorimetric method in which MTS is reduced by 
dehydrogenase enzyme in metabolically active cells, to a brown/purple 
formazan product that is soluble in culture medium. Therefore, the quantity of 
formazan product is directly proportional to the number of viable cells in culture. 
Generally, 2000–10 000 cells were seeded in clear 96-well flat-bottomed plates 
and allowed to adhere overnight for 24h. Cells were then exposed to different 
concentrations of test compound in growth media for another 72h. 20µL of 
MTS/PMS solution was added to each well containing 200µL of growth media, 
and the cells were further incubated  for 3h at 37oC before absorbance 
measurement were made on a Benchmark Plus microplate spectrophotometer 
(Bio-Rad Laboratories, Hercules, CA, USA) at 490nm. 
Absorbance values from treated cells were expressed as a percentage of that 
from control cells to determine the cell growth inhibitory IC50 of the compounds. 






Cell viability was determined from the expression: 
ܥ݈݈݁	ܸܾ݈݅ܽ݅݅ݐݕ ൌ ൫ܣܾݏ݋ݎܾܽ݊ܿ݁௖௘௟௟௦	ା	௖௣ௗ െ ܣܾݏ݋ݎܾܽ݊ܿ݁௖௣ௗ൯ሺܣܾݏ݋ݎܾܽ݊ܿ݁	௖௘௟௟௦	ା	௩௘௛௜௖௟௘ െ	ܣܾݏ݋ݎܾܽ݊ܿ݁௩௘௛௜௖௟௘ሻ ൈ 100% 
Where Absorbance cells + cpd = absorbance of cells in vehicle (media + 0.1% 
DMSO) in the presence of test compound; Absorbance cpd = absorbance of 
vehicle and test compound (to account for absorbance due to test compound at 
490 nm); Absorbance cells + vehicle = absorbance of untreated cells and vehicle; 
Absorbance vehicle = absorbance of vehicle in the absence of cells.  
% Viability readings for each test compound were plotted against log 
concentration on GraphPad Prism version 5.0 (GraphPad Software Inc, San 
Diego, CA, USA), with constraints set at ≥ 0 and ≤ 100%. A sigmoidal curve 
was generated from which IC50 (concentration at which 50% of cells are viable) 
was obtained. Each experiment was repeated at least twice. 
 
2.8.3 Cell cycle analysis 
2.8.3.1 DNA content analysis using propidium iodide (PI) 
Analysis of the cell cycle by quantitation of DNA content is one of the earliest 
applications of flow cytometry. DNA can be stained by DNA-binding dyes such 
as propidium iodide (PI) and 7-aminoactinomycin-D (7-AAD) and they bind in 
proportion to the amount of DNA present in the cell. As such, cells that are in S 
phase will have more DNA than cells in G1 phase. S phase cells will thus 
fluoresce more intensely. Fluorescence will increase further when cells are in 
the G2 phase due to doubling of DNA content but will be reduced after mitosis 
(i.e. in the G1 phase). RCC786.0 cells were treated with increasing 
concentrations of YM155 (20nM, 40nM, 60nM and 80nM) or 0.1% DMSO 
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(control) for 6h, 24h or 48h. Generally, cells need to be fixed or permeabilised 
with absolute ethanol to allow entry of the dye which will otherwise be actively 
pumped out by living cells. Fixation was performed over 30 minutes. Thereafter 
cells can be left at this stage at 4oC for several weeks. Cells were pelleted by 
centrifugation, re-suspended in 100µL of 100µg/mL PI containing 0.1% Triton-
X-100 and 0.5mg/mL RNase A. After incubation for 30 minutes at 4oC, the cells 
were analysed directly by flow cytometry. Appropriate volume of PBS was 
added to dilute the cell suspension if cell density is too high. Using the 
cytometer LSRFortessa (BD Biosciences), a forward scatter (FS) and side 
scatter (SS) plot was displayed to identify the cells in the suspension. Analysis 
of the pulse shape by using pulse area vs. pulse width helped to exclude cell 
clumps and doublets. Single cell population was gated on the scatter plot and 
applied to the PI histogram plot. The percentage of cells in each cell cycle phase 
was quantified from gated populations by using the FlowJo version 10 (Tree 
Star Inc, Ashland, OR, USA) analysis program. 
 
2.8.3.2 S-phase analysis using bromodeoxyuridine (BrdU)  
Direct measurement of new DNA synthesis is based on the incorporation of 
nucleoside analogs such as BrdU into the newly synthesized strand in actively 
proliferating cells. When BrdU is combined with DNA dyes such as PI (Section 
2.8.3.2), cell populations in the various cell cycle, namely G0-G1, G1* (late G1, 
early S), S-G2 (late S, early G2), G2-M phases are readily identified. BD 
Pharmingen™ APC BrdU Flow Kit (BD Biosciences, Franklin Lakes, NJ, USA) 
was used in S phase analysis following manufacturer’s instruction with minor 
modifications. Briefly, BrdU was added to RCC786.0 cells and incubated for 
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1h at 37oC. Cells pulsed with BrdU were rinsed with PBS and increasing 
concentrations of YM155 (20nM, 40nM, 60nM and 80nM) or 0.1% DMSO 
(control) were added for 6h, 24h or 48h. The cells were trypsinized, washed and 
pelleted by centrifugation. BrdU pulse-chase time course experiments are 
commonly used for examining cellular processes over time. Cells were fixed 
with absolute ethanol for a least 30 minutes, washed once with PBS, gently 
vortexed as 2N HCl/Triton-X-100 was added dropwise to denature the DNA 
and the cell suspension was incubated for 30 minutes at room temperature. Next, 
cells were washed once with PBS, neutralized with 0.1 M Na2B4O7, pH 8.5, 
washed twice with PBS and stained with APC fluorochrome-conjugated anti-
BrdU antibody for 1h at 4oC in the dark. Thereafter, the stained cells were 
washed twice with PBS, pelleted by centrifugation and re-suspended in 100µL 
of 100µg/mL PI and 0.5mg/mL RNase A. After 30 minutes incubation at 4oC 
in the dark, an appropriate volume of FACS buffer was added and the cells were 
analysed directly by flow cytometry. Unpulsed cells, cells that were BrdU 
pulse-labelled at 0h, unstained cells, cells stained with BrdU only (no PI) and 
cells stained with PI only (no BrdU) were used as controls to set up 
compensation. Using the cytometer LSRFortessa (BD Biosciences, Franklin 
Lakes, NJ, USA), a forward scatter (FS) and side scatter (SS) plot was displayed 
to identify the cells in the suspension. Cells were further gated based on their 
BrdU and PI content. It should be noted that BrdU is diluted with each cell 
division, resulting in a decrease in the BrdU signal over time. The percentage 
of cells in each cell cycle phase was quantified from gated populations using 




2.9 Apoptosis assays 
2.9.1 Annexin V apoptosis detection 
Apoptosis is characterised by changes in certain morphological features of the 
cell such as, the loss of plasma membrane asymmetry and attachment, 
cytoplasm and nucleus condensation, and cleavage of DNA. The loss of 
membrane integrity is used to detect apoptotic cells and is based on the 
translocation of the phospholipid phosphatidylserine (PS) from the inner to the 
outer side of the plasma membrane. Annexin V is a 35-36kDa phospholipid-
binding protein with a high affinity for exposed PS residues on the cell surface. 
Apoptosis was monitored using a BD Pharmingen™ PE Annexin V apoptosis 
detection kit (BD Biosciences, Franklin Lakes, NJ, USA). The kit contains a 
phycoerythrin (PE) conjugated Annexin V which serves as a sensitive probe for 
flow cytometric analysis of cells in the early stages of apoptosis and a DNA 
binding dye 7-AAD which serves to differentiate early apoptotic cells from cells 
that have undergone apoptotic or necrotic cell death. RCC786.0 cells were 
treated with increasing concentrations of YM155 (20nM, 40nM, 60nM and 
80nM) or 0.1% DMSO (control) for 24h, 48h or 72h. Cells were trypsinized, 
washed twice with cold PBS, blocked with 1% BSA in PBS, pelleted by 
centrifugation and re-suspended in 1X Binding Buffer at a concentration of 1 x 
106 cells/mL. 5μl of Annexin V and 5μl 7-AAD were added to 1 x 105 cells, 
gently mixed and incubated for 20 minutes at room temperature in the dark. An 
appropriate volume of 1X Binding Buffer was added and the stained cells was 
analysed by flow cytometry within 1h.  Unstained cells, cells stained with 
Annexin V only (no PI) and cells stained with 7-AAD only (no Annexin V) 
were used as controls to set up compensation and quadrant plots. The percentage 
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of cells in each quadrant was quantified from gated populations by using the 
FlowJo version 10 (Tree Star Inc, Ashland, OR, USA) analysis program. In this 
study, apoptosis was measured over time. Hence, the movement of cells through 
the quadrants could be tracked and provided the basis for distinguishing 
apoptotic cells from those that have undergone necrotic cell death. 
 
2.9.2 A triplex assay that measures viability, cytotoxicity and caspase 
activation 
The ApoTox-Glo™ Triplex Assay (Promega Corporation, Fitchburg, WI, USA) 
was used to assess viability, cytotoxicity and caspase activation events. Briefly, 
RCC786.0 cells were seeded in 96-well white flat clear bottom culture plate and 
were treated with increasing concentrations of YM155 (20nM, 40nM, 60nM 
and 80nM) or 0.1% DMSO (control) in a total volume of 100µL/well for 24h, 
48h or 72h. The marker for cell viability is a fluorogenic, cell-permeant, peptide 
substrate (glycyl-phenyl-alanyl-aminofluorocoumarin; GF-AFC) and the 
marker of cytotoxity is a fluorogenic, cell-impermeant peptide substrate (bis-
alanylalanyl-phenylalanyl-rhodamine 110; bis-AAF-R110). 20µL of this 
reagent was added to each well in the 96-well plate. After 60 minutes incubation 
at 37oC, fluorescence was measured using two wavelength sets: 400Ex/505Em 
(for viability) and 485Ex/520Em (for cytotoxicity). Thereafter, 100μl of 
Caspase-Glo® 3/7 Reagent which contains a luminogenic caspase-3/7 substrate 
with an optimised tetrapeptide sequence DEVD, was added to all wells and 
incubated for 30 minutes at room temperature. Cleavage of the substrate by 
caspase generated a “glow-type” luminescent signal produced by luciferase. 
The luminescent intensity was proportional to the amount of caspase activity 
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(hallmark of apoptosis) in the cells. A no-cell well was used as a negative 
control for determining background fluorescence and luminescence. 
 
2.10 Statistical Analysis 
The graphing and statistical analysis software GraphPad Prism version 5.0 
(GraphPad Software Inc., San Diego, CA, USA) and Excel (Microsoft 
Corporation, Redmond, WA, USA) were used to plot and analyse data. Graphs 
were plotted to show mean values and error bars which depicted standard error 
of the mean (SEM). The student’s t-test and analysis of variance (ANOVA) with 
Bonferroni post–hoc test were used for the comparison of mean values between 
two and multiple (>2) groups, respectively. A minimum of 95% level of 
significance (p<0.05) was used to define statistical significance. All 





Expression of survivin in RCC and the effect of 
YM155 on the gene expression profile of RCC 
 
3.1 Introduction 
The loss of the functional VHL protein in renal cell carcinoma (RCC) leads to 
the upregulation of IGF1-R expression, a factor that contributes to 
tumourigenesis412 and resistance to apoptosis413-415. However, targeting of 
IGF1-R may lead to metabolic dysfunction including hyperglycaemia as IGF1-
R shares considerable homology with the insulin receptor. On the other hand, 
downregulating protein(s) that lies downstream of IGF1-R may provide the 
same outcome as the targeting of IGF1-R but without the clinical disadvantages. 
To this end, survivin is proposed as a suitable alternative target. Survivin is a 
member of the Inhibitor of Apoptosis (IAP) protein family and is consistently 
overexpressed in a large number of malignancies but not in normal 
differentiated adult tissues144-146, 284. In malignant tissues, survivin expression is 
linked to anti-apoptosis, metastasis and resistance to chemotherapy110, 141, 142. In 
recent years, different approaches to counteract survivin have been proposed 
with the dual aim of inhibiting tumour growth and enhancing the cellular 
response to apoptosis-inducing anti-cancer agents. The 
dioxonaphthoimidazolium analog YM155 is reportedly the 1st compound that 
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selectively inhibits survivin gene transcription and protein expression in several 
tumour cell lines228, 416.    
In view of the foregoing considerations, the aims of this chapter are to (i) to 
analyse the levels of survivin expression in primary and immortalized RCC cell 
lines and to determine if there is a correlation between survivin levels and 
tumourigenicity, (ii) to assess the effects of YM155 on the viability of RCC cell 
lines in which survivin expression has been suppressed or increased and (iii) to 
determine by RNA microarray, other targets of YM155 in treated RCC786.0 
cells. 
 
3.2 Results and Discussion 
3.2.1 Cells without functional VHL protein express higher levels of 
IGF1-R and survivin 
Levels of IGF1-R and survivin were determined in three human RCC cell lines. 
NCC010 is a primary cell line derived from a patient with clear cell RCC. 
RCC786.0 is a clear cell RCC cell line containing a dysfunctional pVHL due to 
a mutation in the VHL gene. This mutation will lead to up-regulation of IGF1-
R. The isogenic pair (RCC786.0/EV, RCC786.0/VHL.HA) is derived by stable 
transfection of RCC786.0 with an empty vector to give RCC786.0/EV or 
haemagglutinin (HA)-tagged VHL to give RCC786.0/VHL.HA.  
Levels of the oncogenic proteins IGF1-R and survivin were probed by 
immunoblotting. The expression of the VHL transgene in RCC786.0/VHL.HA 
was verified by immunoblotting with anti HA-tagged antibody and β-actin as 







Figure 3.1. Immunoblots of whole cell lysates of RCC786.0/EV, 
RCC786.0/VHL.HA and NCC010. β-actin is the loading control. HA-tag 
indicates the presence of the VHL transgene. The expression of survivin 
mirrors that of insulin-like growth factor 1 receptor (IGF1-R), which has 
been shown to be VHL-dependent412. Cells with mutated VHL, which is 
present in >75% of all clear cell RCC, expressed higher levels of IGF1-R 










Figure 3.1 shows detectable levels of IGF1-R and survivin in all three cell lines. 
Interestingly, significantly higher expression levels of both IGF1-R and survivin 
were found in RCC786.0/EV and NCC010 whereas lower levels of both 
proteins were found in RCC786.0/VHL.HA. Clearly, the differentiated levels 
of IGF1-R and survivin in the isogenic pair of RCC786.0 cells are related to 
their VHL status. In view of these VHL-related differences in protein expression, 
subsequent investigations were limited to RCC786.0/EV as approximately 75% 
of all clear cell RCCs harbour inactivating VHL mutations.  
Tentatively, it would seem that the constitutive activation of IGF1-R coupled 
with aberrant expression of survivin has led to abnormal inhibition of apoptosis 
and hence progression of RCC. The higher levels of survivin may be related to 
its longer half-life in VHL-null RCC786.0/EV cells. The breakdown of survivin 
is regulated by the ubiquitin-proteasome pathway and the latter may be 
downregulated when Ras signaling is constitutively activated or when there are 
mutations in the BIR domain417-419. The high levels of IGF1-R and survivin 
expression in NCC010 will be further explored in another study. 
 
3.2.2 Molecular biomarker profiling in RCC 
Anti-angiogenesis based molecular targeted therapy against VEGFR is 
currently the standard therapy for advanced RCC420-422. However, positive 
therapeutic outcomes are observed in slightly less than half of treated patients 
and those who respond, often experienced significant adverse effects. Currently, 
there is still a lack of predictive prognostic markers, both clinical and biological, 
that would enable reliable selection of the right treatment for the right patients. 
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A better understanding of the expression levels of other oncogenic tyrosine 
kinase receptor (TKR) proteins in individual tumours may help in this respect.  
To this end, a RCC tissue microarray was constructed from 302 patient samples 
and the expression levels of VEGFR, EGFR, PDGFR, IGF1-R and survivin 
were investigated. The results are summarised in Figure 3.2. A breakdown of 
the RCC histological subtypes in the microarray showed that the majority 
(73.2%) were of the conventional clear cell type (Figure 3.2A). 
Immunohistochemical analyses of VEGFR, EGFR, PDGFR, IGF1-R and 
survivin were undertaken to assess the expression levels of these proteins in the 
tumour samples. Figure 3.2B gives representative slides of IHC positively and 
IHC negatively stained proteins in tissue samples derived from clear cell RCC. 
The breakdown of IHC positively stained proteins in conventional clear cell and 
papillary RCCs are depicted in Figure 3.2C. A high level of stained protein 
would imply that the protein is upregulated in the tissue. Both clear cell and 
papillary RCCs had broadly similar levels of IHC positive proteins, with the 
exception of VEGFR which was higher in clear cell tumours than papillary 
tumours. Of the investigated proteins, PDGFR was conspicuous in having the 
lowest levels in both tumour types. Figure 3.2D shows the distribution of the 
proteins in tumours of varying grades and stage. High stage tumours (listed as 
4) were associated with high levels of IHC positive IGF1-R and survivin as 
compared to VEGFR, EGFR and PDGFR. However, no statistical correlation 











Figure 3.2. The expression profile of VEGFR, EGFR, PDGFR, IGF1-R 
and survivin in a RCC tissue microarray. (A) Breakdown of the RCC 
histological subtypes in the microarray showed that the majority (73.2%) 
were of the conventional clear cell type. (B) Representative slides of IHC 
positive and negative staining of VEGFR, EGFR, PDGFR, IGF1-R and 
survivin in clear cell RCC. (C) An overview of the percentage of selected 
oncogenic proteins (VEGFR, EGFR, IGF1-R and survivin) which are 










RCC stained positive within stage (%) 
VEGFR EGFR IGF1-R PDGFR Survivin 
1 100.0 100.0 100.0 0.0 100.0 
1a 79.3 96.6 100.0 20.2 86.3 
1b 93.4 98.4 98.4 21.3 80.3 
2 81.0 92.9 97.6 7.1 78.6 
3a 80.3 88.7 95.8 25.7 74.6 
3b 84.4 96.9 93.8 12.5 71.9 
3c 66.7 100.0 100.0 66.7 100.0 
4 66.7 66.7 100.0 0.0 100.0 
Fuhrman 
Grade 
RCC stained positive within grade (%) 
VEGFR EGFR IGF1-R PDGFR Survivin 
1 84.1 93.2 93.2 31.8 88.6 
2 89.5 96.5 96.5 18.1 83.5 
3 74.6 90.5 100.0 15.9 69.8 
4 52.2 91.3 100.0 8.7 69.6 
 
 
Figure 3.2. The expression profile of VEGFR. EGFR, PDGFR, IGF1-R 
and survivin in a RCC tissue microarray. (D) Distribution of IHC positive 
proteins in patient samples further stratified by tumour stage and Fuhrman 
grade. There was an inverse correlation between the expressions of 





The Fuhrman grading system is used to predict metastatic potential of tumours, 
with grade 1 tumours having a statistically lower metastatic rate as compared to 
those with higher grades (Chapter 1, Section 1.1.2, Table 1.4). The results 
showed that Fuhrman Grade 4 tumours are associated with high expression 
levels of IGF1-R, EGFR and survivin. On the other hand, VEGFR and PDGFR 
levels were significantly suppressed in Grade 4 tumours (p<0.05). 
To date, tumour stage and nuclear grade are used as important prognostic 
variables for patients with RCC423, 424 but they do not accurately predict the 
clinical outcome. The profiling of selected oncogenic proteins in patient derived 
RCC tumours have shown that IGF1-R, EGFR and survivin are potential 
molecular markers that could serve as useful adjuncts in Tumour, Node and 
Metastasis (TNM) staging and predicting survival outcomes. They may also 
represent novel therapeutic targets as they are often co-expressed with VEGFR 
(current target of choice) in clear cell RCC.   
 
3.2.3 Targeting survivin alone does not lead to the down-regulation 
of IGF1-R 
Next, we explored the effects of silencing IGF1R on survivin expression and 
the silencing of survivin on IGF1-R expression. Briefly, IGF1R or survivin 
specific siRNAs were used to induce IGF1R or survivin gene silencing 
respectively in RCC786.0/EV (Figure 3.3A), RCC786.0/VHL.HA (Figure 3.3B) 
and NCC010 (Figure 3.3C) cells. Protein levels were determined within 48h 
following siRNA transfection. In all three cell lines, the depletion of IGF1-R by 










        
Figure 3.3. Effects of silencing IGF1R and survivin. Silencing IGF1R led 
to a slight decrease in the expression of survivin. Silencing survivin did not 
affect the expression of IGF1-R. 100nM of IGF1R or survivin specific 
siRNAs was used to effectively induce IGF1R or survivin gene silencing 
respectively in (A) RCC786.0/EV, (B) RCC786.0/VHL.HA and (C) 
NCC010 within 48h following siRNA transfection. Non-targeting siRNA 





On the other hand, silencing survivin did not affect IGF1-R which remained at 
levels comparable to control cells. This is anticipated as survivin is downstream 
of IGF1-R. Thus, targeting survivin would not lead to the downregulation of 
IGF1-R and this is an useful outcome as the most common side effects of IGF1-
R targeted therapy is hyperglycaemia due to the structural similarity of IGF1-R 
with the insulin receptor425, 426.  
 
3.2.4 Silencing survivin by siRNA leads to significant decrease in cell 
survival of clear cell RCC cell lines 
The ability of cells to propagate and form colonies (defined as a cluster of at 
least 50 cells) is an indication of its reproductive capability427. Thus, it was of 
interest to determine the effects of silencing either IGF1R or survivin on the 
proliferative capacities of the transfected cells; RCC786.0/EV, 
RCC786.0/VHL.HA and NCC010. Briefly, 48h after siRNA transfection, cells 
were disaggregated and seeded for clonogenic cell survival assay. Visible and 
discrete colonies were counted at the end of 10-14 days (Fig 3.4A). The 
percentage difference in number of colonies for each transfected cell type is 
tabulated in Figures 3.4B. The results clearly showed that the proliferation of 
cells transfected with IGF1R or survivin specific siRNAs was significantly 
retarded compared to negative control siRNA transfected cells. The retardation 
was particularly marked in survivin-silenced cells where a staggering 95% 
decrease in colony formation was observed as compared to control cells 
(p<0.001). This trend was observed across all three transfected cell lines. 
Proliferation was also inhibited in IGF1R silenced cells (40-50% decrease), 





        
  
 
Figure 3.4. Effects of gene silencing on proliferation of transfected cells 
as assessed by the clonogenic survival assay. Silencing survivin led to a 
more significant decrease in cell survival as compared to silencing of IGF1-
R. (A) Depicts visible and discrete colonies of transfected RCC786.0/EV 
which were counted at the end of 10-14 days. Microscopic images taken at 
100X magnification. (B) The percentage difference in growth for 
RCC786.0/EV, RCC786.0/VHL.HA and NCC010 cells. *** p<0.001 as 




3.2.5 Silencing survivin by siRNA induces apoptosis  
Full-length PARP is a 116kDa protein involved in the repair of DNA, cell 
differentiation and chromatin structure formation. During apoptosis, PARP is 
cleaved by caspase-3, and possibly other caspases, to a smaller 89kDa fragment. 
The cleavage of PARP facilitates cellular disassembly and serves as a marker 
of apoptosis428. The time-dependent expression of cleaved PARP was 
monitored in RCC786.0/EV cells which have been subjected to survivin siRNA-
induced gene silencing. Figure 3.5 shows the appearance of cleaved PARP on 
Day 4, with levels increasing on Day 5 before decreasing on Days 6 and 7.  The 
activation of the apoptotic pathway in these siRNA-transfected cells would 
explain the marked decrease in the ability of RCC cells to form colonies in 
clonogenic survival assay. The loss of cleaved PARP on Days 6 and 7 was 
attributed to the degradation of survivin siRNAs over time. These results are in 
keeping with the role of survivin in the regulation of apoptosis.   
3.2.6 Degradation of survivin siRNA in vitro 
To assess the stability of the siRNA-silenced survivin gene in transfected 
RCC786.0/EV cells, survivin levels were was monitored over a period of 13 
days (Figure 3.6). It is seen that a single transfection using survivin specific 
siRNA achieved >90% (quantified by densitometry) knockdown by day 4 and 
lasted up to 7 days post-transfection. This was followed by a rebound in survivin 
levels on day 10 and 13 due to degradation of the siRNAs and the re-expression 
of survivin within the cellular environment. The variation in expression of 
survivin on day 7 between Figures 3.6 and 3.5 may possibly be due to slight 
difference in transfection efficiency which is usually dependent on health of 







Figure 3.5. The expression of cleaved PARP in RCC786.0/EV cells 
following survivin siRNA-induced gene silencing was time dependent. 
The protein expressions of cleaved PARP and survivin, from Day 0 to 7 
following transient transfection of RCC786.0/EV with survivin specific 
siRNA, were monitored using western immunoblotting analyses. Cleaved 
PARP appeared on day 4, approximately 2 days after the expression of 




Figure 3.6. Duration of survivin specific siRNA induced silencing. The 
protein expression of survivin, from Day 0 to 13 following transient 
transfection of RCC786.0/EV with survivin specific siRNA, was 
monitored using western immunoblotting analyses. The degradation of 
survivin siRNAs began after day 4 as survivin was re-expressed from day 




One of the major hurdles associated with the use of siRNAs as a therapeutic 
approach is the short clearance time of the highly charged and structurally rigid 
siRNA molecules when delivered systematically. Delivery systems are an 
absolute necessity for the effective use of siRNAs but the delivery of synthetic 
siRNAs duplexes in vivo is hampered by the genocompatibility and 
toxicogenomics of the delivery vector, which have an impact on gene-silencing 
activity and specificity. In order to improve the bio-distribution profile, efforts 
have been made to improve the delivery methods through systemic or localized 
delivery, enhancing physical stability by modification to increase resistance to 
nucleases degradation and the employment of conjugates and complexes to 
enhance cellular uptake. In contrast, pharmacological manipulations of the 
cellular response using small molecule inhibitors such as YM155 are not 
associated with these problems. 
 
3.2.7 YM155 targets the survivin protein on a panel of RCC cell lines 
The earlier results have shown that survivin was upregulated in high grade RCC 
tumours and tumours with enhanced metastatic potential. Silencing of survivin 
arrested the proliferative capacity of RCC cell lines and induced apoptotic cell 
death. These findings point to the potential of survivin as a prognostic biomarker 
for poor survivability among patients with clear cell RCC. The high expression 
levels of survivin in RCC cells may contribute to the resistance of these tumours 











Figure 3.7. YM155 (20 nM – 80 nM, 48h) effectively down-regulated 






The survivin suppressor YM155 was investigated for its effects on survivin 
levels in a panel of RCC cell lines. The panel comprised paired isogenic 
transfected cell lines (RCC786.0/EV and RCC786.0/VHL.HA), immortalised 
cell lines (RCC786.0, ACHN and A498) and patient derived cell lines (NCC010, 
NCC035 and P.RCC). All RCC cells are of the clear cell histological subtype, 
with the exception of P.RCC, which is a papillary subtype. RCC786.0, 
RCC786.0/EV, A498, NCC010 and NCC035 lack a functional pVHL due to a 
mutation in the VHL gene. Wild type pVHL is re-expressed in 
RCC786.0/VHL.HA365. ACHN and P.RCC do not carry a VHL mutation. Cells 
were treated for 48h with YM155 (20nM - 80nM).  
Figure 3.7 shows that YM155 effectively down-regulated survivin in a dose-
dependent manner, albeit to varying degrees depending on the cell type. The 
patient derived and papillary RCC cells (NCC010, NCC035, P.RCC) were less 
sensitive to YM155 over this dosage range. Many factors determine the 
sensitivity of a cell line to a drug, including cell type, gene expression profile 
(coding mutation, amplification or homozygous deletion), protein expression 
profile (downregulation or upregulation), drug transporters and metabolic 
enzymes. Here, it would be of interest to first determine if this variation of 







3.2.8 Growth inhibitory activity of YM155 was unaltered in RCC 
cells in which survivin expression has been stably silenced  
In this section, investigations were carried to determine the growth inhibitory 
effect of YM155 on a RCC786.0 clone in which the survivin gene had been 
knocked down. To this end, six different pre-miRNA sequences targeting 
different exons on the survivin gene were selected. DNA sequencing was carried 
out to examine the plasmids for the presence, correct orientation and sequence 
of the non-targeting and survivin miRNA inserts after E.Coli transformation 
(Appendix-Sequencing Chromatogram). Figure 3.8A shows that the m451 
survivin plasmid achieved the greatest “silencing” effect (37% knockdown) on 
mRNA expression after transient transfection (transfection efficiency ~80%) as 
compared to the non-targeting miRNA plasmid (negative control). Blasticidin 
resistance cells transfected with m451 survivin plasmid were selected and 
limited dilution were then carried out to generate a stable clone of RCC786.0 
which constitutively express the survivin miRNA and a control clone which 
express the non-targeting miRNA plasmid. Total genomic DNA was extracted 
and DNA sequencing was again carried out to confirm the presence of the 
correct sequence of the survivin miRNA. m2.13 was selected as the most 
satisfactory survivin knockdown clone. Figure 3.8B shows that the m2.13 clone 
constitutively expressed survivin miRNAs that cleaved cellular survivin mRNA 
transcripts and reduced survivin mRNA expression to only 38% when compared 
to the control clone, N1.1. The protein expression of survivin in m2.13 was also 
significantly lower compared to N1.1 (Figure 3.8C). Despite these differences 
in survivin mRNA levels and protein expression, the growth inhibitory activities 








Figure 3.8. Survivin knockdown stable clones. (A) RCC786.0 cells were transiently 
transfected with one of the seven plasmids, each containing a non-targeting (control) 
or different survivin miRNAs. m451 plasmid achieved the greatest effect (37% 
knockdown, **, p<0.01) on the silencing of the survivin mRNA expression when 
compared to the control plasmid. (B) RCC786.0 cells transfected with m451 plasmid 
or control plasmid were used to generate the stable clones. m2.13 is a clone that 
constitutively expressed survivin miRNA which cleaved survivin mRNA transcripts 
produced inside the cell and led to a survivin mRNA expression of only 38% (**, 
p<0.01) when compared to the control clone, N1.1. (C) Using western 
immunoblotting analyses, the protein expression of survivin in m2.13 was 
significantly lower compared to N1.1. (D) Using MTS assay, the growth inhibitory 
IC50s of YM155 on these clones were similar. 
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YM155 was earlier reported to selectively inhibit the survivin gene core 
promoter activity228, 335. Here, the core promoter is retained in m2.13 and 
differences in the expression of survivin at the translational levels did not affect 
the growth inhibitory activity of YM155, suggesting that YM155 may have 
other targets apart from survivin. 
 
3.2.9 Growth inhibitory activity of YM155 was unaltered in RCC 
cells which survivin expression was stably over-expressed 
Having shown that silencing the survivin gene in RCC786.0 cells had minimal 
effects on the growth inhibitory activity of YM155, investigations were planned 
to examine the effect of survivin overexpression on growth inhibition by 
YM155. While increased amplification of a wild-type gene can be disruptive to 
the cell, overexpression of the drug target can also reverse growth inhibitory 
effects and convey resistance to the drug429-431. Briefly, a ready-to-use 
expression vector which contains a BIRC5 gene insert tagged with a C-terminal 
tGFP was transformed in E.Coli. RCC786.0 cells were stably transfected with 
the expression vector by selecting neomycin resistance cells to generate a stable 
expression clone that constitutively expressed the survivin mRNA and protein 
due to the CMV promoter. An expression clone which contains the expression 
vector without the BIRC5 gene insert was used as control. qRT PCR was used 
to quantify the BIRC5 gene expression in the various clones (V4.1, B1.3, B1.6 
and B2.5) (Figure 3.9A). Among these clones, B2.5 amplified BIRC5 mRNA to 
the greatest extent (~38 fold compared to the control clone V4.1, p<0.001).  This 
translated to the highest protein expression of survivin in B2.5 among the other 






Figure 3.9. Survivin over-expressed stable clones. RCC786.0 cells were stably 
transfected with one of the three expression vectors (B1.3, B1.6, B2.5), each 
containing a different BIRC5 gene insert tagged with a C-terminal tGFP, to generate 
a stable expression clone that constitutively expressed the survivin mRNA and protein. 
An expression clone, V4.1 which contains the expression vector without the BIRC5 
gene insert was used as control. (A) Using qRT PCR analyses, B1.3, B1.6 and B2.5 
constitutively over-expressed BIRC5 mRNA when compared to the control clone 
V4.1. Among these clones, B2.5 had increased amplification of the BIRC5 mRNA to 
the greatest extent (~38 fold, p<0.001). (B) Using western immunoblotting analyses, 
B1.3, B1.6 and B2.5 constitutively over-expressed survivin protein when compared to 
the control clone V4.1. The control clone V4.1 which contains the expression vector 
without the BIRC5 gene insert only expressed tGFP (26kD). Among the clones, B2.5 
increased protein expression of survivin tagged with tGFP (42kD) to the greatest 
extent. (C) Visualisation of the C-terminal tGFP tag under a fluorescence microscope 










Figure 3.9. Survivin over-expressed stable clones. (D) The growth 




As the C-terminal tGFP is readily visualised under a fluorescence microscope, 
this method was used to identify and select transfected cells for stable cell line 
production (Figure 3.9C). Despite higher levels of survivin mRNA and protein 
expression, Figure 3.9D shows that the growth inhibitory IC50s of YM155 on 
these clones did not differ from control cells. Once again, differences in the 
expression of survivin at the translational levels did not affect the growth 
inhibitory activity of YM155, suggesting that YM155 may have other targets 
apart from survivin. 
 
3.2.10 Gene expression profile of YM155 treated cells revealed 
possible mechanism(s) of action of YM155  
The development of microarray technology has revolutionized genomic 
analyses research. In contrast with traditional biological assays, microarray is a 
high throughput screening technology that enables the simultaneous 
measurement of many mRNA transcripts or genomic DNA fragments for the 
study of gene expression or copy number variation. When combined with 
bioinformatics, it offers numerous applications. To analyse the differential 
expression of YM155-treated and control RCC786.0 cells at the “gene-level”, a 
microarray analysis was carried out in the following ways: (i) YM155 at 40nM, 
24h; (ii) YM155 at 40nM, 48h; (iii) YM155 at 80nM, 24h; (iv) YM155 at 80nM, 
48h. Controls for (i) and (iii) were untreated cells, 24h and controls for (ii) and 
(iv) were untreated cells, 48h. Triplicate determinations were made for each 
treatment arm. Results were analysed by Partek statistical analysis and 







Figure 3.10. Microarray analysis on YM155 treated RCC786.0 cells. (A) 
PCA clustering analysis of the results showed significant differences 
between YM155- treated and control cells for each time point (24h, 48h). 
Cells treated for 24h and 48h showed different gene expression profiles. 
No significant difference was observed between the triplicate runs for each 
treatment arm. Cells exposed to different concentrations of YM155 did not 




PCA clustering analysis of the results showed significant differences between 
treated and control cells for each time point (24h, 48h) (Figure 3.10A). Cells 
treated for 24h and 48h also showed different gene expression profiles. 
However, no significant difference was observed between the triplicate runs, 
indicating good reproducibility for each treatment arm. Interestingly, cells 
exposed to different concentrations of YM155 did not show significant 
differences in gene expression at either time point.   
A list of genes (p<0.05 and a differential expression of at least 2 fold) was 
generated and overlaid onto a global molecular network developed from 
information contained in the Ingenuity Pathway Analysis (IPA) knowledge base. 
IPA identified cellular growth and proliferation, cell death and survival as the 
top biological functions associated with YM155 treatment. It generated a graph 
which prioritized the top canonical signaling pathways that were significantly 
affected by each treatment arm (Fig 3.10B-10E). The data sets submitted to IPA 
were 40nM YM155 versus control at 24h (Figure 3.10B), 80nM YM155 versus 
control at 24h (Figure 3.10C), 40nM YM155 versus control at 48h (Figure 
3.10D) and 80nM YM155 versus control at 48h (Figure 3.10E). All four data 
sets identified the p53 connection pathway as the top biological pathway 
associated with YM155 treatment. p53 connection pathway is generally 
associated with p53 signaling, ATM signaling and cell cycle regulation, and 
their molecules are involved in several mechanisms. They can activate repair 
mechanisms when DNA is damage, arrest growth by holding the cell cycle at 











Figure 3.10. Microarray analysis on RCC786.0 cells treated with (B) 
40nM YM155 and (C) 80nM YM155 at the 24h time point: Graphical 
representation of the top canonical signaling pathways that were 
significantly affected by each treatment arm. p53 connection pathway was 








Figure 3.10. Microarray analysis on RCC786.0 cells treated with (D) 
40nM YM155 and (E) 80nM YM155 at the 48h time point: Graphical 
representation of the top canonical signaling pathways that were 
significantly affected by each treatment arm. p53 connection pathway was 






From the p53 connection pathway, selected genes previously reported to play a 
role in the pathogenesis of RCC were identified for further investigation. These 
genes were CYLD (a deubiquitinating enzyme that negatively regulates NF-κB 
transcription factor activity)432, FOXO1 (a transcription factor that acts as a 
tumour suppressor, mediates cell cycle arrest and promotes apoptosis)433, 434, 
ID1 (an inhibitor of DNA binding that interacts and inhibits the transcriptional 
activation ability of basic HLH proteins which leads to tumour growth and 
angiogenesis)435 and BIRC5 (encodes survivin expression)324, 326, 436. To date, 
other studies have yet to report that treatment of RCC with YM155 has an effect 
on the expression of CYLD, FOXO1 and ID1.  
The post-translational modification of different proteins via direct ubiquitin 
attachment is important for various cellular processes. Dysregulation of 
components of the ubiquitin system have been linked to many diseases 
including cancer. CYLD is a deubiquitination enzyme that regulates various 
signaling pathways, including NF-κB signaling by deubiquitinating upstream 
regulatory factors to control cell survival and proliferation. It is a known tumour 
suppressor gene that is mutated in familial cylindromatosis and its 
downregulation has been reported in several malignancies437-440.  
FOXO transcription factors function mainly to promote cell cycle arrest, stress 
adaptive response and apoptosis via regulation of various transcription targets. 
AKT phosphorylation of FOXOs leads to FOXO sequestration in the cytoplasm 
such that they are unable to regulate their gene targets441-444. Aberrant activation 




However, several studies conducted in the context of other cancers revealed that 
pharmacological inhibition of the PI3K-AKT pathway induced new 
compensatory activation of other oncogenic pathways, including FOXO-
mediated up-regulation of RTK expression (such as phosphorylation of AKT 
Ser473), which might limit the clinical utilization of these inhibitors in cancer 
treatment448. FOXO can be used as a novel biomarker to stratify RCC patients 
for PI3K or AKT inhibitor treatment, or a novel therapeutic target to synergize 
with PI3K-AKT inhibition in RCC treatment. 
ID proteins are key regulators of development where they function to inhibit 
differentiation and to stimulate proliferation449. Embryonic and adult stem cells 
have increased expression of ID proteins where they promote cell cycle 
progression, delay senescence and facilitate cell migration450. In differentiated 
cells, deregulation of ID proteins is a contributing factor in tumourigenesis451-
453. Human expresses four types of ID proteins, namely ID1, ID2, ID3, and ID4. 
ID1 expression has been implicated in the regulation of cell growth, 
proliferation, migration and differentiation183, 454. It has been reported that ID1 
is possibly linked to the PI3K/Akt/NF-κB/survivin pathways in many types of 
cancer cells455-458. It can be used to identify endothelial progenitor cells which 
are critical to tumour growth and angiogenesis459, 460. Several studies had 
reported that targeting ID1 led to decreased tumour growth461, 462.  
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3.2.11 Differential expression of key genes and proteins was validated 
using qRT PCR and western immunoblotting  
Having shown from microarray analysis that certain genes were up- or down-
regulated in RCC786.0 cells treated with YM155 at different doses and time 
intervals, the next step was to confirm these findings by determining the 
expression levels of these genes in the treated cells. Genes that were up-
regulated would have higher mRNA expression levels in treated cells relative 
to control cells and vice versa. Validation was carried out using quantitative 
real-time polymerase chain reaction (qRT PCR). The following genes were 
selected for validation: CYLD, FOXO1, ID1 and BIRC5. The results are given 
in Figures 3.11A-D.  
ID1 and BIRC5 were down-regulated while CYLD and FOXO1 were up-
regulated. In the case of the down-regulated genes ID1 and BIRC5, mRNA 
expression was reduced to approximately the same degree at either 
concentration (40nM, 80nM) of YM155. BIRC5 mRNA levels were reduced by 
~2.8 fold at 24h and ~5 fold at 48h at both test concentrations (Figure 3.11A). 
There were significant differences between control and treated samples 
(p<0.001) and between treatment durations (p=0.0047) but there was no 
significant difference between treatment doses (p>0.05). ID1 mRNA levels 
were reduced by ~5 fold at both test concentrations and time points (Figure 
3.11B). There was a significant difference between control and treated samples 
(p<0.001) but no significant difference between treatment durations (p=0.681) 
and between treatment doses (p>0.05).  




              
         
 
 
Figure 3.11. Validation of selected genes associated with p53 connection 
pathway induced by YM155 was carried out using quantitative real-time 
polymerase chain reaction (qRT PCR). (A) BIRC5 mRNA levels were 
reduced by ~2.8 fold at 24h and ~5 fold at 48h at both test concentrations. 
(B) ID1 mRNA levels were reduced by ~5 fold at both test concentrations 
and time points. (C) CYLD mRNA levels were increased by ~2 fold at 24h 
but returned to basal levels at 48h at both test concentrations. (D) FOXO1 
mRNA levels were increased by ~2.4 fold at 24h and ~1.8 fold at 48h at 




Of the genes that were up-regulated by YM155, the effect of time was generally 
more prominent compared to that of dose, in keeping with the PCA clustering 
pattern (Figure 3.10A). CYLD mRNA levels were increased by ~2 fold at 24h 
but returned to basal levels at 48h at both test concentrations (Figure 3.11C). 
There were significant differences between control and treated samples 
(p<0.001) at 24h and between treatment durations (p=0.0002) but not between 
treatment doses (p>0.05). FOXO1 mRNA levels were increased by ~2.4 fold at 
24h and ~1.8 fold at 48h at both test concentrations (Figure 3.11D). As before, 
significant differences were detected between control and treated samples 
(p<0.001) and between treatment durations (p=0.046) but not between treatment 
doses (p>0.05). 
To confirm that protein levels would change in tandem to up- or down-
regulation of the said genes, western immunoblotting was carried on RCC786.0 
cells treated with increasing doses of YM155 after an exposure period of 24h. 
The results, as shown in Figure 3.11E, were confirmatory. YM155 decreased 
the protein expression of tumour promoters BIRC5 and ID-1 and increased the 
protein expression of tumour suppressors FOXO1 and CYLD (Figure 3.11E). 
The reduction in survivin (encoded by the inhibitor of apoptosis BIRC5 gene) 
was observed only at 80nM YM155 (equivalent to 2x IC50) at the 24h time point. 
However, at 48h time point, lower concentrations of YM155 were required to 
suppress survivin levels (Figure 3.7). Unlike survivin, ID-1 levels were strongly 
suppressed at 40nM YM155 (1x IC50) after 24h. In the case of the upregulated 
genes FOXO1 and CYLD, increases in the corresponding proteins were 








Figure 3.11. Validation of selected proteins associated with p53 
connection pathway induced by YM155 was carried out using western 
immunoblotting. (E) The protein expression of survivin reduced slightly 
while a dose-dependent decrease in ID-1 and increase in FOXO1 and 






RCC cells (RCC786.0/EV, NCC010) lacking a functional VHL gene expressed 
significantly higher levels of IGF1-R and survivin than cells that possess a 
functional VHL gene (RCC786.0/VHL.HA). A tissue microarray analysis on 
clinical samples showed that VEGFR, EGFR, IGF1-R and survivin were highly 
expressed in clear cell RCC. Of these oncogenic proteins, a trend towards higher 
expression of IGF1-R and survivin in clinically advanced tumour samples was 
noted. VEGFR is currently the target of choice for clear cell RCC but the present 
findings showed that IGF1-R, EGFR, survivin were also elevated alongside 
VEGFR suggest that they could be potential therapeutic targets for clear cell 
RCC as well. It was also shown that silencing IGF1R with its siRNA caused a 
slight decrease in survivin levels but silencing survivin did not affect IGF1-R 
levels, which was anticipated since survivin is downstream of IGF1-R. With the 
use of survivin specific siRNAs, profound down-regulation of survivin was 
achieved in RCC cell lines. These cells showed a marked apoptogenic response 
and diminished survivability in the clonogenic assay. Cells transfected with 
survivin siRNA induced the formation of cleaved PARP, which is a marker of 
apoptosis. Survivin is the smallest member of the IAP family of proteins which 
are endogenous caspase inhibitors that specifically target caspases 3, 7 and 9 
and lead to the suppression of apoptosis. Increase in the expression of cleaved 
PARP underscores the potential of survivin as a key prognostic biomarker 
predictive of RCC aggressiveness and treatment response. The prognostic 
significance of survivin protein provides an opportunity for the development of 
new therapeutic interventions for cancer treatment. YM155 is the most widely 
investigated small molecule inhibitor of survivin whose mode of action involves 
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selective inhibition of survivin gene transcription and protein expression228, 416. 
Here, YM155 effectively inhibited survivin expression on a panel of RCC cell 
lines in a dose dependent manner and independently of VHL status. When stable 
clones of RCC786.0 which constitutively overexpress or inhibit the expression 
of survivin were generated and tested for their susceptibility to YM155, it was 
observed that neither clone differed from parental/control RCC786.0 cells in 
their responses to YM155. These striking observations support the view that the 
anti-proliferative activity of YM155 was not affected by the changes in the 
levels of survivin and suggests that other factors or mechanism(s) are involved 
in its growth inhibitory activity. Support for this notion came from the RNA 
microarray analysis on RCC786.0 cells which showed that YM155 affected 
genes involved in cell death and survival, cellular growth and proliferation and 
cell cycle control. The majority of differentially expressed genes were 
associated with the p53 connection pathway. Four of these genes were selected 
for follow-up. While these genes were significantly altered in YM155-treated 
RCC786.0 cells, their selection from a group of ~150 differentially expressed 
molecules associated with the p53 connection pathway was admittedly random. 
Two tumour promoter genes BIRC5 and ID1 were down-regulated and two 
tumour suppressor genes FOXO1 and CYLD were up-regulated by YM155. 
These were confirmed by qRT PCR and western blotting. Up-regulation of 
FOXO1 leads to cell cycle arrest and an increase in CYLD leads to suppression 
of the tumourigenic NF-κB pathway. Taken together, there is a clear indication 
that YM155 affects several signaling molecules and their related pathways and 
does not exclusively inhibit survivin. In the following chapters, the significance 





Anti-proliferative activity and induction of 
apoptosis by YM155 in RCC 
 
4.1 Introduction 
YM155 is reportedly the 1st compound to selectively inhibit survivin228, 416. In 
Chapter 3, the anti-proliferative activity of YM155 was shown to be unaffected 
by changes in the translational levels of survivin in RCC cells. Clear cell RCC 
is the predominant histological subtype of all RCCs and a majority of them 
harbours germline mutations in the VHL gene463, The VHL protein is part of an 
E3 ubiquitin ligase complex that targets HIF for degradation. Without a 
functioning VHL protein, the heterodimeric HIF transcription factor 
constitutively transactivates many genes, including those that regulate cell 
proliferation464, 465. To examine the association between VHL expression and 
growth inhibitory response to YM155, a panel of RCC cells with and without 
functioning VHL protein was assembled and their viabilities in the presence of 
YM155 was assessed. 
The cell cycle is central to the proliferation of cells. In eukaryotes, the cell cycle 
is divided into four phases: M (mitosis), G1 (period between mitosis and 
initiation of nuclear DNA replication), S (period of nuclear DNA replication), 
and G2 (period between the completion of nuclear DNA replication and mitosis). 
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It is controlled by a conserved set of CDK complexes, composed of a regulatory 
cyclin subunit and a catalytic cyclin-dependent kinase (CDK) subunit, which 
are responsible for triggering the major cell cycle transitions (G1 to S, G2 to 
mitosis). Passage through each of these points requires the transient activation 
of a CDK by a specific cyclin, the levels of which vary according to the rate of 
its synthesis and degradation. In addition to regulation by cyclins, CDK activity 
is controlled by the state of phosphorylation (activating or inhibitory) of the 
catalytic unit and the presence of inhibitory proteins (CDK inhibitors, CKIs). 
The expression of these CKIs is tightly controlled by phosphorylation and 
ubiquitin-dependent proteasomal degradation. In response to extracellular 
stimuli, these multiple modes of CDK regulation are integrated to control cell 
cycle progression. Examples of extracellular stimuli include (i) growth factors 
that would promote cell proliferation, (ii) poor environmental conditions (such 
as cell-cell contact, lack of nutrients) which would direct cells to a quiescent 
state, and (iii) stressful stimuli and DNA damaging agents that would promote 
cell cycle arrest, presumably to allow time for cell repair. To understand the 
response cascade that potentially contributes to the potent growth inhibitory 
activity of YM155, the changes in the expression of cell cycle regulatory 
molecules will be examined. 
Manipulation of the cell cycle may either prevent or trigger an apoptotic 
response. Apoptosis is a crucial mode of programmed cell death aimed at 
eliminating unwanted and defective cells. The induction of cell apoptosis in 
tumour tissue is thus recognized as an efficient strategy for cancer 
chemotherapy and a useful indicator of treatment outcome466. Cell cycle 
regulation and apoptosis probably share common pathways467, 468. The down-
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regulation of survivin by upstream cell cycle regulators has been shown to 
enhance apoptosis146, 469-471. In this chapter, the ability of YM155 to induce 
apoptosis in RCC cells will be evaluated. 
 
4.2 Results and Discussion 
4.2.1 YM155 exhibited nanomolar anti-proliferative potency on a 
panel of RCC cell lines  
Figure 4.1 gives an overview of the cell growth inhibitory activity of YM155 
on a panel of eight RCC cell lines which included three patient derived cells. 
Seven of the cell lines were of the clear cell histological subtype while a single 
cell line - the patient-derived primary cell line P.RCC – belonged to the 
papillary histological subtype. YM155 exhibited nanomolar growth inhibitory 
activity on all the RCC cell lines, with IC50 values ranging from 14nM to 535nM 
at the 72h time point.  
The isogenic pair (RCC786.0/EV and RCC786.0/VHL.HA) which differed in 
their VHL status, was among the cell lines evaluated. It was found that YM155 
was twice more potent on the VHL positive RCC cells (RCC786.0/VHL.HA, 
IC50 34nM) than VHL null cells (RCC786.0/EV, IC50 70nM). The differential 
cell killing activity observed suggests that VHL status of cells may affect their 
susceptibility to YM155. Of the other VHL-null cells in the panel, the IC50 
values of YM155 were 40nM on the commercially available RCC786.0, 14nM 














Figure 4.1. Dose-response curves of YM155 on a panel of RCC cell lines with varying VHL 
status. RCC786.0/EV, RCC786.0, A498, NCC010, NCC035 are VHL null and 
RCC786.0/VHL.HA, ACHN and papillary RCC (P.RCC) are VHL positive. Cells were 
incubated with YM155 for 72 hours. YM155 is reportedly the 1st compound to selectively 




Paradoxically, YM155 was less potent on A498 (IC50 226nM), another VHL 
null cell line, and more active on ACHN (IC50 49nM) which has functional VHL. 
YM155 was also significantly less potent on the patient derived papillary RCC 
cell line (P.RCC, IC50 535nM) which did not have dysfunctional VHL. Thus, 
the impact of VHL status on the growth inhibitory activity of YM155 remains 
an open question. Earlier in Section 3.2.7, the survivin levels of the same panel 
of cells were monitored after exposure to increasing concentrations of YM155. 
A dose-dependent suppression of survivin levels was observed and there was 
no significant trend to suggest that suppression was more pronounced in cells 
with functional VHL as compared to VHL null cells. Hence, YM155 growth 
inhibitory activity does not appear to be dependent on either the VHL status or 
survivin mRNA/protein expression levels of the investigated cell line. 
 
4.2.2 YM155 halts cell cycle progression at the S phase in RCC786.0 
by 24h 
To elucidate the possible mechanisms underlying YM155’s potent anti-
proliferative activity on RCC cells, investigations were carried out to determine 
the phase of the cell cycle which is intercepted by YM155. These investigations 
centred on the use of the synthetic nucleotide 5-bromodeoxyuridine (BrdU) to 
quantify the amount of newly synthesized DNA in proliferating / replicating 
cells. BrdU is an analog of thymidine and is incorporated in place of thymidine 
during DNA replication which occurs in the S phase of the cell cycle. Briefly, 
the method involves “pulsing” asynchronous proliferating RCC786.0 cells with 
BrdU, followed by washing and incubation with increasing concentrations of 
YM155 (20-80 nM). At 6h, 24h and 48h time points, treated RCC cells were 
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fixed and stained with propidium iodide (PI) and anti-BrdU primary antibodies.  
PI provides a measure of the DNA content in the cells while the incorporated 
BrdU is stained with fluorescently labelled anti-BrdU antibodies for 
measurement by flow cytometry.  The results are depicted in a bivariate plot of 
total DNA content based on PI staining along the X axis versus BrdU 
incorporation detected by FITC labelled antibodies to BrdU on the Y axis 
(Figure 4.2).  
The sub-G1 pool of apoptotic cells were not considered in order to obtain a 
clearer view of the cell population at different phases of the cell cycle. Non-
proliferating cells generally enter the resting phase or a state of senescence at 
Gap 0 (G0) and some cells may remain quiescent for long periods of time. Cells 
increase in size at the G1 phase, then commence DNA replication at the 
synthesis (S) phase.  At the Gap 2 (G2) phase, cells continue to grow until 
mitosis where each cell splits to two daughter cells.   
Single parameter DNA analysis with PI alone cannot distinguish cells in very 
early or late S phase from those in G1 and G2 phases (Appendix, Supplementary 
Figure 4.2). This is only possible when PI staining is combined with BrdU 
pulsing. The proportion of cells in the different phases - G0-G1, G1* (late G1, 







Figure 4.2. Cell cycle analysis using combined propidium iodide (PI) and BrdU staining (PI-BrdU). 
Asynchronous proliferating BrdU pulsed RCC786.0 cells were treated with increasing 
concentrations of YM155 for (A) 6h and (B) 24h. Cells were then fixed and stained with PI and 
anti-BrdU primary antibody. Quantitation of the cell cycle phases was analysed by FACS. Data 
obtained were analysed using FlowJo (vX.0.7) and the sub-G1 pool was excluded. The relative 
proportion of cells in each of the G0-G1, G1* (late G1, early S), S-G2* (late S, early G2), and G2-
M gates are shown. There is a small significant change in the proportion of cells in each of the 
different phases when RCC786.0 was treated with higher concentrations of YM155 for 6h. 
Following 24h of treatment with increasing concentrations of YM155, there was a significant 
depletion of cells in the G0-G1, G1* and G2-M phases and an accumulation of cells primarily in 







Figure 4.2. Cell cycle analysis using combined propidium iodide (PI) and BrdU staining (PI-
BrdU). Asynchronous proliferating BrdU pulsed RCC786.0 cells were treated with increasing 
concentrations of YM155 for (C) 48. Cells were then fixed and stained with PI and anti-BrdU 
primary antibody. Quantitation of the cell cycle phases was analysed by FACS. Data obtained 
were analysed using FlowJo (vX.0.7) and the sub-G1 pool was excluded. The relative 
proportion of cells in each of the G0-G1, G1* (late G1, early S), S-G2* (late S, early G2), and 
G2-M gates are shown. Following 48h of treatment with increasing concentrations of YM155, 
there was a significant depletion of cells in the G0-G1, G1* and G2-M phases and an 
accumulation of cells primarily in the S-G2* phase of the cell cycle. (D) Cell cycle distribution 
profile  before treatment and graphical quantitation of the change in the respective cell cycle 
phases from (A), (B) and (C) when RCC786.0 was treated with YM155 at its IC50 (40nM). *, 
p < 0.05 and ** p < 0.01 from S-G2* phase of control cells. 
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Figure 4.2A shows the bivariate plot of PI versus BrdU content in RCC786.0 
cells treated with YM155 at the 6 h time point. As seen from the summary plot, 
there were no significant changes in the proportion of cells at the different 
phases except at the highest concentration (80nM) of YM155 where an increase 
in the proportion of cells at the S phase was observed. When longer time points 
of 24h and 48h were employed, significant dose-dependent changes increases 
in the proportion of S-G2* cells were observed (Figures 4.2B, C).  
Figure 4.2D summarizes the changes observed at 40nM YM155 (equivalent to 
IC50 of YM155) at the 6h, 24h and 48h time points. These changes involved a 
depletion of cells in the G0-G1, G1* and G2-M phases and an increase in cells 
at the S-G2* phase as compared to the control/untreated cells. Under normal 
conditions, BrdU-labelled cells in the S phase would move sequentially to the 
G2/M phase and then to the G1 phase. An increase in the proportion of S phase 
cells with concurrent reductions in G1 and G2 phases is indicative of an S-phase 
arrest and this appears to be the main effect of YM155 on the cell cycle of 
RCC786.0 cells. 
In a recent paper472, YM155 treatment yield increased in the sub-G1 and G0-
G1 population but not in S. However, the cell line used was Renca, which was 
derived from a tumour that arose spontaneously as a renal cortical 
adenocarcinoma in Balb/cCr mice. In this study, the cell line used was 
RCC786.0 which was derived from a human primary clear cell adenocarcinoma. 
Mouse is biological similar (share 95% of the same genes) to human and is often 
genetically manipulated to mimic a disease condition. The pattern of growth of 
this mouse tumour accurately mimics that of human adult renal cell carcinoma. 
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However, to choose a mouse that closely resembles every single biological 
feature of a human disease to yield similar treatment response is an unrealistic 
expectation. Therefore, the results of YM155 testing in RCC cells of murine 
origin cannot be accurately extrapolated to all RCC cells of human origin. In 
addition, heterogeneity is a trait that makes the process of drug testing 
challenging. In cancer treatment, heterogeneity between tumours in different 
patients can translate to diverse treatment responses. In vitro, molecular and 
genetic characteristics of different cell lines affect the sensitivity and 
responsiveness to the drug. On hindsight, only the ‘right’ cell line allows one to 
capably predict the effect clinically. Hence, an emerging trend is to use 
personalized xenograft models in which tumour cells are taken from a patient's 
tumour and propagated directly in mice. Then again, questions have been raised 
about the degree of heterogeneity that is maintained over time.  
 
4.2.3 YM155 induces the expression of key stress-related molecules - 
H2A.X, p53 and cyclin dependent kinase inhibitors  
The DNA damage response is initiated in response to a variety of stress signals 
that are encountered during physiological processes or in response to exogenous 
cues such as ionizing radiation or DNA damaging therapeutic agents. Under 
these conditions, DNA strand breaks are generated and these are detected by the 
sensor proteins ATM and ATR. The checkpoint kinases ATM and ATR play a 
critical role in transducing the DNA damage checkpoint responses. These occur 
via the phosphorylation of H2A.X (Ser 139) at the sites of the strand breaks, 
activation of Chk1 and Chk2 and inactivation of Cdc25A that prevent activation 
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of CDK2-cyclin E and consequently cell cycle arrest, and activation of p53 
signaling leading to the transcription of the CDK inhibitor p21.  
The tumor suppressor protein p53 is a sequence-specific transcription factor that 
stimulates a wide network of signals in reponse to stress and plays a key role in 
the cellular response to DNA damage and other genomic aberrations. Activation 
of p53 leads to either cell cycle arrest and DNA repair or apoptosis. Stimulation 
of the p53 pathway is widely endorsed as a means of arresting tumour growth473-
481. 
YM155 induced dose dependent increases in H2A.X and phospho-H2A.X 
(Ser139) at the 24h time point on both cell lines (Figure 4.3). The increases were 
synchronized and observed at 60nM and 40nM YM155 on RCC786.0 and 
ACHN respectively. Similar observations were made at the longer 48h time 
point (Appendix, Supplementary Figure 4.3). YM155 has been reported to 
induce a DNA damage response which is purportedly central to its anti-cancer 
properties340, 360. The phosphorylation of H2A.X in response to DNA strand 
breaks is rapidly initiated. Thus, the present finding that phospho-H2A.X levels 
were elevated only at relatively high concentrations of YM155 (>IC50 on 
RCC786.0 and IC50 on ACHN) even after 48h, was unexpected. 
Phosphorylation of H2A.X is not only triggered by the DNA damage response. 
It is also required for DNA fragmentation during apoptosis. In fact, some 
investigations suggest that H2A.X phosphorylation was dispensable for the 
initial steps of the DNA damage response but was  needed to maintain levels of 
the CDK inhibitor p21 and hence, cell cycle arrest482. In the absence of H2A.X 





    
 
  
Figure 4.3. Effects of YM155 on the expression of stress related molecules 
at 24h. RCC786.0 and ACHN were treated with increasing concentrations of 
YM155 for 24h. In western immunoblotting analysis, a critical protein in the 
DNA damage response cascade, histone H2A.X was up-regulated. Post-
translational modification of the tumour suppressor protein p53 by increased 
phosphorylation of serine 15 aims to stabilise the elevated levels of p53 and 
thus prevent its degradation. Cyclin-dependent kinases (CDKs) are controlled 
by two families of low molecular weight cyclin-dependent kinases inhibitors 
(CKIs), Cip/Kip and INK4. The Cip/Kip family, which includes p21Cip1/Waf1 
(p21) and p27Kip1 (p27) interacts with a broad range of cyclin–CDK 
complexes, while the INK4 family, which includes p18INK4C (p18), inhibits 
CDK4 and CDK6 kinases. Treatment with YM155 led to the up-regulation of 
p18 and p21 and down-regulation of p27. Similar trends were observed for 




Treatment with YM155 led to dose-dependent increases in the levels of p53 and 
phospho-p53 (Ser15) in RCC786.0 and ACHN cells (Figure 4.3 and Appendix, 
Supplementary Figure 4.3). Phosphorylation of p53 prevents p53 from 
interacting with its negative regulator, the E3 ubiquitin ligase MDM2, hence 
diverting p53 from ubiquitination and proteasomal degradation. Consequently, 
transcriptionally active p53 accumulates in the nucleus and activates several 
genes involved in the cell cycle, specifically the gene encoding for p21. 
CDKs are controlled by two families of low molecular weight CKIs, Cip/Kip 
and INK4. The Cip/Kip family, which includes p21Cip1/Waf1 (p21) and p27Kip1 
(p27),  interacts with a broad range of cyclin–CDK complexes, while the INK4 
family, which includes p18INK4C (p18), inhibits CDK4 and CDK6 kinases. 
Figure 4.3 shows YM155-induced increases in p18 and p21 at the 24h time 
point, possibly in line with the elevated phospho-p53 levels. However, p27 
levels showed a marked decline. p27 is an important regulator of G1-S transition 
and its protein levels have been reported to decrease progressively from the mid 
G1 to the late G2 phase485-487.  In Section 4.2.2, it was shown that YM155 caused 
an arrest in the S-phase of the cell cycle and this could have contributed to the 
decline in p27 levels. Interestingly, decreases in all three CKIs (p18, p21 and 
p27) were noted at the longer 48h time point (Appendix, Supplementary Figure 
4.3). Inhibition of the respective CDKs activity will halt the cell cycle 
progression and arrest the cells at a particular phase to enable DNA repair to 
take place. However, when DNA damage is extensive and irreparable, 
degradation of p21 which is a known inhibitor of caspase-3488 would be stepped 




4.2.4 YM155 activates critical checkpoint kinases (Chk1 and Chk2) 
and effector (pRb)  
Cell cycle checkpoints consist of a complex network of DNA repair pathways 
that monitor and maintain genome integrity. These signalling pathways sense 
various types of genotoxic stress and trigger a multi-faceted cellular response 
which activates DNA repair and delays cell-cycle progression. If the extend of 
the damage exceeds repair capacity, checkpoint kinases activate additional 
signaling cascades to eliminate such cells, usually by apoptosis. As mentioned 
in Section 4.2.3, DNA damage or errors in cell cycle events activate checkpoint 
kinases of the phosphatidylinositol 3-kinase family, ATR and ATM which in 
turn phosphorylate and activate downstream effector kinases, Checkpoint 
kinase 1 (Chk1) and Checkpoint kinase 2 (Chk2) respectively. Chk1 and Chk2 
coordinate the DNA damage response and cell cycle checkpoint responses. 
Notably, they induce the phosphorylation of the phosphatase Cdc25 leading to 
its degradation and consequently cell cycle arrest, and the phosphorylation of 
p53 leading to increased transcription of the anti-mitogenic p21 gene.  
As seen in Figure 4.4, YM155 induced dose-dependent increases in phospho-
Chk1 and phospho-Chk2 in RCC786.0 and ACHN cells at the 24h time point. 
Total Chk2 levels were unchanged but total Chk1 levels showed a decline at 
higher doses of YM155. At the longer 48h time point, phospho-Chk1 levels 
decreased but phospho-Chk2 levels remained elevated possibly because cell 
death had set in (Appendix, Supplementary Figure 4.4). Both total Chk1 and 






    
 
 
Figure 4.4. Effects of YM155 on the expression of checkpoint kinases at 24h. 
RCC786.0 and ACHN were treated with increasing concentrations of YM155 
for 24h. In western immunoblotting analysis, there were increased 
phosphorylation of Chk1 and Chk2. In response to DNA damage or errors in 
cell cycle events such as DNA replication and chromosome segregation, 
checkpoint kinases of the phosphatidylinositol 3-kinase family, ATR and 
ATM phosphorylate and activate downstream effector kinases, Chk1 and 
Chk2 respectively. Following genotoxic stress, retinoblastoma tumour 
suppressor protein, pRb is not phosphorylated, which elicits cell cycle arrests 
and leads to suppression of the E2F family of transcription factors. A decrease 
in the phosphorylation of pRb was observed but this is likely to be due to the 
dose dependent decrease in the expression of total pRb with YM155 treatment. 




Another critical checkpoint effector is the retinoblastoma tumour suppressor 
protein, pRb which plays a pivotal role in regulating the passage of cells from 
the G1 to S phase. In the event of DNA damage and other genotoxic stresses, 
pRb will repress proliferation-associated genes by inhibiting the activity of E2F 
transcription factors until the effects of the genotoxic stress have abated. This is 
achieved by suppressing the phosphorylation of pRb which would hamper its 
dissociation from E2F transcription factors and hence repress E2F-dependent 
transcription activation of S-phase genes required for cell cycle progression491.  
Noxious stimuli can also trigger the proteolytic degradation of pRb which will 
then lead to apoptotic cell death in affected cells. The induction of apoptosis 
was reported to be overcome by exogenous over-expression of pRb492-496. 
Similarly, a higher level of apoptosis was detected in human cell lines or mouse 
embryos that lack functional pRb497-499. The loss of pRb leads to release of E2F 
transcription factors which up-regulate genes (including E-type cyclins), which 
play a crucial role in S phase entry and cell cycle progression. In the absence of 
pro-survival signals, E2F is stabilised but can still promote apoptosis by 
activating the transcription of pro-apoptotic target genes such as caspase 7 and 
p73500-504. In fact, an intrinsic protective mechanism exists to eliminate cells that 
have lost their pRb function by triggering the p53 apoptotic pathway505-507. 
Specifically, E2F family of transcription factors indirectly affects p53 by up-
regulating the expression of many proteins that stabilize and activate p53508.  
A decrease in the phosphorylation of pRb was observed when both cell lines 
were treated with YM155 for 24h but this is likely to be due to the dose-
dependent decrease in the expression of total pRb. Levels remained depressed 
at the 48h time point.  In contrast, E2F levels remain largely unaffected over 
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both time periods. Notwithstanding, the compelling loss of pRB in the presence 
of YM155 could have allowed expression of E2F target genes, many of which 
are involved in the disruption of the cell cycle and induction of apoptosis.  
 
4.2.5 YM155 exerts a differential effect on the expression of various 
cyclins (regulators of cyclin-dependent kinases)  
Cyclins are a family of proteins that control the progression of cells through the 
cell cycle by activating CDKs. During the cell cycle, their concentrations vary 
in a cyclical fashion in order to direct specific CDKs to subcellular locations in 
a timely fashion. G1/S cyclins are essential for the regulation of the cell cycle 
at the G1/S transition. Cyclin D/CDK4, Cyclin D/CDK6, and Cyclin E/CDK2 
control the transition from G1 to S phase while Cyclin A/CDK2 is active in the 
S phase. G2/M cyclins are essential for the regulation of the cell cycle at the 
G2/M transition. G2/M cyclins accumulate steadily during G2 and are abruptly 
destroyed as cells exit from mitosis. Cyclin B/CDK1 controls progression from 
G2 to M phase. Treatment with increasing concentrations of YM155 for 24h 
(Figure 4.5) and 48h (Appendix, Supplementary Figure 4.5) led to decreases in 
the levels of cyclin A2, cyclin B1, cyclin D1 and cyclin D3 but an increase in 
cyclin E1. Cyclin E1 regulates the transition of cells from the G1 to S phase and 
the increase in its expression may be due to an increase in E2F transcription 
activity. Unrestrained E2F activity forces cells into the S phase and also 
promotes apoptosis509. However, continued progression of cells from the S 
phase to other phases would be interrupted because YM155 reduced the 





         
 
 
Figure 4.5. Effects of YM155 on the expression of various cyclins at 24h. 
RCC786.0 and ACHN were treated with increasing concentrations of 
YM155 for 24h. In western immunoblotting analysis, there were a decrease 
in the expression levels of cyclin A2, cyclin B1, cyclin D1 and cyclin D3 
and an increase in the expression level of cyclin E1. Cyclins are a family 
of proteins that control the progression of cells through the cell cycle by 
activating cyclin-dependent kinase (CDK). During the cell cycle, their 
concentrations vary in a cyclical fashion to target specific CDKs to 
subcellular locations in a timely fashion. Similar trends were observed for 






4.2.6 YM155 alters the expression and activity of the cyclin-
dependent kinases (CDKs)  
CDKs are a family of protein kinases involved in the regulation of the cell cycle. 
CDKs are regulated by (i) cyclin binding, (ii) activating and inhibitory 
phosphorylation and (iii) CDK inhibitory subunits (CKIs). The G1-S transition 
is controlled by CDK4 and CDK2 whereas Cdc2 (also known as CDK1) 
controls the G2-M transition. Full activation of CDKs requires binding to a 
specific regulatory protein partner (cyclin) and phosphorylation on an activating 
site such as Thr160 in CDK2. On the other hand, inhibitory phosphorylation of 
a conserved Tyr15 leads to inhibition of Cdc2, thus preventing mitotic 
progression.  
Treatment with increasing concentrations of YM155 led to decreases in total 
CDK4, CDK2 and phospho-CDK2 (Thr160) (Figure 4.6 and Appendix, 
Supplementary Figure 4.6). Cdc2 levels were elevated but phospho-Cdc2 
(Tyr15) declined at the 24h time point (Figure 4.6). Cdc2 would thus be 
activated since the inhibitory phosphorylation at Tyr15 has been lifted. In spite 
of its activated status, Cdc2 cannot drive the G2 to M transition because as 
shown earlier, cyclins A2 and B1 levels were depressed by YM155.  
Cdc25 is a dual-specificity phosphatase which controls the entry and 
progression through various phases of the cell cycle. Cdc25A-C are members 
of the Cdc25 family and they act by removing inhibitory phosphate residues 
from target CDKs. Notably, Cdc25 mediates the de-phosphorylation of Tyr15 







Figure 4.6. Effects of YM155 on the expression of cyclin-dependent kinases (CDKs) 
at 24h. RCC786.0 and ACHN were treated with increasing concentrations of YM155 
for 24h. In western immunoblotting analysis, there were a decrease in total CDK4, 
total CDK2 and its phosphorylated state. However, an increase in total Cdc2 and a 
decrease of its tyrosine phosphorylated state were observed and this is expected to 
activate Cdc2. CDKs are a family of protein kinases involved in the regulation of the 
cell cycle. CDKs are regulated via cyclin binding, activating and inhibitory 
phosphorylation and binding of CDK inhibitory subunits (CKIs). CDK binds with its 
regulatory protein partner, cyclin to form an active kinase complex which is capable 
of phosphorylating substrates appropriate for the particular cell cycle phase. The G1-
S transition is controlled by CDK4 and CDK2 whereas Cdc2 (also known as CDK1) 
controls the G2-M transition. Phosphorylation of a conserved Tyr15 leads to 
inhibition of Cdc2, thus preventing mitotic progression. Cdc25 is a dual-specificity 
phosphatase which controls the progression through various phases of the cell cycle 
and it acts by removing inhibitory phosphate residues from target CDK. Treatment 
with YM155 led to a decrease in total Cdc25C and its phosphorylated state. Similar 




Activated Cdc2 will further activate Cdc25 by phosphorylation to form a 
positive feedback loop that drives mitotic progression. YM155 treatment 
decreased total Cdc25C as well as phospho-Cdc25C (Ser216). This may imply 
that these cells could not proceed beyond the G2-M phase because Cdc25C 
phosphatase which mediates cellular entry to mitosis was transcriptionally 
down-regulated by the activated p53 (Section 4.2.3).  
Intriguingly, the increase in cyclin E1 levels (Section 4.2.5) suggest that YM155 
treated cells could proceed from the G1 phase to the S phase, in spite of 
reductions in the levels of other CDKs and cyclins (CDK2, CDK4, CDK6, 
cyclin A, cyclin D) which are required to drive G1-S phase transition. The 
elevated levels of cyclin E1 coincides with the increase in total Cdc2 levels 
observed here and suggest that cyclin E1 binds to and activates Cdc2 instead of 
its usual CDK partner (CDK2) to drive the G1 to S transition. This entry into 
the S phase of the cell cycle via the ability of cyclin E1 to bind to and activate 
Cdc2 independently of CDK2 has been reported510, 511. Others have also 
provided strong evidence that Cdc2 may compensate for the loss of CDK2 in 
cell cycle progression512, 513.  
Cdc2 has been proposed to function as a pro-apoptotic mediator and that 
activated Cdc2 would initiate apoptosis in proliferating cells514, 515. A study on 
neuronal apoptosis has established a link between Cdc2 and the selective 
phosphorylation of Bad at Ser128, thereby activating Bad-mediated apoptosis516. 
In contrast, growth factors induce cell survival by triggering the 
phosphorylation of Bad at Ser136 and Ser112 which initiate the sequestration 
and inhibition of BAD by cytosolic 14-3-3 proteins517, 518.  
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4.2.7 YM155 induced profound apoptosis in RCC786.0 by 48h 
Apoptosis is a distinctive and important mode of programmed cell death in 
which a tightly controlled sequence of events leads to the elimination of cells 
without the release of harmful substances into the surroundings. Normally, 
apoptosis occurs during development and ageing where it plays a crucial role in 
maintaining the health of the cell populations by eliminating old, unwanted and 
unhealthy cells. It can also be triggered as a defence mechanism in response to 
cellular damage arising from disease or exposure to noxious agents such as 
irradiation or drugs used in cancer chemotherapy.  
Thus far, YM155 has been shown to cause dose-dependent increases in the 
levels of p53 and phospho-p53. These increases were significant and sustained 
up to the 48h time point. The consequences of prolonged stabilization and 
activation of p53 would be cell cycle arrest which has been demonstrated in 
earlier sections, and the induction of apoptosis by a p53 dependent pathway, if 
DNA damage is irreparable and cannot be contained by cell cycle arrest519-521.  
To determine if YM155 induced p53 dependent apoptotic cell death, a 
fluorescence-activated cell sorting (FACS) analyses of YM155-treated 
RCC786.0 cells double stained with phycoerythrin (PE)-Annexin V and 7-
aminoactinomycin (7-AAD) at different time points (24h, 48h, 72h) were 
undertaken. The method is based on the translocation of phosphatidylserine 
from the inner to outer surface of cell membranes upon induction of apoptosis. 
Once positioned in the outer membrane, the phosphatidylserine residues bind to 







Figure 4.7. Effects of YM155 on the induction of apoptosis. RCC786.0 was treated with increasing 
concentrations of YM155 for (A) 24h (B) 48h. Cells were then stained with PE-conjugated Annexin V 
and 7-AAD. The binding of annexin V to phospholipid phosphatidylserine exposed on the external 
membrane of cells indicates the beginning the apoptotic process while 7-AAD binds to the cellular DNA 
of cells with compromised membrane integrity. Quantitation of the cell populations was analysed by 
FACS and the data obtained was analysed using FlowJo (vX.0.7). The relative proportion of cells in 
each of the quadrants (live, early apoptosis, late apoptosis and necrosis) are shown. There was no 
significant difference in the proportion of cells in each of the different quadrants when RCC786.0 was 
treated with increasing concentrations of YM155 for 24h. Following 48h of treatment with increasing 
concentrations of YM155, there was a significant increase in the apoptotic cell population. *, p < 0.05, 






Figure 4.7. Effects of YM155 on the induction of apoptosis. RCC786.0 was treated with increasing 
concentrations of YM155 for (C) 72h. Cells were then stained with PE-conjugated Annexin V and 7-AAD. 
The binding of annexin V to phospholipid phosphatidylserine exposed on the external membrane of cells 
indicates the beginning the apoptotic process while 7-AAD binds to the cellular DNA of cells with 
compromised membrane integrity. Quantitation of the cell populations was analysed by FACS and the data 
obtained was analysed using FlowJo (vX.0.7). The relative proportion of cells in each of the quadrants (live, 
early apoptosis, late apoptosis and necrosis) are shown. Following 72h of treatment with increasing 
concentrations of YM155, there was a significant increase in the apoptotic cell population. (D) Graphical 
quantitation of the apoptotic cells population from (A), (B) and (C) when RCC786.0 was treated with 




On the other hand, 7-AAD (a DNA intercalator) only binds to the DNA of cells 
with compromised membranes and is excluded from viable cells. Thus, viable 
cells are not stained by Annexin V and 7-AAD (Annexin V negative, 7-AAD 
negative) while cells in early apoptosis are Annexin V positive and 7-AAD 
negative. Cells that are in late /end-stage apoptosis or non-viable (necrotic) are 
Annexin V positive and 7-AAD positive. To determine if cell death has occurred 
by apoptosis or necrosis, it is necessary to monitor the proportion of cells at the 
various stages - viable, in early apoptosis and late apoptosis/non-viable – over 
time (24h, 48h and 72h). If a progressive time dependent change in the 
proportion of cells is observed over these three stages, this would be indicative 
of apoptosis.  
The distribution of cells in the various phases under different treatment 
conditions are given in Figure 4.7. Figure 4.7A depicts results obtained from 
cells treated with increasing concentrations of YM155 at the 24h time point. It 
can be seen that the proportion of cells in the different phases did not differ 
significantly from those found in untreated cells. When treatment times were 
extended to 48h (Figure 4.7B) and 72h (Figure 4.7C), significant increases in 
the early and late apoptotic populations of treated cells became evident. Earlier, 
it was shown that YM155 triggered cell cycle arrest at the S phase at the 24h 
time point (Section 4.2.2) and here, the induction of apoptosis was observed at 
the 48h time point. Figure 4.7D summarizes the proportion of cells in early and 
late apoptosis at 24h, 48h and 72h on treatment with YM155 at its growth 
inhibitory concentration (40nM).  The striking increases in the population of 
cells in early and late apoptosis over the 24h to 72h time points supports the 
notion that the main mode of cell death induced by YM155 is apoptosis.  
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4.2.8 YM155 significantly increased caspase-3/7 activity with 
negligible cytotoxicity effect 
The stereotypical events that occur during the activation of apoptosis is 
coordinated by members of the caspase family of cysteine aspartases. In 
response to pro-apoptotic signals, initiator caspases (caspase-8, caspase-9 and 
caspase-10) are activated and proceed to cleave and activate downstream 
“effector” caspases (caspase-3, caspase-6, and caspase-7). Caspases execute 
apoptosis through the recognition and cleavage of essential proteins such as 
those involved in the maintenance of cell shape. Processing by caspases do not 
degrade the substrate proteins but activate or inactivate the function (s) of these 
proteins.  Hydrolysis occur specifically at the peptide linkage after an aspartate 
acid residue522. Caspase-3 and caspase-7 share similar substrate specificity and 
recognize a common tetra-peptide motif (Asp-x-x-Asp). Activation of these 
caspases is one of the definitive markers of apoptosis.  
To assess the effects of YM155 on caspase-3/7 activity, a multiplex assay 
(ApoTox-Glo™ Triplex Assay, Promega) which simultaneously monitors 
viability, cytotoxicity and apoptosis of the cells on YM155 treatment, was 
employed. Briefly, viability and cytotoxicity are monitored in the assay by the 
activities of two proteases (“live-cell” protease and “dead-cell” protease) on 
their respective peptide substrates. The substrate (glycylphenylalanyl-
aminofluoro- coumarin, GF-AFC) for the “live-cell” protease enters intact cells 
where it is cleaved to release a fluorophore which generates a fluorescence 
signal that is proportional to the number of live cells. When the cell undergoes 








Figure 4.8. Effects of YM155 on the viability, cytotoxicity and caspase-3/7 activity.  
RCC786.0 (A, B and C) and ACHN (D, E and F) were treated with increasing 
concentrations of YM155 for 24h, 48h and 72h respectively. *, p < 0.05, **, p < 0.01 







Figure 4.8. Effects of YM155 on the viability, cytotoxicity and caspase-3/7 activity.  
RCC786.0 (A, B and C) and ACHN (D, E and F) were treated with increasing 
concentrations of YM155 for 24h, 48h and 72h respectively. ApoTox-Glo™ Triplex Assay 
(Promega) was used to assess the viability, cytotoxicity and caspase activation events at 
the indicated time points. Glycylphenylalanyl-aminofluorocoumarin (GF-AFC) enters 
intact cells where it is cleaved by the live-cell protease activity to generate a fluorescent 
signal proportional to the number of living cells. Dead-cell protease activity is measured 
using Bis-alanylalanyl-phenylalanyl-rhodamine 110 (bis-AAF-R110), which is released 
from cells that have lost membrane integrity. Another luminogenic caspase-3/7 substrate, 
which contains the tetrapeptide sequence DEVD will generate a luminescent signal when 
it is cleaved by caspases. Luminescence measured is proportional to the amount of caspase 
activity present and this measurement value was normalised to the cell viability within each 
assay. A decrease in cell viability was observed with no apparent changes in the 
cytotoxicity level when the cells were exposed to increasing concentrations of YM155 for 
24h, 48h and 72h. There was a significant increase in caspase-3/7 activity in YM155 treated 
cells at 48h and 72h. (G) Graphical representation of caspase-3/7 activity from (A), (B) 
and (C) when RCC786.0 was treated with YM155 at its IC50 (40nM). (H) Graphical 
representation of caspase-3/7 activity from (D), (E) and (F) when ACHN was treated with 
60nM of YM155 (above its IC50 of 49nM). *, p < 0.05, **, p < 0.01 and ***, p < 0.001 
from its control in terms of caspase-3/7 activity. 
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“Dead-cell” proteases are released into the surrounding medium and act on a 
cell-impermeable substrate (bis-alanylalanyl-phenylalanyl-rhodamine 110, bis-
AAF-R110) to generate a different fluorescent signal. If cell viability decreases 
without a concurrent increase in necrosis (cytotoxicity), then apoptosis, not 
necrosis, is the major mechanism of cell death. Confirmation of apoptosis is 
provided by the 3rd component of the assay which detects the release of caspases 
3 and 7. The caspases remove luciferin from a peptide substrate which contains 
the signature tetrapeptide sequence (DEVD). Luciferin then reacts with 
luciferase to generate a luminescence signal that is proportional to the amount 
of active caspases.  
RCC786.0 and ACHN were treated with increasing concentrations of YM155 
for 24h, 48h and 72h respectively (Figure 4.8). The multiplex assay was used to 
assess the viability, cytotoxicity and caspase activation events at the indicated 
time points. At all time-points, RCC cells that were treated with increasing 
concentrations of YM155 demonstrated dose-dependent decreases in cell 
viability with negligible changes in the cytotoxicity marker.  
Onset of apoptosis as seen from increases in caspase-3/7 activities were evident 
at the 48h and 72h time points, an observation that is consistent with the 
detection of apoptotic cells by 48h (Section 4.2.7). RCC786.0 treated with 
40nM (IC50) of YM155 initiated a more significant increase in caspase-3/7 
activity (Figure 4.8G) as compared to ACHN treated with 60nM (> IC50 which 




4.2.9 YM155 down-regulates anti-apoptotic proteins and up-
regulates pro-apoptotic proteins 
Proteins involved in apoptosis regulation are of intense biological interest as 
many are potential oncogenic targets. To understand the effects of YM155 on 
the regulation of apoptosis in RCC cells, the expression of apoptosis-associated 
proteins were probed in western immunoblotting (Figure 4.9). The following 
proteins were monitored in YM155-treated RCC786.0 and ACHN cells at the 
48h time point: (i) Survivin and XIAP which are members of the Inhibitor of 
Apoptosis (IAP) family, (ii) antiapoptotic proteins Mcl-1 and Bcl-xl, (iii) 
proapoptotic proteins Bax and Bad, and (iv) apoptotic marker proteins cleaved 
caspase 3 and cleaved PARP.  
Broadly similar trends were observed on the two cell lines. YM155 caused dose 
dependent decreases in the levels of survivin and XIAP. The reduction in 
survivin was anticipated as YM155 is a survivin inhibitor. A point to note is that 
the decrease in survivin had a slow onset and was prominent only after 48h 
which may imply that YM155 did not only affect survivin but other proteins or 
pathways that lie upstream of survivin. Levels of the anti-apoptotic proteins 
Mcl-1 and Bcl-xl were also decreased. These proteins have been reported to be 
NF-κB target genes523-526 and the role of the NF-κB signalling pathway in the 
mechanism(s) of action of YM155 will be investigated in the Chapter 5. XIAP 
and survivin also inhibit caspase activation, and since their levels decline on 
YM155 treatment, caspase inhibition would be lifted. This was duly observed 
from the appearance of cleaved caspase 3 and cleaved PARP. Increases in both 
apoptotic marker proteins were more evident after 48h as compared to 24h 





    
 
 
Figure 4.9. Effects of YM155 on the expression of apoptosis-associated proteins. 
RCC786.0 and ACHN were treated with increasing concentrations of YM155 for 
48h. In western immunoblotting analysis, a treatment concentration dependent 
down-regulation of anti-apoptotic proteins (survivin, XIAP, Bcl-xl and Mcl-1) and 
up-regulation of pro-apoptotic proteins (Bad and Bax) were observed. Caspase 3 
was cleaved which led to the cleavage of PARP and this indicated the induction of 




YM155 treatment led to dose dependent increases in the levels of the pro-
apoptotic proteins Bad and Bax. These proteins are transcriptionally regulated 
by p53527, 528. Interestingly, a concurrent increase in the phosphorylation of Bad 
at Ser112 which would inhibit Bad mediated apoptosis, was observed. The 
phosphorylation of Bad at serine 112 may be an adaptive response by the tumor 
cells as they develop compensatory mechanisms to counter the effect of YM155. 
However, this retaliative response may potentially be neutralized by the 
increase in Cdc2516 by YM155 as mentioned earlier (Section 4.2.6). More in 





YM155 exhibited nanomolar anti-proliferative activity on a panel of RCC cell 
lines which were either VHL-null or VHL-positive. YM155 did not demonstrate 
a clear cut preference for either cell type and it is not possible to conclude that 
its growth inhibitory activity is dependent on the VHL status of the cells. The 
present investigations showed that YM155 caused cell cycle arrest and this is 
followed by the eventual death of the cells by apoptosis.  
YM155 intercepted the cell cycle of RCC cells at the S phase. Pulsing with 
BrdU revealed accumulation of cells in the S phase with concurrent reductions 
in the G1 and G2 phases. YM155 has been reported to trigger the DNA damage 
response in cells and this may be the main factor driving cell cycle arrest. Cell 
cycle progression is a tightly controlled sequence of events moderated by 
interactions between cyclins, CDKs and CDK inhibitors. The present results 
revealed that YM155 affected the levels of these proteins in such a way as to 
bring about cell cycle arrest. First, YM155 induced the activation of Chk1 and 
Chk2 which are the major mediators of cell cycle checkpoints in response to 
genotoxic stresses.  A key substrate of these checkpoint kinases is Cdc25, a 
tyrosine phosphatase which removes inhibitory phosphates from CDKs, thus 
enabling their participation in G1-S and G2-M transitions. YM155 induced a 
sustained reduction in total Cdc25C levels which would prevent it from 
facilitating the transition of cells at the G1-S and G2-M phases. This would 
result in S phase arrest that was duly observed with YM155. Second, YM155 
decreased the levels of cell cycle cyclins and CDKs, except for cyclin E  which 
is important for driving G1-S transition and cdc2 (CDK1) which is important 
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for G2-M transition. It is noted however that others have reported that cyclin E1 
is able to bind and activate Cdc2 in place of its usual binding partner CDK2 to 
regulate the transition of cells from G1 to S phase.  Notwithstanding the elevated 
levels of cyclin E1 and Cdc2, progression of the cell cycle would not proceed 
due to the absence of other key cyclins and CDKs. Third, YM155 induced 
increases in the CDK inhibitors p21 and p18. The elevated level of p21 is 
particularly significant as sequestration of p21 by the cyclin E/CDK2 complex 
leads to inactivation of the complex, and thus inhibition of G1-S phase transition. 
p21 is also sequestered by cyclinD/CDK4 but in view of the diminished levels 
of cyclin D and CDK4 in the presence of  YM155, this may not occur. pRB is 
an important substrate for cyclin D-associated CDK4 (possibly in complex with 
p21) and cyclin E-associated CDK2 kinases but in the absence of these kinases, 
pRB may remain bound to E2F and thus continue to inhibit the transcriptional 
activity of E2F.  However, pRB levels were reduced in the presence of YM155, 
possibly because of the absence of active cyclin/CDK complexes. This could 
conceivably increase the transcription of E2F controlled genes, many of which 
have important regulatory roles in the cell cycle. Loss of pRB may also trigger 
the p53 apoptotic pathway. E2F and p53 are pivotal regulators of cell 
proliferation and both cooperate in activating many pro-apoptotic genes to 
induce apoptosis500, 529 and the present results indicate that both contribute to 
the growth inhibitory effects of YM155.  
YM155 treated RCC cells showed a dose-dependent decline in viability with no 
concurrent increase in cytotoxicity. Loss in cell viability was accompanied by a 
measurable increase in caspase-3/7 activity, a profile that is consistent with cell 
cycle arrest and early phase apoptosis. An evaluation of the expression of 
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proteins involved in apoptosis regulation revealed that the activation and 
stabilization of p53 led to the up-regulation of pro-apoptotic proteins (Bax and 
Bad) in YM155 treated RCC cells. In addition, there was a down-regulation of 
the protein expression of anti-apoptotic proteins (Mcl-1, Bcl-xl, XIAP and 
survivin) which have been reported to be NF-κB target genes. The role of NF-
κB signaling pathway in the mechanism(s) of action of YM155 will be 
discussed in Chapter 5. These changes in the expression of apoptosis-associated 
proteins eventually trigger the increase in caspase-3 activity and cleavage of 












Role of NF-κB signaling pathway in the 
mechanism of action of YM155 in RCC 
 
5.1 Introduction 
Nuclear factor-kappaB (NF-κB) activity plays a central role in regulating cell 
proliferation, growth and apoptosis. Dysfunctional NF-kB activity has been 
implicated in various cancers, including RCC186-190, 192, 530. Members of the NF-
κB family mediate differential gene expression in response to a wide variety of 
extrinsic and intrinsic stimuli170, 531, 532, such as inflammatory cytokines (such 
as TNF-α), ultraviolet light, ionizing radiation, growth factors and 
chemotherapeutic agents533. In an environment where the survival signals 
dominate, NF-κB signaling cascade promotes cell survival through induction of 
target genes, whose products inhibit components of the apoptotic machinery534.  
One such product is the IAP protein survivin182. Hence, overexpression of 
survivin is a biological sequela of NF-κB activation in cancer.  
YM155 is a transcriptional inhibitor of the survivin promoter and in view of the 
causality between NF-κB signaling and survivin expression, this chapter seeks 




5.2 Results and Discussion 
5.2.1 DNA binding activity of NF-κB was disrupted by YM155 
NF-κB is an inducible transcription factor which is maintained in an inactive 
state in the cytosol. When activated, it dissociates from its inhibitory protein, 
IκB and translocates to the nucleus where it binds to specific sequences of DNA 
(response elements, RE). The DNA/NF-κB complex then recruits other proteins 
such as co-activators and RNA polymerases to activate the transcription of a 
number of molecules responsible for cytokine activation, cell proliferation and 
cell survival. To determine if YM155 interfered with the binding of NF-κB 
dimers to their consensus sequences, an enzyme-linked immunosorbent assay 
was carried on a commercially purchased kit. Briefly, nuclear extracts from 
treated cells were added to a 96 well plate to which oligonucleotides 
corresponding to the κB consensus sites were immobilized. Once bound to the 
κB site, the NF-κB subunit was detected by its primary antibody (p65), followed 
by a HRP-conjugated secondary antibody to provide the chemiluminescent 
signal which measured the extent of binding. RCC786.0 was treated with 
increasing concentrations of YM155 (20-160nM) in the presence or absence of 
TNF-α. The experiments were carried out at two time points of 6h and 24h.  
Figure 5.1A shows that YM155 increased the binding affinity of the p65 NF-
κB subunit to its consensus sequences at the 6h time point. Increases were 
observed in the presence and absence of TNF-α but was more pronounced (by 








Figure 5.1. Effects of YM155 on the DNA binding activity of p65 NF-κB. 
RCC786.0 was treated with 20nM, 40nM, 80nM and 160nM of YM155 for 
6h and 24h in the absence or presence of TNF-α stimulation. The nuclear 
fraction was extracted and used in an ELISA based p65 transcription factor 
assay kit. (A) YM155 increased binding affinity of p65 NF-κB to its 
consensus sequence at 6h. (B) YM155 decreased DNA binding affinity of 
p65 NF-κB to its consensus sequence after 24 hours. Cells that were not 
subjected to TNF-α stimulation showed a greater change in DNA binding 
activity. *, p < 0.05 and **, p < 0.01 from its control.  
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Curiously, the opposite trend was observed at the 24 h time point. As shown in 
Figure 5.1B, YM155 decreased binding affinity of the p65 subunit to its 
consensus sequences. Decreases were observed in cells that were stimulated 
with TNF-α or otherwise but were more marked in cells that were not stimulated 
with TNF-α.   
It would seem that YM155 had a biphasic time dependent effect on the binding 
of p65 to its consensus sequence, namely an early increase in binding affinity 
(6h) followed by a decline at the longer 24h time point. Both effects were 
concentration dependent and more pronounced in cells that were not stimulated 
by TNF-α.  
 
5.2.2 Transcription activity of NF-κB was disrupted by YM155 
An increase in the binding affinity of the p65 subunit to its consensus sequences 
would lead to a corresponding increase in the transcription of NF-κB controlled 
genes and vice versa. To investigate the effect of YM155 on the transcription 
activity of the NF-κB, RCC786.0 cells were transiently co-transfected with a 
luciferase reporter gene whose expression was regulated by NF-κB. These cells 
were treated with 40nM (1x IC50) of YM155 for 6h and 24h, in the absence or 
presence of TNF-α.  
At the 6h time point, YM155 had no detectable effect on the transcriptional 
activity of NF-κB (Figure 5.2A). This was not in keeping with the earlier finding 
that YM155 increased the binding affinity of the p65 subunit to its DNA 








Figure 5.2. Effects of YM155 on the transcription activity of NF-κB. 
RCC786.0 was treated with 40nM (1x IC50) of YM155 for 6h and 24h in 
the absence or presence of TNF-α stimulation. In a luciferase reporter 
assay, (A) YM155 did not affect the transcription activity of NF-κB at 6h.  
(B) YM155 reduced the transcription activity of NF-κB to 73% of the 










Figure 5.2. Effects of 9AA on the transcription activity of NF-κB. A 
known inhibitor of NF-κB dependent transcription, 9-aminoacridine 
(9AA) was employed as positive control. (C) 9AA had an IC50 of 4.32µM 
on RCC786.0 cells. (D) 9AA reduced the transcription activity of NF-κB 
to 69% of the control when subjected to a treatment concentration of 10µM 




At the 24h time point, YM155 decreased the transcriptional activity of NF-κB 
(Figure 5.2B), consistent with the decline in binding affinity of p65 to the 
consensus sequences observed earlier. The reduction (~27%) was observed only 
in the presence of TNF-. The experiments were repeated with 9-aminoacridine, 
a known inhibitor of NF-κB dependent transcription195. 9-aminoacridine had an 
IC50 of 4.32µM on RCC786.0 cells after 72h incubation (Figure 5.2C). It 
reduced the transcriptional activity of NF-κB by 31% at 10µM after 3h and only 
in the presence of TNF-α (Figure 5.2D).  
Therefore, the present results showed that YM155 reduced the binding of p65 
to its consensus sequences in the nucleus and consequently, the transcription of 
genes linked to this event. These effects were observed only after 24 hours and 
in RCC786.0 cells that were subjected to stimulation by TNF-α. The anomalous 
observations at the 6h time point will be addressed in the following section. 
 
5.2.3 Cellular localisation of p65 NF-κB was disrupted by YM155 
Transcription factors such as p65 NF-κB are ubiquitous and present in 
abundance in cells. This enables their rapid conversion to their active states by 
post-translational mechanisms in response to specific signals. To determine the 
effects of YM155 on p65 at the gene expression level, RCC786.0 cells were 
treated with 40nM YM155 in the presence or absence of TNF-α for 1h, 3h, 6h 
and 24h. No significant changes in the mRNA expression levels of p65 were 









Figure 5.3. Effects of YM155 on the mRNA expression of p65 NF-κB. 
RCC786.0 was treated with 40nM (1x IC50) of YM155 for 1h, 3h, 6h and 24h 
in the absence or presence of TNF-α stimulation. The mRNA expression levels 
of p65 was monitored using qRT PCR analysis. (A) There was no significant 











Figure 5.3. Effects of YM155 on the protein expression of p65 NF-κB. 
RCC786.0 was treated with 40nM (1x IC50) of YM155 for 6h and 24h in the 
absence or presence of TNF-α stimulation. In western immunoblotting 
analysis, the expression levels of the phosphorylated (phospho-) and total p65 
were probed. In the nuclear extract of YM155 treated cells, (B) there was an 
increase in p65 NF-κB at 6h, (C) there was a decrease in p65 NF-κB at 24h. 
The increased/decreased was greater in cells stimulated with TNF-α. There 
was no concurrent increase in levels of phosphorylated p65. In the cytoplasmic 
extract of YM155 treated cells, (D) there was an increase in phospho-p65 but 
total p65 was not affected at 6h, (E) there was no significant change in total 





In response to a wide variety of NF-κB stimulants such as TNF-α, the 
phosphorylation of p65 was widely observed but was rapidly dephosphorylated 
by certain protein phosphatases in the nucleus535-538.  Phosphorylation of p65 is 
essential as it promotes interaction with CBP/p300 coactivator complexes, 
resulting in histone and p65 acetylation and increases transcription of target 
genes171. Phosphorylation of p65 can be found at many sites, but the most 
extensively studied are serine 276 as well as serine 468 and 536 which are both 
found in the C-terminal transactivation domain539-541. High-resolution 
microscopy revealed serine 536 phosphorylated p65 was found predominantly 
in the cytosol, while serine 468 phosphorylated p65 mainly localized in the 
nucleus542. The impact of p65 phosphorylation on gene expression has also been 
shown to be highly gene specific. Phosphorylation at serine 276 results in 
conformational changes that allows binding of CREB-binding protein 
(CBP)/p300539, while phosphorylation of serine 536 favours binding of TATA-
binding protein-associated factor II31, a component of TFIID543. 
Next, investigations were carried out to assess the effects of YM155 on p65 
protein expression levels. RCC786.0 cells were treated with 40nM YM155 in 
the presence or absence of TNF-α for 6h and 24h. Levels of total and 
phosphorylated p65 in the nucleus and cytosol were determined by 
immunoblotting. Figure 5.3B shows increased levels of p65 NF-κB in the nuclei 
of cells treated with YM155 for 6h. The increase was greater in cells stimulated 
with TNF-α, indicating that YM155 potentiated the stimulatory activity of TNF-
α, leading to more p65 being translocated to the nuclei. However, a concurrent 
increase in levels of phosphorylated p65 (Ser536) could not be detected. As for 
cytosolic p65, levels were unchanged in the presence of YM155 at the 6h time 
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point. There was however an increase in cytosolic phospho-p65 (Ser536). 
Similar observations were made in the absence or presence of TNF- (Figure 
5.3D). Taken together, these findings suggest that YM155 promoted an early 
translocation of p65 to the nucleus but did not affect its total mRNA or protein 
expression levels.  
The increase in the levels of nuclear p65 observed here would had led to greater 
DNA binding which was duly observed in Section 5.2.1. There was however no 
accompanying increase in p65 transcriptional activity (Section 5.2.2). One 
reason may be that the transcriptional activity of p65 requires the participation 
of several processes. Notably, post-translational modifications such as 
phosphorylation and acetylation of specific residues on p65538, 544-546, as well as 
the presence of essential co-activators and co-repressors539, 547-551, have been 
shown to be critical.  The lack of these essential components or the interception 
of significant processes may have blunted p65 transcriptional activity. 
At the 24h time point, YM155 induced a decrease in nuclear p65 levels but as 
observed earlier, did not alter phospho-p65 which remained at (low) basal levels 
(Figure 5.3C). Cytosolic p65 and phospho-p65 remained unchanged (Figure 
5.3E). These observations were consistent in cells treated with or without TNF-
. Thus, at the longer time point, YM155 intercepted the nuclear translocation 
of p65 which stands in contrast to the increase in nuclear translocation which 
was observed at the shorter 6h time point.  
Taken together, these findings support the view that YM155 had a time 
dependent effect on the nuclear translocation of p65 in RCC786.0 cells. An 
early (6h) increase in the nuclear translocation of the p65 subunit was followed 
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by a subsequent (24h) decrease which led to diminished binding to p65 
consensus sequences and a decline in the transcription of affected genes.  
 
5.2.4 Protein expression of the molecules associated with the NF-κB 
signaling pathway was disrupted by YM155 
To further our understanding of the effects of YM155 on the NF-κB signaling 
pathway, three other critical proteins in the pathway were probed. These are 
IκBα which is responsible for retaining the p65-p50 heterodimer in its inactive 
state in the cytosol and IKK which when activated, phosphorylates IκBα and 
directs it towards proteasomal degradation. One other protein is cylindromatosis 
(CYLD), a tumour suppressor deubiquitinating enzyme involved in removing 
the K63-linked polyubiquitin chain from TRAF2. Without its ubiquitin side 
chain, TRAF2 is unable to activate IKK. Consequently, IKK will fail to 
phosphorylate IκBα and the NF-κB heterodimer p65/p50 will be retained as an 
inactive complex with IκBα in the cytosol. Consequently, inhibition or 
inactivation of CYLD enhances the activity of NF-κB and leads to increased 
resistance to apoptosis and carcinogenesis.  
Microarray analyses and validation with qRT PCR had earlier identified the up-
regulation of CYLD mRNA expression in YM155 treated RCC786.0 cells 
(Chapter 3). Here, western immunoblotting analysis showed that levels of 
CYLD protein were increased in the presence of YM155 at 6h and 24h, 
particularly in cells stimulated with TNF-α (Figure 5.4A, B). Up-regulation of 
CYLD would lead to the suppression of IKK and consequently diminished 
phosphorylation of IκBα. These sequence of events would lower levels of 
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phospho- IKK while maintaining total IKK unchanged at basal levels. The 
resulting stabilisation of IκBα would mean that total IκBα levels would be 
maintained or increased compared to control cells while phospho- IκBα levels 
would be negligible. The results shown in Figure 5.4B provide collateral 
evidence for this notion. Treatment of RCC786.0 cells with YM155 for 24h did 
not change levels of total or phospho- IKKβ. Hardly any phospho- IκBα was 
detected in the treated cells which would be the case if IκBα was stabilized. 
Total IκBα levels were increased in YM155 treated cells, particularly in cells 
that were concurrently stimulated with TNF-α. Stabilization of IκBα would 
restrict the nuclear translocation of p65 heterodimers and indeed, expression 
levels of total p65 NF-κB were reduced in the nuclear compartments of YM155 
treated cells as described in Section 5.2.3.  
When CYLD, IKK and IκBα levels were probed in cells exposed to YM155 for 
a shorter period (6h), their levels remained largely unchanged at basal levels 
(Figure 5.4A). There was however an increase in phospho- IKK levels in 
YM155 treated cells but phospho- IκBα levels remained unchanged compared 
to those found in control cells. This would further support the notion that 
YM155 has a time dependent effect on NF-κB signaling, with suppression 









Figure 5.4. Effects of YM155 on molecules associated with the NF-κB 
signaling pathway. RCC786.0 was treated with 40nM (1x IC50) of YM155 
for 6h and 24h in the absence or presence of TNF-α stimulation. In western 
immunoblotting analysis, the expression levels of total IKKβ, IκBα and 
their phosphorylated (phospho-) states and CYLD were probed. (A) At 6h, 
YM155 increased phospho- IKK but other molecules remained largely 
unchanged compared to control cells. (B) At 24h, YM155 decreased 
phospho- IκBα, stabilised total IκBα and increased CYLD in the presence 
of TNF-α stimulation. Quantification of the expression of CYLD using 




5.2.5 Expression of chemokine Interleukin 8 (IL-8), a downstream 
target gene of transcription factor NF-κB was up-regulated by 
YM155 after 3h 
Clear cell RCCs are highly vascularised tumours largely due to VHL mutations. 
Thus, the development of effective agents against the angiogenesis pathway is 
a highly attractive chemotherapeutic option for RCC. Interleukin 8 (IL-8) plays 
an important role in tumour growth, angiogenesis, and metastasis and has been 
reported to mediate resistance to anti-angiogenic agents552-554.  
IL-8 enhances the proliferation of cancer cells by promoting the transition of 
cells from the G1 to S phase of the cell cycle. It also triggers an angiogenic 
response by activating endothelial cells in tumour vasculature553, 555, 556. 
Furthermore, it recruits neutrophils and promotes their infiltration into the 
tumour site to induce metastasis and assist in the evasion of stress-induced 
apoptosis557-560. In xenograft and orthotopic in vivo models of solid cancers, IL-
8 expression has been shown to correlate with angiogenesis, tumourigenicity 
and metastatic potential561, 562. This adaptive response in the form of induction 
and secretion of IL-8 was also observed in cancers cells exposed to 
chemotherapeutic agents such as 5-fluorouracil, paclitaxel and dacarbazine563-
565. In this context, developing strategies to target IL-8 may sensitise cancer cells 
to conventional chemotherapeutic agents and improve treatment response. 
Disruption of the NF-κB signaling pathway will disrupt the expression of its 
downstream target genes. IL8 is a NF-κB target gene as the consensus sequences 
of the transcription factor NF-κB are found in the IL8 promoter region566, 567. 
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Any increase or decrease in DNA binding and transcription activity will thus be 
reflected in the levels of IL-8 mRNA and protein expression.  
To further validate the present hypothesis that YM155 suppressed NF-κB 
signaling, it is essential to demonstrate that the suppression extended to genes 
that are regulated by NF-κB. To this end,  the mRNA expression of IL-8 in 
RCC786.0 cells treated with 40nM (Ix IC50) YM155 was monitored over 1h, 3h, 
6h and 24h by qRT PCR. Signals obtained from drug treated samples were 
normalised to their respective controls (without/with TNF-α) which was set at 
1.  As seen from Figure 5.5A, YM155 elicited significant increases in IL-8 
mRNA expression levels in RCC786.0 cells over time (3h to 24h). In keeping 
with the elevated mRNA levels, there was a concurrent increase in secreted IL-
8 levels as detected by an ELISA assay. The increases were observed in both 
RCC786.0 (Figure 5.5B, C) and ACHN cells (Figure 5.5D, E), with or without 
TNFα stimulation.   
The determination of IL-8 levels was carried out by an ELISA technique which 
measured the accumulative amount of IL-8 secreted by the RCC cells in the 
culture media. Over time, levels would thus be expected to increase and this was 
duly observed for YM155-treated cells with or without stimulation by TNF-α. 
There were however two striking observations. First, increases in IL-8 levels at 
the 6h time point were consistently higher than those observed at the 24h time 
point. Second, in spite of the increases in IL-8 levels at both time points, the 















Figure 5.5. Effects of YM155 on the mRNA expression level of chemokine IL8. 
(A) RCC786.0 was treated with 40nM (1x IC50) of YM155 for 1h, 3h, 6h and 24h 
in the absence or presence of TNF-α stimulation respectively. The mRNA 
expression levels of IL-8 in YM155 treated RCC cells at the indicated time points 
were determined using qRT PCR. The signals were normalised to their respective 
controls (without/with TNF-α and time-points) which is equivalent to 1. YM155 
induced a significant increase (~2- to 5-fold) in the mRNA expression of IL8 from 





Figure 5.5. Effects of YM155 on the level of secretion of chemokine IL-8. (B, C) 
RCC786.0 and (D, E) ACHN were treated with increasing concentrations of YM155 
for 6h and 24h in the absence or presence of TNF-α stimulation respectively. The 
levels of IL-8 in the culture media of YM155 treated cells at the indicated time points 
were determined using ELISA. Increasing concentrations of YM155 induced an 
initial increasing trend in the secretion of IL-8 at 6h. However, this trend began to 
decline at treatment concentrations above the IC50 (40nM) by the 24h. *, p < 0.05 
and ***, p < 0.001 from the other time point at the same treatment concentration. 
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This was particularly evident at the 24h time point and implied that less IL-8 
was secreted into the culture media when cells were exposed for a longer period 
(24h versus 6h) to YM155. Although the increase in IL-8 secretion slowed down 
at the 24h time point, IL-8 can be expected to exert profound effects on the 
tumour microenvironment554. The diminishing rate of IL-8 secretion at the 24h 
time point further support the notion that YM155 caused a time dependent 
suppression of the transcriptional activity of NF-κB. 
 
5.2.6 NF-κB signaling may play a role in the anti-survivin activity of 
YM155 
In Chapter 4, YM155 was found to increase the proportion of cells in early and 
late apoptosis (based on Annexin V staining) only after 48h of exposure. The 
apoptogenic effects of YM155 were further confirmed by the suppression of 
survivin and other anti-apoptotic proteins at the same time point. Preceding 
sections in this chapter have revealed that  the effects of YM155 were time 
dependent and suppression of NF-κB signaling was apparent only after 24h of 
treatment at the  IC50 of YM155 (40nM). The expression of the IAPs are 
generally thought to be regulated by NF-κB signaling180, 182, 568, 569. Thus it was 
of interest to examine the transcriptional activity of the survivin gene (BIRC5) 
under conditions at which YM155 suppressed the NF-κB pathway.   
Here, RCC786.0 cells were treated with YM155 at 40nM in the presence or 
absence of TNF- α. BIRC5 mRNA levels of YM155 treated cells were then 









Figure 5.6. Effects of YM155 on the mRNA expression level of BIRC5. (A) 
RCC786.0 was treated with 40nM (1x IC50) of YM155 for 1h, 3h, 6h and 24h in 
the absence or presence of TNF-α stimulation respectively. The mRNA 
expression levels of BIRC5 in YM155 treated RCC cells at the indicated time 
points were determined using qRT PCR. The signals were normalised to their 
respective controls (without/with TNF-α and time-points) which is equivalent to 
1. YM155 induced a significant decrease (~28%) in the mRNA expression of 





    
 
  
Figure 5.6. Effects of TNF-α and YM155 on the expression level of survivin 
(BIRC5). (B) RCC786.0 was treated with 20ng/ml of TNF-α for 1h, 3h, 6h and 
24h and the mRNA expression levels of BIRC5 were determined using qRT PCR. 
TNF-α did not significant increase/decrease the mRNA expression of BIRC5 at 
tested all time points. p > 0.05. In the absence or presence of TNF-α stimulation, 
RCC786.0 was treated with 40nM (1x IC50) of YM155 for (C) 6h and (D) 24h 
respectively. Using western immunoblotting, YM155 decreased the protein 
expression of survivin at 24h but not at 6h. Stimulation with TNF-α reduced basal 
level of survivin protein expression at 6h and 24h, making the decrease due to 
YM155 inhibition less marked.   
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Figure 5.6A shows that YM155 significantly decreased the expression of BIRC5 
mRNA levels at 24h but not at earlier time points. Nuclear p65 levels was shown 
to decline at the 24h time point (Figure 5.3C) and this would suppress the 
transcription of NF-κB regulated genes, including BIRC5 as observed here. 
Interestingly, the YM155-induced decrease in mRNA levels of BIRC5 was 
significant only in RCC786.0 cells that were not stimulated by TNF-α (Figure 
5.6A).  
Follow up experiments on the protein levels of survivin showed a concurrent 
decline in YM155 treated cells at the 24h time point (Figure 5.6D). A decrease 
in survivin levels was also observed in YM155- treated RCC786.0 cells that 
were stimulated by TNF-α and a similar band intensity was also observed in 
treated cells in the absence of TNF-α, thereby indicating that TNF-α does not 
potentiate the anti-survivin activity of YM155. Moreover, when the control 
blots from cells not stimulated with TNF-α were compared to those from cells 
stimulated with TNF-α, it can be seen that TNF-α treatment by itself, reduced 
survivin levels (Figure 5.6C, D). Thus the apparent decrease in survivin in cells 
treated with YM155 in the presence of TNF-α should be reconsidered as the 
declines may not be entirely induced by YM155. Subsequent experiments 
revealed that the differential effects of TNF-α on survivin levels did not extend 
to the transcription of the survivin gene. As shown in Figure 5.6B, mRNA levels 
of BIRC5 were largely unaltered in cells with or without TNF-α. Opposing 
views have been reported in the literature regarding the effects of TNF-α on 
survivin expression. Schmidt et al reported an upregulated of survivin 
expression in rat dendritic cells stimulated with TNF-α570, while others observed 
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that TNF-α treatment either had no effect on mRNA/protein expression or 
decreased survivin at the protein level252, 571, 572. 
Taken together, YM155 significantly reduced the expression of survivin 
mRNA/protein at 24h but not at earlier time-points, suggesting that NF-κB 
played a role in the transcriptional repression of survivin in YM155 treated 
RCC786.0 cells. However, TNF-α mediated NF-κB activation does not 
potentiates the anti-survivin activity of YM155 in RCC.   
 
5.2.7 The interaction between p65 NF-κB and its DNA binding sites 
at the survivin and IL8 promoter regions was decreased and increased 
by YM155 respectively 
A transcription factor is a sequence-specific DNA-binding protein that binds to 
specific DNA consensus sequences (response elements or cis-regulatory 
elements) and controls the rate at which genetic information is transcribed from 
DNA to messenger RNA. Most transcription factors work in tandem with other 
proteins (co-regulators) to promote (activator) or block (repressor) chromatin 
remodeling, initiate complex formation and the recruitment of RNA polymerase 
and transcriptional initiation/elongation547, 573. Promoters are elements of DNA 
(directly upstream of the transcription start site (TSS) of a gene) that bind RNA 
polymerase and other proteins to initiate transcription. Enhancers are non-
coding DNA sequences that contain multiple activator and repressor binding 
sites. The regulation of a gene expression is mediated by “DNA looping” which 
brings together promoters, enhancers, transcription factors and RNA processing 
factors574. Research over the past two decades has shed considerable light on 
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the extent to which each target gene may be differentially regulated by its 
transcription factors170, 575. Remarkably, a NF-κB responsive gene can be 
regulated in a cell- and stimulus- specific fashion531, 576 and regulation of the 
gene expression of IL8 and BIRC5 (survivin) are said to involve members of the 
NF-κB family180-182, 567, 577, 578.  
To systematically investigate the recruitment of p65 NF-κB to NF-κB-
dependent promoters, the chromatin immunoprecipitation (ChIP) assay was 
employed. Briefly, this powerful and versatile technique is able to capture a 
snapshot of the interaction between p65 NF-κB and its DNA binding site on the 
target gene within the natural chromatin context of the cell. Primers designed to 
flank the NF-κB DNA binding region were used to amplify the chromatin 
fragments immunoprecipitated by the p65 NF-κB antibody. In this manner, the 
extent to which the p65 NF-κB subunit binds to the IL8 and BIRC5 promoter 
region can be quantified by qRT PCR.  
RCC786.0 cells were first treated with 40nM (1x IC50) YM155 for 24h and fixed 
with formaldehyde for analysis by ChIP. Treatment with YM155 led to 
approximately 2 fold reduction in the binding of p65 NF-κB to two sites of the 
BIRC5 promoter region (Figure 5.7A, B) and approximately 2.5 fold increase 
in the binding of p65 NF-κB to one site of the IL8 promoter region (Figure 5.7C). 
This observation is consistent with the gene expression results described in 
earlier sections (Section 5.2.5 and Section 5.2.6) where treatment with 40nM 
(1x IC50) YM155 for 24h led to a decrease in the levels of mRNA and protein 







       
 
   
 
Figure 5.7. Effects of YM155 on the recruitment of p65 NF-κB to binding site 1 of the BIRC5 promoter. 
(A) RCC786.0 was treated with 40nM (Ix IC50) YM155 for 24h. To capture a snapshot of the interaction 
between p65 NF-κB and its DNA binding site on the promoter of BIRC5 gene, this protein-DNA 
complex was cross-linked by fixation. Chromatin fragments were immunoprecipitated using the p65 
NF-κB antibody and its corresponding IgG was used as a control. Input consists of chromatin fragments 
that were not subjected to immunoprecipitation. Amplification of purified DNA showed a decrease in 
band intensity in YM155 treated cells. Quantitation using qRT PCR (signals normalised to their 
respective input) showed a 2 fold reduction in the binding of p65 NF-κB its binding site 1 on the BIRC5 




   
 
      
 
   
 
Figure 5.7. Effects of YM155 on the recruitment of p65 NF-κB to binding site 2 of the BIRC5 promoter. 
(B) RCC786.0 was treated with 40nM (Ix IC50) YM155 for 24h. To capture a snapshot of the interaction 
between p65 NF-κB and its DNA binding site on the promoter of BIRC5 gene, this protein-DNA 
complex was cross-linked by fixation. Chromatin fragments were immunoprecipitated using the p65 
NF-κB antibody and its corresponding IgG was used as a control. Input consists of chromatin fragments 
that were not subjected to immunoprecipitation. Amplification of purified DNA showed a decrease in 
band intensity in YM155 treated cells. Quantitation using qRT PCR (signals normalised to their 
respective input) showed a 2 fold reduction in the binding of p65 NF-κB its binding site 2 on the BIRC5 










Figure 5.7. Effects of YM155 on the recruitment of p65 NF-κB to binding site of the IL8 promoter. 
(C) RCC786.0 was treated with 40nM (Ix IC50) YM155 for 24h. To capture a snapshot of the 
interaction between p65 NF-κB and its DNA binding site on the promoter of BIRC5 gene, this protein-
DNA complex was cross-linked by fixation. Chromatin fragments were immunoprecipitated using 
the p65 NF-κB antibody and its corresponding IgG was used as a control. Input consists of chromatin 
fragments that were not subjected to immunoprecipitation. Amplification of purified DNA showed an 
increase in band intensity in YM155 treated cells. Quantitation using qRT PCR (signals normalised 
to their respective input) showed a 2.5 fold increase in the binding of p65 NF-κB its binding site on 
the IL8 promoter region. P1, forward primer; P2, reverse primer; TSS, transcription start site. 
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The expression of NF-κB responsive genes in a particular cell type subjected to 
a given stimulus or treatment can be highly variable. Despite the down-
regulation of nuclear p65 NF-κB in YM155 treated RCC786.0 cells at 24h 
(Section 5.2.3), p65 NF-κB was still bound to the IL8 promoter, giving rise to 
relatively high levels of mRNA expression (Section 5.2.5). This could be due to 
greater stability of the IL8 promoter-NF-κB complex which would result in an 
increase in the duration of gene transcription. Alternatively, the latter could have 
been due to the increased stability of IL8 mRNA in the presence of YM155. The 
kinetics of the gene expression, such as the rate of gene induction, duration of 
functional promoter bound complexes and rate of mRNA degradation are tightly 
regulated such that not all NF-κB responsive genes are activated 
simultaneously531 and this could have been the case for BIRC5 and IL8. A 
complete understanding of how these genes are selected to become NF-κB 
responsive and how different transcription factors/co-regulators cooperate with 
NF-κB to coordinate cellular response will be an area that require further 






This chapter explored the effects of YM155 on the NF-κB signaling pathway in 
RCC786.0 cells. The main findings at the 24h time point in the absence of TNF-
α stimulation are summarized as follows.  
YM155 diminished the DNA binding affinity of the p65 NF-κB subunit to its 
consensus sequences in the nucleus. The decrease in binding affinity suppressed 
the transcriptional activity of the p65 subunit (but only in cells subjected to 
TNF-α stimulation). In keeping with the suppressed transcriptional activity of 
p65, diminished levels of total p65 levels in the nucleus were detected. This 
decrease was not accompanied by concurrent changes in the cytosolic levels of 
p65 in treated cells which implied that the key process intercepted by YM155 
was translocation of p65 from the cytosol to the nucleus. Further support for 
this notion came from the unaltered levels of IκBα (responsible for sequestering 
p65 in the cytosol) and IKK (responsible for phosphorylating/activating IκBα, 
promoting its degradation by ubiquitination, and hence liberating p65 for 
nuclear translocation) in treated cells. Such a profile pointed to an inhibition of 
the phosphorylating activity of IKK and stabilization of IκBα. The inhibition of 
IKK is attributed to the elevation of the tumour suppressor CYLD by YM155.  
Upregulation of CYLD would trigger a sequence of events culminating in the 
retention of p65 in the cytosol. To confirm that YM155 suppressed 
transcriptional activity of the p65 subunit, investigations were carried out on 
IL8 and survivin, as the expression of both genes are regulated by NF-κB 
mediated transcriptional activity. YM155 reduced both the mRNA and protein 
levels of survivin. On the other hand, YM155 increased the mRNA levels of 
IL8 but decreased the rate at which it was secreted into the cellular environment. 
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The degree of interaction between p65 NF-κB and the promoters of these two 
genes was established using the ChIP assay and the results were consistent with 
the observed mRNA/protein expression. 
The suppression of NF-κB signaling by YM155 was found to be time dependent 
and at the shorter 6h time point, no suppression was observed. Some of the 
results pointed to an activation of the pathway but there were noticeable gaps in 
the findings. Notably, YM155 did not increase p65 transcriptional activity at 6h. 
Neither did it induce an increase in phospho- IκBα levels which would be 
expected if the pathway is upregulated. Thus, the effects of YM155 on NF-κB 
signaling at 6h remained inconclusive in contrast to its suppressive effects at 
24h which were well supported.  
Another point that requires mention is the influence of TNF-α on the effects of 
YM155. Broadly similar findings were obtained regardless of whether cells 
were treated with TNF-α or otherwise, although some effects were more marked 
in the presence of TNF-α. Notably, YM155 suppressed the transcriptional 
activity of p65 only in cells stimulated by TNF-α. 
Taken together, the available data are in line with the time dependent (24h) 
suppression of NF-κB signaling cascade by YM155 in RCC786.0 cells which 
was independent of TNF-α stimulation. The suppression may be due to 
diminished ubiquitination induced by increased activity of CYLD. A possible 
direct inhibition of IKK by YM155 should not be ruled out either. Given that 
NF-κB dysfunction is central to oncogenic processes and already a target of 
interest for anti-cancer treatment, the suppressive effects of YM155 provide a 





In vitro growth inhibitory activities of YM155 in 
combination with sorafenib or bortezomib and 
the in vivo assessment of YM155 on a patient-
derived RCC xenograft model in SCID mice 
 
6.1 Introduction 
The benefits of using combinations of various active agents to treat disease 
states have been demonstrated in traditional and modern medical practices579, 
580. One reason may be that interconnected molecular pathways are more 
susceptible to the simultaneous action of several drugs as compared to a single 
agent581-584. In therapeutic regimens, drug combinations are employed to 
achieve better efficacy, dose and toxicity reduction and to reduce the risk of 
drug resistance. The rationality of this approach has been widely embraced as 
the standard of care for several diseases, in particular cancer585. In addition, the 
discovery of new molecular entities and reformulation of existing drugs into 
new combination products has provided new strategies for improving current 
therapeutic intervention. However, when two drugs are combined, the resulting 
combination will behave like a “third drug” with unknowns related to the 
pharmacokinetic and pharmacodynamic properties of the combination586. Thus, 
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prior to clinical trials on the combination, the rationale and therapeutic benefits 
of the combination must be established by in vitro and/or in vivo preclinical 
studies. Chou and Talalay introduced the term “combination index” (CI) to 
quantitatively describe the possible outcomes of combinations, namely 
synergism, additive effect and antagonism406. The method requires a 
comparison of the non-linear regression of the dose-effect curves of individual 
drugs in vitro or in vivo to provide a quantitative measure of the extent of drug 
interaction at a given level587-590.  
In this chapter, sorafenib and bortezomib were selected for combination with 
YM155 and the extent of their interactions were evaluated by the combination 
index. Sorafenib is a kinase inhibitor drug approved by the U.S. Food and Drug 
Administration (FDA) for advanced renal cancer, while bortezomib, a 
proteasomal inhibitor, is widely employed for the treatment of hematological 
malignancies. A Phase 3 randomized controlled trial of oral sorafenib therapy 
reported an extension of progression-free survival in clear cell RCC patients 
who failed to respond to first-line therapy. However, this improvement was 
associated with an increased number of adverse events compared with placebo84. 
A clinical trial of bortezomib in RCC patients showed a low response rate591, 592, 
but this was attributed to the fact that the majority (75%) of RCC tumours are 
VHL-deficient and thus likely to be chemoresistant593. RCC cells that expressed 
wild type VHL were more sensitive to bortezomib than those which were VHL-
deficient. Investigations revealed that the differential sensitivity was due to the 
VHL-mediated down-regulation of NF-κB activity594, 595 and that NF-κB 
inhibition is a crucial mediator of bortezomib-induced apoptosis in RCC cells596. 
In another study, EGFR inhibition sensitized RCC cells to the cytotoxic effects 
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of bortezomib597. YM155 was reported to induce EGFR suppression in 
pancreatic cancer cells356 and this inhibition of EGFR expression was also 
observed in RCC cell lines treated with YM155 (data not shown). In addition, 
Chapter 5 has shown that YM155 disrupted NF-κB activity in RCC cell lines. 
Hence, there is a sound rationale for investigating the growth inhibitory 
properties of a YM155-bortezomib combination in RCC. With this background, 
the in vitro growth inhibitory effects and dose-reduction index of YM155 in 
combination with a sorafenib or bortezomib are investigated in this chapter. 
Another objective of this chapter is to examine the effects of YM155 on a 
patient derived xenograft model in mice. Several studies have shown that the 
patient derived tumour xenograft model present several advantages over cell 
line xenografts. First, they are histologically and genetically similar to their 
parental tumours598-604. Consequently, they are more appropriate models for 
therapeutic investigations605 and have been widely used to evaluate the effects 
of targeted agents on RCC332, 606. Second, in vitro propagation of RCC cell lines 
generally lead to the acquisition of genetic alterations not found in the original 
tumour607 and they are usually unable to recapitulate the heterogeneity of 
tumours found in patients604, 608. In this chapter, a patient-derived RCC 
xenograft model in SCID mice developed by Professor Hung Huynh of the 
Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, 




6.2 Results and Discussion 
6.2.1 YM155 in combination with a sorafenib or bortezomib 
To evaluate the interaction of YM155 with sorafenib or bortezomib, the growth 
inhibitory activity of the combination mixture (YM155-sorafenib or YM155-
bortezomib), was determined on RCC786.0 cells at the 72h time point.  
The IC50s of the two drugs on RCC786.0 were determined. Figure 6.1A shows 
that sorafenib had an IC50 of 6.73 ± 1.04µM but its growth inhibitory effect did 
not exceed 64%, thus casting doubt on the accuracy of this value. However, the 
IC50 values of bortezomib (3.24 ± 0.14nM) could be determined accurately. The 
IC50 of YM155 under similar conditions was 40nM. YM155 was combined with 
each drug in the following ways: (i) both drugs at their 0.5x IC50 values, (ii) 
both drugs at their IC50 values, (iii) at the IC50 of one drug and 0.5x IC50 for the 
other drug.  
The growth inhibitory effect of each combination was then determined on 
RCC786.0 cells (72h). Figure 6.1B shows that when YM155 and 
sorafenib/bortezomib were used at concentrations equivalent to 0.5x IC50 of 











Figure 6.1. Growth inhibitory activity of sorafenib and bortezomib alone 
and in combination with YM155. In MTS cell proliferative assay, (A) 
sorafenib had an IC50 of 6.73 ± 1.04 µM but the growth inhibitory effect 
does not go below 64%. The IC50 value of bortezomib was 3.24 ± 0.14 nM. 
(B) Drugs in combination at 0.5x IC50 of each drug resulted in a growth 




The Combination Index (CI) was determined for each combination using the 
Chou and Talalay equation406. Briefly, a CI of 0.9 to 1.1 indicates an additive 
effect while a value that is less than 0.90 indicates synergism. If the CI is > 1.10, 
this is indicative of antagonism. Chou and Talalay defined synergism as a more 
than expected additive effect, and antagonism as a less than expected additive 
effect. Based on these cut off values, it is seen that a combination of sorafenib 
and YM155 at concentrations corresponding to 0.5x IC50 of each drug resulted 
in a desirable synergistic effect (CI: 0.80 ± 0.07) (Table 6.1A). However, 
synergism was not evident when YM155 was combined with bortezomib (0.5x 
IC50 of each drug). Instead, the combination resulted in an additive effect (CI: 
0.95 ± 0.05). Other combinations of YM155 and sorafenib or bortezomib gave 
CI values that were not indicative of synergism. Most combinations were 
antagonistic (CI > 1.10) except for the combination of sorafenib (0.5x IC50) and 
YM155 (IC50) which was additive (CI: 1.06 ± 0.04). Therefore only the 
combination of YM155 and sorafenib at concentrations equivalent to 0.5x IC50 
showed the desired synergism. This combination should be optimized in 
preclinical studies before the commencement of clinical testing in humans579. A 
good dosage range can be obtained by serial dilution of the synergistic 















Another parameter that was deduced from the combination study is the dose-
reduction index (DRI) which is a measure of how many times the dose of each 
drug in a synergistic or additive combination may be reduced at a given effect 
level compared with the dose of each drug alone. DRI is important in clinical 
situations where dose-reduction leads to reduced toxicity while retaining 
therapeutic efficacy. Table 6.1B shows the DRI of the drugs in combination at 
0.5x IC50 and indicates that when used in combination, the dose of each drug 
can be reduced by at least 2 fold or more.  
Practically, real benefit is realized only when both drugs have no overlapping 
toxicities and this aspect would need to be established in in vivo experiments 
using patient-derived RCC xenograft in SCID mice. In vivo experimentation 
would be necessary to address some of the limitations of the in vitro 
combination study. First, the combination experiments were conducted on 
specific cancer cell lines, which may not be representative of all the RCCs 
occurring in the general population. Second, they do not take into account 
natural cell-cell interactions of cancer cells with normal cells which may result 
in variations in the treatment response. To get a more accurate picture, the ideal 





6.2.2 YM155 suppressed the tumour growth of a patient-derived 
clear cell RCC xenograft model in SCID mice  
The advantages of patient-derived xenograft models versus those established 
using immortalized cell lines were highlighted in Section 6.1. Here, a patient-
derived clear cell RCC xenograft model was established in SCID mice. This 
pre-clinical model provides an in vivo means of assessing the tumour response 
to YM155. At a dose of 3mg/kg, YM155 did not elicit overt toxicity in SCID 
mice (Figure 6.2A). Symptoms of toxicity as seen from weight loss, unkempt 
appearance, mortality and distressful behaviour in YM155-treated animals over 
the treatment period of 15 days were not observed. To evaluate the ability of 
YM155 to supress the growth of patient-derived RCC xenograft, mice bearing 
RCC-19-0809 tumours (clear cell histological subtype) were randomised (10 
mice per group) and treated with vehicle (PBS) or increasing doses of YM155 
(1, 2 and 3 mg kg-1 twice a day) for 15 days. As shown in Figure 6.2B, the 
growth rate of RCC-19-0809 decreased at higher doses of YM155 (2 and 3 mg 
kg-1). At the end of the treatment period, animals were sacrificed and the 








Figure 6.2. In vivo assessment of YM155 using a patient-derived RCC 
xenograft model in SCID mice. Mice bearing RCC-19-0809 tumours were 
randomised (10 mice per group) and treated with vehicle (PBS) or 
increasing doses of YM155 (1mg, 2mg and 3mg kg-1 twice a day) for 15 
days. (A) The mean body weight of the mice in response to the treatment 
showed that YM155 was well tolerated with no significant decrease in 
body weight. (B) The mean tumour volume of vehicle- and YM155- 
treated mice at the given time-points showed a decrease in the rate of 
tumour growth at higher doses of YM155.  *, p < 0.05 and **, p < 0.01 









Figure 6.2. In vivo assessment of YM155 using a patient-derived RCC 
xenograft model in SCID mice. Mice bearing RCC-19-0809 tumours were 
randomised (10 mice per group) and treated with vehicle (PBS) or increasing 
doses of YM155 (1mg, 2mg and 3mg kg-1 twice a day) for 15 days. (C) A 
picture representative of vehicle- and YM155 treated tumours. (D) The mean 
tumour weight of vehicle- and YM155- treated mice on the day of animal 
sacrificed. (E)  Lysates of 3 tumours from each group were pooled and 
subjected to western immunoblotting analysis. Representative blots shown 
indicated a dose-dependent reduction in the protein expression of survivin 
in the tumours of YM155-treated mice. *, p < 0.05 and ***, p < 0.001 using 
one-way anova/post-hoc test. 
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Tumour weights of mice treated with 2 and 3 mg kg-1 YM155 for 15 days were 
approximately 70% and 50% that of control tumours respectively (Figure 6.2D). 
To determine whether the inhibition of survivin was involved in the in vivo 
effects of YM155, lysates of 3 tumours from each group were pooled and 
subjected to western immunoblotting analysis. YM155 induced dose dependent 
reduction in survivin levels as seen from representative blots in Figure 6.2E. 
This finding is evidence of the inhibition of survivin and induction of apoptosis 
by YM155 in treated tumours. Other have noted that inhibition of survivin not 
only reduce tumour growth, but had the added benefit of sensitizing tumour 
cells to chemotherapeutic agents146.  
The anti-tumour effects of YM155 have been evaluated in a wide variety of 
human cancer cell lines and xenograft models609-613. To date, this is the first 
study that reports YM155’s ability to suppress tumour growth in a murine RCC 
xenograft model derived from a nephrectomised patient with clear cell RCC. 
However, murine xenograft models have several inherent limitations. In general, 
the uptake rate of the xenograft in SCID mice is approximately 30%. In view of 
the limited number of RCC xenografts, results should be interpreted with 
caution. Second, the behaviour of the tumour in the micro-environment of the 
RCC in patients may not be replicated in a non-orthotropic environment in mice. 
Thus, the observed responses may not be reproduced clinically. Nevertheless, 
the established patient-derived RCC xenograft is still a useful model that can be 
used to examine other molecular changes in RCC xenografts in response to 
treatment by YM155 or combinations of YM155 with other chemotherapeutic 
drugs.        
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6.2.3 Combination of YM155 with sorafenib did not give a synergistic 
effect in patient-derived clear cell RCC xenograft model in SCID 
mice  
Although sorafenib is widely endorsed as the standard of care for RCC, up to 
35% of patients on sorafenib require dose reduction and about half of these 
patients eventually cease treatment due to adverse effects84. Hence, there is a 
need for additional treatment options for patients who cannot tolerate the full 
dose of sorafenib. Combination therapy may serve to address this deficit. In a 
previous study, sorafenib was reported to induce dose-dependent inhibition of 
angiogenic targets in various RCC xenograft lines regardless of histological 
subtypes332. In Section 6.2.2, YM155 induced a tumour growth suppression of 
a patient-derived RCC xenograft and in Section 6.2.1, in vitro combination of 
YM155 and sorafenib showed a desired synergistic effect. Here, the effect of 
combination of YM155 and sorafenib was investigated in vivo using the same 
patient-derived RCC xenograft model described in Section 6.2.2. This 
experiment seek to achieve sustained anti-tumour activity with low dose 
sorafenib, thus minimising adverse effects.    
YM155 (2mg/kg) and sorafenib (10mg/kg) used alone and in combination were 
well tolerated in mice as seen from the absence of significant weight loss in 
treated mice (Figure 6.3A). To evaluate the ability of YM155/sorafenib to 
suppress the growth of patient-derived RCC xenograft, mice bearing RCC-19-
0809 tumours were randomised (10 mice per group) and treated over a period 
of 15 days with either (i) vehicle (PBS), (ii) YM155 (2 mg kg-1 twice a day), 
(iii) sorafenib (10mg kg-1 once a day) or (iv) a combination of YM155 (2 mg 




        
 
 
Figure 6.3. In vivo assessment of combination of YM155 and sorafenib using a patient-
derived RCC xenograft model in SCID mice. Mice bearing RCC-19-0809 tumours were 
randomised (10 mice per group) and treated over a period of 15 days with either (i) vehicle 
(PBS), (ii) YM155 (2mg kg-1 twice a day), (iii) sorafenib (10mg kg-1 once a day), or (iv) 
YM155 (2mg kg-1 twice a day) and sorafenib (10mg kg-1 once a day). (A) The mean body 
weight of the mice in response to the treatment showed that all treatments were well 
tolerated with no significant decrease in body weight. (B) The mean tumour volume of 
vehicle-, YM155-, sorafenib- and (YM155-sorafenib)- treated mice at the given time-points 
showed a decrease in the rate of tumour growth when compared to the vehicle control. 
However, there was no significant difference between treatment with sorafenib alone and in 






Figure 6.3. In vivo assessment of combination of YM155 and sorafenib using a patient-
derived RCC xenograft model in SCID mice.  Mice bearing RCC-19-0809 tumours 
were randomised (10 mice per group) and treated over a period of 15 days with either 
(i) vehicle (PBS), (ii) YM155 (2mg kg-1 twice a day), (iii) sorafenib (10mg kg-1 once a 
day), or (iv) YM155 (2mg kg-1 twice a day) and sorafenib (10mg kg-1 once a day). (C) 
A picture representative of control and treated tumours. (D) The mean tumour weight 
of control and treated mice on the day of animal sacrificed. There was a significant 
difference between YM155 alone and sorafenib alone, but no significant difference 
between sorafenib alone and in combination with YM155. (E) Lysates of 3 tumours 
from each group were pooled and subjected to western immunoblotting analysis. 
Representative blots shown indicated a reduction in the protein expression of survivin 
in the tumours of all treated mice. However, combined YM155-sorafenib resulted in a 
slightly higher levels of survivin as compared to sorafenib alone.  **, p < 0.01 and ***, 
p < 0.001 using one-way anova/post-hoc test. 
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As illustrated in Figure 6.3B, the growth rate of RCC-19-0809 slowed down in 
all treated mice. However, there was no significant difference in the growth 
rates of tumour bearing mice treated with sorafenib alone and sorafenib 
combined with YM155. At the end of the treatment period, animals were 
sacrificed and the tumours were surgically removed for weight determination.  
Tumour weights of mice treated with YM155 alone (2 mg kg-1), sorafenib alone 
(10mg kg-1) and YM155 (2 mg kg-1) + sorafenib (10mg kg-1) for 15 days were 
approximately 80%, 63% and 61% that of the control respectively (Figure 6.3D). 
As expected, sorafenib resulted in significant tumour weight loss. However, 
there was no significant difference in the tumour weights of mice treated with 
sorafenib alone and in combination with YM155.  
Survivin has been recognised as a useful diagnostic marker for tumour 
recurrence and treatment response227. As such, measuring the expression of 
survivin in the course of or post treatment is an effective way to monitor 
response to chemotherapy. To determine whether survivin was inhibited in the 
various treatment groups, lysates of 3 tumours from each group were pooled 
and subjected to western immunoblotting analysis. As seen from representative 
blots in Figure 6.3E, survivin was inhibited in all drug-treated groups, albeit to 
varying degrees. Notably, the expression of survivin in the combined YM155-
sorafenib group was slightly higher than that of sorafenib alone. This is 
consistent with the observation that the tumour volume and weight of the two 
treatment groups were similar, thereby indicating that there was no apparent 
advantage and synergistic effect when YM155 and sorafenib were used at this 
in vivo combination. 
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A number of factors may account for the absence of synergistic effect observed 
in vivo, in contrast to the promising results obtained in vitro. First, there are still 
lapses in our understanding of the mechanism(s) of action of the individual 
drugs in the combination. If both drugs intercept common pathways, 
combination therapy would not be beneficial. Second, the cell line used in vitro 
is different from the patient-derived xenograft line in vivo. Hence the growth 
inhibitory effect may not have been successfully replicated. Third, the doses 
used in the in vivo combination have not been optimised. As mentioned earlier, 
the IC50 of sorafenib could not be accurately determined from the DRC of 
sorafenib (Figure 6.1A). No effort was made here to optimize the dose of each 
drug used in the combination and it is conceivable that the doses employed in 
the YM155-sorafenib combination were not optimal. Greater effort at 
optimizing the doses of the two drugs in the combination may yet result in the 
desired synergistic outcome. Lastly, the dosing schedule was made without due 
consideration of the pharmacokinetic profiles of either drug. YM155 is usually 
given by a continuous IV infusion228 and the intra-peritoneal route of 
administration employed in the combination may have compromised its 
efficacy. 
Immunohistochemistry and western immunoblotting analyses on key oncogenic 
biomarker in tumour tissues obtained from mice may give an idea of the absence 
of synergistic effect for this drug combination in vivo. In addition, a well-
designed in vivo study in orthotopic RCC mouse model will greatly enhance the 




The advantages of combination therapies are well recognized605. The 
combination of YM155 and sorafenib at concentrations equivalent to 0.5x IC50 
was found to be synergistic, as deduced from its combination index <0.9. 
Synergism was not observed when YM155 was combined with bortezomib. The 
dose response indices showed that the dose of each drug can be reduced by >2 
fold when used in combination, without compromising growth inhibitory 
activity. This is potentially beneficial because it will result in a level of efficacy 
that is comparable to the active drug but at the lower concentration employed in 
the combination. The benefits would be a better safety profile with decreased 
toxicity due to dose reduction. With the optimised combination concentrations, 
the combination mixture can be serially diluted to allow similar testing to be 
carried out on other RCC cell lines. Such preclinical studies assist in the 
determination of the potential of the drug combination to support further 
progression into clinical studies.  
There is a greater genetic divergence in cell line xenograft derived from in vitro 
culture versus a direct xenograft derived from patient (biologically stable when 
passaged in mice)614. YM155 was shown to suppress the tumour growth of a 
patient-derived xenograft model in SCID mice and the extent to which tumour 
growth was arrested correlated with the degree of survivin inhibition. 
Regrettably, combination of YM155 and sorafenib failed to give a synergistic 
effect in vivo. Notwithstanding, this patient-derived RCC xenograft model can 
be further exploited for other drug combination studies, elucidation of 
mechanism(s) of action, identification of predictive biomarkers and hopefully, 





Conclusions and future directions 
 
7.1 Conclusions 
The objectives of this study were, first, to determine the expression of survivin 
in RCC and the effect of YM155 (a known survivin inhibitor) on the gene 
expression profile of RCC. Second, to assess the anti-proliferative activity of 
YM155 and elucidate the possible mechanism(s) underpinning its activity. 
Third, to explore the therapeutic potential of a YM155-sorafenib combination 
in vitro. When the combination was found to be synergistic, an in vivo 
evaluation was initiated on a patient-derived RCC xenograft model in SCID 
mice. 
The work presented in Chapter 3 indicated that immortalized and advanced 
stage patient-derived RCC cell lines that lacked a functional VHL expressed 
significantly higher levels of survivin. Silencing of survivin in these cells with 
survivin specific siRNAs resulted in elevated levels of cleaved PARP, an 
indication that apoptosis has been activated in these cells. Thus, survivin may 
potentially be employed as a key prognostic marker of RCC aggressiveness and 
treatment response. YM155 is reportedly the 1st compound that selectively 
inhibits survivin gene transcription and protein expression228, 416 and it 
effectively down-regulated survivin in a panel of RCC cell lines. Unusually, its 
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inhibitory effect was found to be independent of VHL status or the extent to 
which survivin was expressed in cells. RNA microarray analyses of the 
differential gene expression between treated and control cells indicated that 
YM155 affected genes that were involved in cell death and survival, cellular 
growth and proliferation and cell cycle control. The majority of these genes 
were associated with the p53 connection pathway, indicating that YM155 does 
not exclusively inhibit survivin. The process of carcinogenesis is evidently 
complex and involves many underlying factors and multiple targets. The 
molecular “promiscuity” of YM155 may serve to expand its repertoire of targets 
and conceptually, this may be a better therapeutic approach. 
The second part of the study aimed to elucidate the mechanism(s) of action that 
account for the potent anti-proliferative activity of YM155. p53 (Chapter 4) and 
NF-κB (Chapter 5) are transcription factors that interact and play key roles in 
the regulation of cell viability and cell death. Extensive crosstalk between these 
two pathways allow low levels of DNA damage to predominantly induce cell 
cycle arrest and DNA repair, whereas extensive levels of DNA damage will lead 
to apoptosis615. Pro-apoptotic activity of NF-κB has the collateral benefit of 
stabilising p53. This would augment rather than diminish a therapeutic 
response197, 198. Indeed, it was shown that YM155 induced stabilisation of p53 
and initiated a bi-phasic response on NF-κB (a quick up-regulation of IL-8 but 
rate of secretion decreased with time, followed by a down-regulation of 
survivin). These events would account for the initial cell cycle arrest and 
eventual induction of profound apoptosis in YM155 treated RCC cells. Finally, 
Chapter 6 revealed that the in vitro drug combination of YM155 and sorafenib 
achieved a greater efficacy than either drug given alone at the same dose. Dose 
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reduction will have the useful effect of decreasing toxicity and achieving a 
better patient safety profile. In vivo, the combination was found to be less 
successful in reducing tumour growth. Reasons may be related to lapses in the 
understanding of the mechanism(s) of the individual drug, differences between 
cell line and xenograft line, un-optimized doses and dosing schedule.  However, 
YM155 suppressed the tumor growth of the patient-derived RCC xenograft 
model and the extent of tumor reduction was correlated to degree of survivin 
suppression. 
Taken together, these findings highlighted the therapeutic potential of YM155 
in RCC and support the view that strategies designed to block the function or 





7.2 Future directions 
In recent years, the advent of molecular targeted therapy has revolutionised the 
therapeutic treatment strategy of cancer. In pre-clinical studies, YM155 
exhibited remarkable nanomolar anti-tumour activity against a number of 
human cancers, such as prostate, breast, thyroid, gastric, pancreatic228, 356, 357, 616-
619. Its activity against clear cell RCC was demonstrated for the first time in this 
report. As such, investigating YM155 for other cancer types may be a 
worthwhile effort. YM155 has demonstrated collateral benefits of a low toxicity 
profile coupled with minimal and rapidly reversible side effects in human 
trials352. Notwithstanding, clinical trials which employed YM155 as a mono-
therapeutic agent had proven to be rather disappointing620. Uncertainty over the 
mechanistic profile of YM155 and the absence of predictive biomarkers for 
RCC may have contributed to difficulties in stratifying patients for treatment 
and this could have resulted in treatment failures with YM155. The RNA 
microarray analyses described in Chapter 3 have identified several genes that 
were differentially expressed on YM155 treatment, namely, ID1 and FOXO1. 
Recently, a solute carrier SLC35F2 was verified as a key determinant of the 
cellular uptake of YM155340. Using the RCC tissue microarray constructed 
earlier, immunohistochemical staining analyses of the differential expression of 
these biomolecules in individual tumours may allow a more accurate means of 
patient stratification and thus permit selection of the right treatment for the right 
patients.  
In the therapeutic control of complex disease systems, drugs that are designed 
to act against individual molecular targets are usually found to be less 
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effective621, 622. The limitations of monotherapies can be overcome by multi-
target therapeutic agents or the combination of two or more drugs that act on 
multiple targets simultaneously. This rational approach has proven to be more 
efficacious and less prone to adaptive drug resistance579. Many studies have 
reported the potency of YM155 when used in combination with other drugs or 
modulators but the clinical validity of such combinations have yet to be 
verified407, 612, 613, 623. The promiscuous nature of YM155 has been shown in this 
report and may help to select suitable drugs for combination studies. In Chapter 
6, the potential synergistic effect was identified through the systematic 
combination of YM155 and sorafenib in vitro. The optimised concentrations of 
this combination may be applied to other RCC or cancer cells lines to obtain a 
good dosage range and efficacy. It may also reveal unexpected but 
therapeutically relevant interactions between novel targets or disease-relevant 
pathways624, 625.  
In oncology drug development, pre-clinical animal models aid in the prediction 
of the clinical efficacy of novel anti-cancer agents. A patient-derived xenograft 
animal model is a better platform than a standard cell line xenograft model 
because it reflects the heterogeneity (histological, molecular and genetic) and 
complexity of the original tumours in the human body. A patient-derived RCC 
xenograft model has been established by Professor Hung Huynh and this 
valuable resource can be used to assess the activity of various novel anti-cancer 
drugs, similar to the in vivo evaluation of YM155 described in Chapter 6. 
Informative and relevant animal studies include discovery of 
predictive/prognostic biomarkers, drug combinations/cocktails and their 
associated toxicities. Additive toxicity is not inconceivable as combination of 
234 
 
numerous mono-therapeutics may accentuate undesired severe adverse effects, 
which are likely emerge in a pre-clinical animal model. In-depth investigation 
of the molecular changes in various pathways; associated with the treatment of 
a single drug or in combination with other agents, can lead to a greater 
understanding of the biological aspects of disease development626. 
YM155 can be administered safely as continuous intravenous infusion over 7 
days346, 348, 351. This route of drug administration maintains steady levels in the 
serum but it restricts patient mobility and increases the risk of undetected 
infiltration. Studies have shown that chemotherapy that is administered 
intravenously affects the patients quality of life and is often associated with 
psychological distress, longer hospital stays and other medical complications 
such as infection, bleeding, and venous thrombosis627-629. On the contrary, oral 
chemotherapeutic agents offer greater convenience, fewer visits to hospital, less 
physical/psychological pain and reduced problems related to medical 
complications. Thus, most patients prefer oral chemotherapeutics630-632, if it 
does not compromise therapeutic efficacy633. Given YM155’s clinical potential, 
it may be worthwhile to invest in an oral delivery platform for YM155 that does 
not compromise its efficacy and safety. 
Controlled drug delivery system via encapsulation is a promising approach as it 
offers significant advantages. It effectively protects the encapsulated cargo 
(active agent) against degradation, controls its rate of release so to achieve 
steady plasma levels and is readily administrated634. YM155 is a hydrophilic 
drug which is rapidly cleared and its delivery remains a challenge because many 
hydrophilic small molecule drugs undergo suboptimal encapsulation. Recent 
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studies reported various strategies to enhance encapsulation of hydrophilic 
drugs and increase bio-availability at the target sites635-638. A liposomal 
formulation of YM155 has been developed and may be an alternative to the 
current practice of continuous infusion of YM155 in clinics343, 639. The safety 
profile of the formulation is still under evaluation.  
With the demonstration of the clinical efficacy of molecular targeted therapies 
such as sunitinib, sorafenib and temsirolimus for RCC84, 92, 640, the application 
of these new therapeutic agents is currently being extended to the adjuvant and 
neoadjuvant settings641. Efforts in biomarker-based studies in RCC may 
potentially predict the efficacy of these targeted agents but their implementation 
remains challenging642. If the inhibition of survivin proves to have potent anti-
cancer activity in the clinical setting, it will be insightful to extend the 
development of this approach in the same direction, raising the prospects of a 
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